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ABSTRACT
In the United States, stroke is the fifth leading cause of death and stroke survivors often face
long-term disability. After ischemic stroke, the ischemic territory can expand and recruit
previously viable tissues into the lesioned area. During this critical period, there is an unsettling
lack of interventions that prevent or treat secondary neuronal loss and cognitive decline.
Clinical subdural recordings have revealed a close link between infarct progression and waves
of spreading depolarizations (SD) in the acutely injured brain. SD is a slowly progressing
wave of near-complete neuroglia depolarization that is extremely energetically demanding and
this additional metabolic ‘hit’ of SD in vulnerable tissues (i.e. penumbra) could underlie
secondary lesion progression. While deleterious to metabolically impaired neurons, SD may
theoretically promote recovery and repair processes in otherwise healthy cortex, distant from
the initial injury site. This dissertation work characterized the impact of tissue metabolic status
on deleterious consequences of SD in order to test interventions that reduce neuronal injury
without preventing SD outright. From this work, we now know that SD consequences can be
targeted to limit deterioration of vulnerable tissues without preventing any theoretical benefits
in remote brain regions that may play a role in cortical reorganization and recovery after focal
ischemia.

iv

Table of Contents
DEDICATION ....................................................................................................................... iii
ABSTRACT .......................................................................................................................... iv
Table of Contents ..................................................................................................................v
List of Figures...................................................................................................................... vii
1.

INTRODUCTION .......................................................................................................... 1
1.1 Acute ischemic stroke ................................................................................................. 1
1.2 Cellular mechanisms of injury ..................................................................................... 3
1.3 Spreading depolarization (SD): a new target for stroke intervention ..........................13
1.4 Reevaluating mechanisms of the ischemic cascade in the context of SD ..................26
1.5 Potential beneficial outcomes of SD ..........................................................................32
1.6 Rationale for targeting SD consequences ..................................................................38
1.7 Goals of this study .....................................................................................................40

2.

Ketamine reduces deleterious consequences of spreading depolarizations.................44
2.1 Abstract .....................................................................................................................45
2.2 Introduction................................................................................................................46
2.3 Materials and Methods ..............................................................................................48
2.4 Results ......................................................................................................................54
2.5 Discussion .................................................................................................................63
2.6 Conclusions ...............................................................................................................68
2.7 Acknowledgements ...................................................................................................68
2.8 Supplementary Figures .............................................................................................69

3. Novel model of metabolic compromise increases brain slice vulnerability to deleterious
consequences of spreading depolarization ..........................................................................71
3.1 Introduction................................................................................................................72
3.2 Materials and methods ..............................................................................................74
3.3. Results .....................................................................................................................81
3.4 Discussion .................................................................................................................88
3.5 Conclusions ...............................................................................................................91
4. Metabolic heterogeneity influences excitotoxic consequences of spreading
depolarization in vivo ...........................................................................................................92
4.1. Abstract ....................................................................................................................93

v

4.2 Introduction................................................................................................................94
4.3 Materials and Methods ..............................................................................................96
4.4 Results ....................................................................................................................103
4.5 Discussion ...............................................................................................................110
4.6 Supplementary Figures ...........................................................................................120
5.

DISCUSSION ............................................................................................................122
5.1 Summary .................................................................................................................122
5.2 Brain slice model of metabolic compromise .............................................................125
5.3 Experimental design to evaluate injury mechanisms during SD after in vivo stroke .139
5.4 Excitotoxic consequences of SD..............................................................................143
5.5 Ketamine reduces excitotoxic consequences of SD.................................................151
5.6. Summary of studies ................................................................................................157
5.7 Future studies and beneficial outcomes of SD .........................................................159
5.8 Conclusions .............................................................................................................162

6.

APPENDICIES ..........................................................................................................165
Appendix A: Effect of memantine on spreading depolarization consequences in brain
slices .............................................................................................................................165
Appendix B: Theoretical protective effects of SD ...........................................................184
Appendix C: The degree of SD-induced excitotoxic glutamate increases is related to
extent of brain slice metabolic impairment .....................................................................187

7.

REFERENCES ..........................................................................................................188

vi

List of Figures

FIGURE 1.1 ...........................................................................................................................41
FIGURE 2.1 ...........................................................................................................................53
FIGURE 2.2 ...........................................................................................................................55
FIGURE 2.3 ...........................................................................................................................57
FIGURE 2.4 ...........................................................................................................................59
FIGURE 2.5 ...........................................................................................................................61
FIGURE 2.6 ...........................................................................................................................62
SUPPLEMENTARY FIGURE 2.1 ................................................................................................69
SUPPLEMENTARY FIGURE 2.2 ................................................................................................70
FIGURE 3.1 ...........................................................................................................................81
FIGURE 3.2 ...........................................................................................................................83
FIGURE 3.3 ...........................................................................................................................85
FIGURE 3.4 ...........................................................................................................................87
FIGURE 4.1 .........................................................................................................................104
FIGURE 4.2 .........................................................................................................................106
FIGURE 4.3 .........................................................................................................................108
FIGURE 4.4 .........................................................................................................................110
FIGURE 4.5 .........................................................................................................................120
FIGURE 4.6 .........................................................................................................................121
FIGURE 5.1 .........................................................................................................................124
FIGURE 5.2 .........................................................................................................................127
FIGURE 5.3 .........................................................................................................................162
FIGURE 6.1 .........................................................................................................................174
FIGURE 6.2 .........................................................................................................................176
FIGURE 6.3 .........................................................................................................................178
FIGURE 6.4 .........................................................................................................................187

vii

1. INTRODUCTION
1.1 Acute ischemic stroke
In the United States, approximately 795,000 strokes occur each year accounting for ~1 out of
every 20 deaths. In 2013, stroke was the second-leading cause of death worldwide, behind
ischemic heart disease (Benjamin et al., 2017) while stroke survivors often face serious longterm physical and/or mental disability. The vast majority (~87%) of individuals suffer ischemic
strokes that occur when blood flow to the brain is reduced or blocked by an intravascular blood
clot.

1.1.2 Current therapies are limited for stroke treatment
In 1996 the U.S. Food and Drug Administration (FDA) approved clinical use of tissue
plasminogen activator (tPA), a pharmaceutical “clot-busting” agent, for the management of
acute ischemic stroke patients. Infusion of tPA results in the conversion of the proteolytic
enzyme, plasminogen, to its active form which solubilizes the clot to eventually restore blood
flow. Since the original randomized controlled trial of tPA in patients (“Tissue Plasminogen
Activator for Acute Ischemic Stroke,” 1995), subsequent trials have revealed that, while
ground-breaking in the treatment of stroke, benefits of tPA are limited to a narrow window of
time up to 4.5 hours from initial symptom onset (Powers et al., 2018). This limited therapeutic
window, along with various tPA contraindications, prevent the most ischemic stroke patients
from receiving treatment. As such, studies reveal that only 3-5% of ischemic stroke patients
receive tPA during this narrow window, further highlighting major limitations of intravenous
thrombolytic efficacy (Albers and Olivot, 2007; Benjamin et al., 2017).
1

In addition to tPA, other reperfusion therapies (e.g. mechanical thrombectomy) have recently
been incorporated into the 2018 healthcare professional guidelines for the early management
of acute ischemic stroke patients (Powers et al., 2018). Mechanical thrombectomy is a
minimally invasive surgical procedure for blood clot removal in order to improve cerebral
perfusion after stroke. Recently, five randomized controlled trials have shown that mechanical
thrombectomy can 1) improve global disability outcomes (Jovin et al., 2015) 2) be used as a
stand-alone treatment or in conjunction with intravenous tPA (Bracard et al., 2016; Campbell
et al., 2015; Goyal et al., 2015; Saver et al., 2015) and 3) be performed up to 24 hours after
symptom onset in select ischemic stroke patients (Nogueira et al., 2018). While the 24h
window increases the proportion of patients eligible for treatment (to 5-10% of acute ischemic
stroke patients) (Bhaskar et al., 2018; Meurer et al., 2017), the procedure requires advanced
imaging (not routinely preformed at time of presentation), a highly trained stroke specialist
team, and is less effective for certain types of occlusions (i.e. small vessel occlusions, posterior
circulation strokes, more distal clots) (Bhaskar et al., 2018). These challenges must be
overcome in order to implement mechanical thrombectomy more widely for stroke
management.

Ultimately, while systemic thrombolysis and endovascular mechanical

thrombectomy reperfusion therapies have revolutionized clinical standard of care guidelines,
it is estimated that approximately 85% of all acute ischemic stroke patients still do not meet
criteria for treatment (Bhaskar et al., 2018).

1.1.3 Progression of stroke injury when there are no available interventions
In addition to the rapid injury that occurs in brain regions directly supplied by the blocked
vessel(s), tissue surrounding the infarct (i.e. the ischemic penumbra) remains susceptible to
2

further damage.

This observation suggests that other mechanisms, secondary to initial

ischemia, are contributing to lesion development and poor neurological outcomes. This is
highlighted by clinical observations that the first 48 hours after ischemic stroke are
characterized by patient instability, and up to 40% of patients are at risk of developing further
neurological deficits and/or tissue deterioration during this time (DeGraba et al., 1999;
Helleberg et al., 2016). This group of patients are prone to lengthy hospital stays and worse
outcomes, including death, compared to stable patients without infarct progression (Helleberg
et al., 2016). It is thus striking that no strategies are available beyond 24 hours (Powers et al.,
2018) to limit the expansion of brain injury after ischemia. In order to improve therapeutic
interventions that target delayed stroke injury, it is central to understand the fundamental
mechanisms that contribute to initial as well as secondary brain injury following a sudden drop
in cerebral blood supply.

1.2 Cellular mechanisms of injury
1.2.1. Rapid neuronal consequences of oxygen and/or glucose deprivation
Observations regarding the importance of cerebral circulation have been noted throughout
history. Ancient civilizations of Mesopotamia utilized carotid artery compression to reduce
the pain of circumcision, and magicians in the Middle Ages employed discrete occlusion
techniques to cause rapid loss of consciousness in goats, thus puzzling their audiences (HOFF
et al., 1945). The earliest documented experiments of ischemia were conducted in the spinal
cord of animals in the 1600’s, but it was not until 1836 that Astley Cooper developed a
consistent method of artery occlusion in dogs for evaluating cerebrum pathology (“Astley
Cooper,” 1836; HOFF et al., 1945). Over the course of the next century, functional and
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structural changes following cerebral anemia were examined and highlighted the importance
of oxygen and glucose delivery, as well as metabolite clearance, for proper brain function.

When cerebral perfusion is occluded, brain tissue is deprived of important metabolic
substrates, namely oxygen and glucose, that are primarily utilized for proper neuronal function.
Although the brain represents only ~2% of the total body weight in humans, it consumes more
energy compared to all other organs. It is estimated that brain utilizes ~20% of the body’s total
glucose-derived energy (Magistretti and Allaman, 2015; Mergenthaler et al., 2013) and is thus
estimated to receive ~1/3 of the left ventricle’s cardiac output in humans (Rossen et al., 1943).
Evolutionary studies suggest that the preferential delivery of blood flow to the brain emerged
during the development of higher cognitive centers that are characterized by increased glucose
utilization and upregulation of genes involved in metabolism (Magistretti and Allaman, 2015).
The tight relationship between neuronal firing and vascular supply is exploited by imaging
modalities that monitor cerebral blood flow (CBF) as a proxy for determining relative levels
of neuronal activity in certain brain regions. This coupling of CBF to neuronal activity (i.e.
neurovascular coupling) provides the basis of techniques used for clinical studies or patient
diagnoses including functional magnetic resonance imaging (fMRI) and near infrared
spectroscopy (NIRS). After injury or ischemia, reduced blood flow is an immediate obstacle
in matching vascular supply with neuronal energy demands.

Research into brain metabolic requirements became more widespread around the time of
World War II. At this time, advances in aircraft technology enabled pilots to preform
maneuvers at faster speeds and higher altitudes thus revealing “pilot fatigue,” a phenomenon
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characterized by rapid loss of consciousness (HOFF et al., 1945). In hopes of aiding the war
effort, experiments by the neurophysiologist Herman Kabat and colleagues, found that
complete arrest of cerebral circulation in dogs resulted in loss of consciousness within ~10
seconds, followed by loss of respiratory movements (~20-30s) (Kabat et al., 1941). Translating
these findings into humans in 1941 Kabat, together with Lieutenant Ralph Rossen and John
Anderson in Red Wing Minnesota, employed a compression cuff designed by Anderson
(named the Kabat-Rossen-Anderson (KRA) apparatus) that enabled complete arrest of CBF
within two heartbeats (Rossen et al., 1943). These “Red Wing experiments” demonstrated
strikingly rapid loss of consciousness (~ 4-10s) in otherwise healthy adult men. While periods
of cerebral circulation arrest were luckily short and minimized any potential for development
of permanent injury, these early studies in animals and humans emphasized how quickly
neurons respond to low nutrient environments, and specifically to loss of substrates (oxygen
and glucose) central to ATP production in neurons.

The largest proportion of ATP consumption appears to be in neurons for the maintenance of
neurotransmission (Mergenthaler et al., 2013). This is supported by the enrichment of
mitochondria at synapses where presynaptic vesicle recycling and postsynaptic sodiumpotassium (Na+ / K+) ATPases hydrolyze ATP for the maintenance of electrochemical
gradients and synaptic activity (Magistretti and Allaman, 2015; Mergenthaler et al., 2013).
Additionally, energy-consuming clearance of neurotransmitters from the extracellular space
by both neurons and glia can be severely impaired by low levels of ATP. Rapid loss of
consciousness during Red Wing experiments could thus be a result of the shutdown of energy-
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expensive cortical activity in the seconds following a precipitous drop in CBF (discussed in
upcoming sections).

Beyond the rapid consequences to consciousness, early studies by Kabat and colleagues found
that prolonged CBF arrest (≥ 8 minutes, using pressure cuff like the KRA apparatus) inevitably
resulted in long term behavioral deficits or death in dogs (Kabat et al., 1941). In this model,
follow up studies showed that brains subjected to ≥ 8 minutes of anoxia were further
characterized by severe damage throughout most of the cerebral cortex, cerebellum, and
brainstem (GRENELL, 1946). Although these early studies induced cerebral ischemia on a
global scale, the immediate (~minutes) processes that occur are likely similar in brain regions
during focal ischemia that are reliant on the blocked vasculature. This rapid development of
neuronal injury residing near the occluded vessel(s) indicates that, by the time a stroke is
confirmed in patients (often hours−days after onset), the initial core of an ischemic lesion is
largely established and includes necrotic or unsalvageable tissue. Therefore, it is important that
interventions target mechanisms of secondary injury to prevent the recruitment of neurons into
the largely irreparable core of the infarction, when administered at later time points after
ischemic stroke.

1.2.2 The ischemic cascade
In the 1950s the combined discoveries that glutamate elicited depolarization of neurons
(CURTIS et al., 1959) and was toxic to cells led to the concept of injury induced by excessive
excitation, or excitotoxicity (Lai et al., 2014). The discovery of excitotoxicity reshaped the
stroke field and initiated development of drugs targeting key neurotoxic sequelae of ischemia
on the cellular level. Today, it is largely accepted that excitotoxicity, commonly referred to as
6

the “ischemic cascade” in stroke research, is a fundamental mechanism behind neuronal death;
as a result, extensive research focuses on targeting mechanisms that either limit glutamate
and/or downstream effectors in the excitotoxic cascade (Lai et al., 2014; Wu and Tymianski,
2018), as described below.

1.2.3 Contributions of glutamate
In 1959, Van Harreveld reported the first link between glutamate toxicity and ischemic stroke
damage by identifying the presence of glutamate in brain extracts taken a few minutes after
circulatory arrest (Harreveld, 1959).

Later work employing micro-dialysis techniques,

revealed that after 10-minutes of complete cerebral ischemia in rats, extracellular glutamate
had increased by 8-fold compared to baseline levels (Benveniste et al., 1984). Over the next
two decades, multiple studies confirmed that glutamate rapidly increased in the brain after
ischemia (Dawson et al., 2000; Mitani et al., 1990) and thus the development of drugs targeting
this “first-responder” was thought to be the best strategy for improving stroke treatments.

1.2.4 Targeting glutamate release
In vivo glutamate release mechanisms including calcium (Ca2+)-dependent vesicular release
(Drejer et al., 1985) and reversed operation of glutamate transporters (Rossi et al., 2000) have
been proposed as primary mechanisms involved in excitotoxic glutamate accumulation.
However, the relative importance of these different mechanisms depends on the in vitro model
or degree of ischemia.

In cultured cells, blockade of voltage-gated sodium (Nav) channels

using tetrodotoxin (TTX) inhibits vesicular glutamate release and also reduces neuronal death
induced by hypoxia (Lai et al., 2014 and Smith et al., 1993). Thus, it was proposed that
hyperexcitability and action potential mediated vesicular release (Benveniste et al., 1984;

7

Dawson et al., 2000) were mainly involved in neuron demise. This led to the development of
drugs targeting synaptic release mechanisms, including Nav blockers and N-type Ca2+ channel
antagonists, which effectively reduced glutamate levels and was cerebroprotective in vivo
when given prior to or shortly after (15-60min) experimental ischemia (Gaspary et al., 1994;
Okiyama et al., 1995; Smith et al., 1993). Unfortunately, subsequent human trials with these
new drugs, administered within a 12-hour treatment window post stroke onset, showed no
significant improvement and/or had severe side-effects that prevented their progression beyond
Phase II or III status (Lai et al., 2014, 2011).

In addition to synaptic glutamate release, impairment or reversal of glutamate uptake by
neurons and glia has been proposed to contribute to ischemic cell death (Rossi et al., 2000).
Excitatory amino acid transporters (EAATs) are located on both neurons and glia are are
responsible for the clearance of extracellular glutamate from synaptic and extrasynaptic sites
during neurotransmission. EAATs rely on the electrochemical gradient of largely Na+, but also
protons (H+) and K+, to move one molecule of glutamate into the cytosolic contents (three Na+
and one H+ in and one K+ out) (Kandel, 2013). The massive disruption or complete breakdown
of ionic gradients in hypoxic, ischemic, or other pathologic conditions (discussed in subsequent
sections) may thus promote reversal of EAATs leading to glutamate accumulation and further
excitotoxic effects. While further studies are needed to determine the role of EAAT-mediated
glutamate accumulation in conditions of low ATP availability, current compounds that target
EAATs also prevent essential synaptic and extrasynaptic clearance functions of these
transporters and thus are not desirable for further trials in human stroke. Interventions designed
to prevent only reverse transport, without preventing normal clearance, may hold some
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promise for reducing glutamate and protecting rat hippocampal neurons from oxygen-glucose
deprivation damage (Colleoni et al., 2008).

While the mechanisms and contributions of glutamate are not yet resolved, the above studies
suggest that indeed glutamate does accumulate after ischemia and is in part mediated by
vesicular release and/or reverse transport of EAATs. Additionally, they provide evidence that
targeting glutamate release can be protective in cell culture and animal models. However,
neuroprotection was highly dependent on the experiment of choice; including the duration of
ischemia (or oxygen-glucose deprivation, OGD in vitro) and the time-course of drug
administration (prior to or shortly after stroke onset and the duration of drug delivery).
Furthermore, many questions remain with regards to the duration and localization of detected
glutamate increases. In in vivo studies, glutamate levels were sampled on minute-to-minute
time scales which lack sufficient temporal resolution and also provide very little spatial
resolve—both of which may offer further insight into physiological mechanisms of the
developing injury. Hints that alternative or additional processes are involved in excitotoxic
neuronal demise after stroke lies in the unsettling disconnect and translatability of pre-clinical
to clinical benefits of drugs targeting glutamate.

1.2.5 Contributions of calcium (Ca2+) and NMDARs
Glutamate activates postsynaptic receptors causing depolarization primarily via influx of Na+,
which was initially believed to be the primary driver of excitotoxicity in response to glutamate
exposure. This was initially supported by findings that glutamate exposure induced acute cell
swelling in somata and dendrites, locations enriched with Na+ channels and characterized by
substantial depolarization (Lai et al., 2014). However, it was soon realized that Na+ removal
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during glutamate challenge in vitro completely prevented acute swelling but did not prevent
cell death ~24 hours later (Choi, 1987).

In addition to Na+-driven depolarization, ionotropic glutamate receptor activation (described
below) can increase membrane permeability to the divalent cation calcium (Ca2+) which serves
as an important second messenger in many cellular processes across virtually all cell types. In
neurons, increased intracellular Ca2+ concentration ([Ca2+]i) is not only essential for
presynaptic transmitter release, but is also involved in postsynaptic activity-dependent gene
expression, activation of Ca2+-sensitive ion channel conductance, and other cellular functions.
Due to the role of Ca2+ in many cellular processes, cytosolic Ca2+ levels are normally tightly
regulated (in the low nanomolar range) via intracellular sequestration and extrusion processes.
Evidence from cytotoxicity in non-neuronal tissues, including the heart, muscles, and liver
largely converge on cytoplasmic and nuclear events initiated by intracellular Ca2+ (Lai et al.,
2014). The connection between glutamate, Ca2+, and neuronal death were noted in vitro
following exposure of rat cortical neurons to excitatory amino acids, including glutamate. In
these studies, glutamate exposure resulted in intracellular Ca2+ dysregulation and neuronal
death (Berdichevsky et al., 1983). Of note, the glutamate analog N-methyl-DL-aspartate
(NMDA) was the most potent activator for increasing intracellular Ca2+ concentrations which
in turn identified the NMDA receptor’s (NMDAR) involvement in the excitotoxic injury
process (Berdichevsky et al., 1983; Lai et al., 2014). Ensuing studies confirmed the role of
intracellular Ca2+ entry in vitro by demonstrating that extracellular removal of this cation
during glutamate exposure could prevent the occurrence of delayed cell death in the wake of
substrate removal (Choi, 1987). These studies underscore Ca2+ influx and identify ionotropic
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glutamate receptors, namely the NMDAR, as key mediators of excitotoxicity along the
ischemic cascade.

The majority of excitatory neurotransmission is mediated by glutamate and its target
metabotropic and ionotropic receptor families. There are three main families of ionotropic
glutamate receptors including ⍺-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid

(AMPA), kainate, and NMDA receptors containing GluN1, GluN2A-D, and GluN3A-B
subunits. Compared to other glutamate receptors, the NMDAR has unique biophysical

properties thus positioning these channels as noteworthy mediators for numerous neuronal
processes. Exemplifying their fundamental role in proper brain function, NMDAR hyper or
hypo-activation is implicated in a multitude of disease states including Alzheimer’s disease,
depression, schizophrenia, other neurological disorders, as well as excitotoxic injury
mechanisms.

In conditions of energy depletion, insufficient pumping of Na+/ K+ against their
electrochemical gradients causes neuronal depolarization and neurotransmitter release,
including glutamate. These “excitotoxic” conditions set the stage for increased NMDAR cation
permeability that requires ligand-binding and relief of magnesium (Mg2+) blockade from
within the channel pore. Opening of NMDARs is thus accomplished via depolarizing Na+
influx, (e.g. through AMPARs, and other cation/ Na+ permeable channels) which liberates
Mg2+ from the NMDAR channel only when glutamate and co-agonist (i.e. D-serine/glycine)
are both present. While NMDARs are nonselective cation channels, they are distinctively
highly permeable to Ca2+ and thus crucial intermediaries of activity-dependent cellular tasks
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like hippocampal-dependent learning, for example. Furthermore, recent studies have shown
that NMDARs can exert metabotropic functions via their C-terminal cytosolic domains,
capable of recruiting “death complexes” of proteins (Tu et al., 2010) even when Ca2+ influx is
prevented (using potent NMDAR antagonists like MK-801, described next) (Weilinger et al.,
2016).

MK801 is an uncompetitive NMDAR antagonist that has been widely studied and consistently
demonstrated to serve neuroprotective roles by reducing infarct expansion after ischemia and
preventing neuronal death in vitro (Lai et al., 2011). However, like the failure of drugs targeting
glutamate release mechanisms, clinical testing of NMDAR antagonists (especially competitive
antagonists) was unsuccessful. In addition to the development of severe side-effects that
included nausea, vomiting, cardiovascular, and psychomimetic effects (Wu and Tymianski,
2018), NMDAR blockade was also associated with increased mortality resulting from
infarction in acute ischemic stroke patients (Lai et al., 2014, 2011).

While initial translation failures of drugs targeting excitotoxic mechanisms after stroke in
humans are multi-factorial (Gladstone et al., 2002), it is largely believed that these failures are
due to the pathophysiology of glutamate release during the proposed ischemic cascade.
Specifically, it is widely assumed that glutamate release occurs only in rapid succession
(minutes) following occlusion onset and thus has already activated NMDAR-mediated cell
death signaling cascades by the time a patient arrives at the hospital (Lai et al., 2014; Wu and
Tymianski, 2018). Another train of thought emerging from failed clinical tests developed
alongside modern techniques in animals identifying and elucidating distinct NMDAR subtypes
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and their role in opposing cellular processes. This suggests that complete and nonspecific
blockade of NMDARs may actually be detrimental to normal neuronal function as well as
survival and repair mechanisms essential for brain recovery after injury (Wu and Tymianski,
2018). Combined with prior assumptions about glutamate time courses, the major focus of preclinical stroke research has shifted neuroprotective efforts towards identifying and targeting
specific intracellular signaling cascades to either enhance cell survival and/or inhibit cell death
pathways that are downstream of NMDAR activation. These efforts are important for the
development of specific interventions with less side-effects as well as clarifying steps in the
death process of neurons. However, given that ischemic stroke patients with worsening injury
still have elevations in glutamate in their CSF (Berdichevsky, 1983) observations that
substantial brain injury can still progress over a period of days or more in some individuals;
the assumption that excitotoxicity has ran its course by the time a patient reaches the hospital
may be incorrect.

1.3 Spreading depolarization (SD): a new target for stroke intervention
Over the last four decades studies in animals and humans have revealed important excitotoxic
factors that contribute to rapid brain injury upon loss of metabolic substrate supply. However,
only relatively recently has detection of a long-known, but usually ignored physiological
phenomenon emerged as an important contributor to human brain injury (Dohmen et al., 2008;
Dreier et al., 2006; Fabricius et al., 2006; Strong et al., 2002). This phenomenon called
spreading depolarization (SD) is characterized by many cellular disruptions discussed
previously under the umbrella term of “excitotoxicity,” and could thus be an important new
candidate for neuroprotective strategies.

13

1.3.1 SD Terminology
Over the course of this dissertation project, coordinated efforts by the COSBID consortium
have been underway with a main goal of refocusing and uniting investigators in the SD field
(Hartings et al., 2017). Since Leão’s initial reports of SD conducted in 1944-1947, a growing
division amongst researchers seems to have been exacerbated by terminology. As discussed
previously (see Introduction), Leão described the phenomenon of SD as a “spreading
depression” that can be initiated in the healthy cortex, as exemplified by migraine aura.
Subsequent work examining brain physiology after stroke, asphyxiation, cardiac arrest, or
other injury demonstrated that cortical depression after SD is less obvious or even absent (due
to the loss of cortical potentials shortly after ischemia in vivo). This led to the development of
terms like: “anoxic depolarization” (describing SD that occurred in response to complete
substrate deprivation, like anoxia or OGD) and “peri-infarct depolarization” (SDs that erupted
along the rim of an infarcted brain region). While these terms did provide insight into the
conditions that initiated SD, they divided investigators in the field with regards to mechanisms
of SD in different brain states. As such COSBID promoted the idea that massive tissue
depolarization and resulting consequences occur along a continuum and depend on the
metabolic status of tissue in which events propagated (Hartings et al., 2017). In this
dissertation, spreading depolarization has will be used to describe the overall phenomenon of
SD, but this terminology can also be used with specific modifiers that provide more
information. Examples include transient (SDs that are short-lasting and do not cause damage),
prolonged (SDs that are longer in duration and may indicate underlying tissue dysfunction),
persistent (depolarization that does not recover until conditions change) or terminal
(depolarization that cannot recover and indicate tissue injury). These modifiers have been
14

described in a recent review by COSBID (Hartings et al., 2017) in hopes of unifying the field
of SD researchers and are thus used throughout this dissertation work.

1.3.2 Spreading Depolarization (SD)
SD is a slowly progressing (in mm min-1) wave of depolarization that occurs with high
incidence after stroke, acute brain injuries, and during migraine. Originally described as
“spreading depression,” SD was discovered in 1944 by the Brazilian neurophysiologist
Aristides Leão while examining seizure activity in the rabbit cortex (Leao, 1944). In this initial
report, Leão applied a local stimulus to the exposed brain and, instead of eliciting a seizure,
observed depression of cortical activity in the alternating current (AC) range (> 0.5 Hz) that
progressed in a spreading fashion and enveloping in all directions from the stimulated region.
In follow-up studies, Leão noted the same spreading depression in response to asphyxiation
and hypothesized that this phenomenon could play a role in pathologies including cerebral
ischemia and migraine (LEAO, 1947; Leao and Morison, 1945). Indeed, Leão noted a large
extracellular depolarization after non-spreading suppression of cortical activity in the ischemic
cortex. Today, we know that Leão’s “spreading depression” of spontaneous and evoked
activity is one consequence of spreading depolarization ((Hartings et al., 2017).

Mounting evidence suggests that SD could be an evolutionary conserved and/or an intrinsic
property of nervous tissue that is tightly packed, though further studies are needed to confirm
this notion. Thus far, SD has been detected in gray matter in vertebrates (amphibians, birds,
and mammals) and invertebrates alike. In vertebrates, central nervous system (CNS) structures
including the cortex (Leao, 1944), hippocampus (Müller and Somjen, 2000) brain stem
(Karunasinghe and Lipski, 2013), spinal cord (van HARREVELD, 1946; HARREVELD and
15

HAWES, 1946), striatum (Bureš and Hartman, 1967), and retina (Gorelova and Bures, 1983)
all support propagation of the SD wave. Depending on the tissue cytoarchitecture (e.g. gliato-neuron and intra- to extracellular space ratios, energetic demands of different cell types,
capillary support, etc.), certain brain regions are more sensitive or resistant to SD initiation
and/or propagation. This variability in brain region vulnerability to cerebral oxygen and/or
glucose deprivation was seen in many studies prior to Leão’s observations of SD following
ischemia in 1947. In a review by Hoff et al. in 1945, authors highlighted that similar cellular
changes were observed in the brain across seemingly different causes of death (i.e. ischemia,
anoxia, asphyxia, hypoglycemia, etc.), and that life-supporting brainstem centers (e.g.
medulla) were more resistant while cognitive areas (cortical layers) were extremely susceptible
to histopathological injury (HOFF et al., 1945). Perhaps this variable susceptibility to hypoxiainduced injury is related to changes in SD threshold across cytoarchitecturally different central
nervous system (CNS) tissues.

Most studies have examined SD and its consequences in the context of injury. In the past
decade, SD has been implicated as a causal event leading to the development of macular
degeneration in the retina ((Yu et al., 2012). Mice with Kv1.1 or Scn1a mutations (K+ and Na+
channel mutations, respectively) are prone to seizure-induced death via SD-initiation in the
life-supporting centers in the brainstem. This relates to patient cases of sudden unexpected
death in epilepsy (SUDEP) (Aiba and Noebels, 2015) and perhaps brainstem SD is involved
in other disorders such as sudden infant death syndrome (SIDS). In the above cases, retina and
brainstem SD are clearly implicated in tissue deterioration and/or death, however
consequences of SD are not always detrimental to organisms. For example, in locusts SD has
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been observed in the metathoracic ganglia and shuts down ventilatory central pattern generator
(GCP) center activity that is responsible for ventilation. In this instance, respiratory depression
after SD does not cause death but instead may serve as a potential survival mechanism for
inducing coma in locusts in response to noxious stimuli (e.g. hypo- or hyperthermia, anoxia).
The global reduction in the animal’s metabolic rate preserves energy until the stimulus is
removed (Rodgers et al., 2010, 2007). This supports the idea that not all instances of SD cause
injury and/or indicate the presence of injured tissue; instead, SD could serve as a mechanism
for suppressing neuronal over-excitability (as in seizure) or reducing metabolic expenditure in
environments of possible injury (such as drowning or cardiac arrest).

1.3.3 SD initiation and propagation
There are numerous types of stimuli that can initiate SD in the CNS including electrical
stimulation (Leao, 1944), ischemia (LEAO, 1947; Leao and Morison, 1945), chemical
application (Leao and Morison, 1945), hypoxia (HARREVELD and HAWES, 1946), and
others; therefore there has been much debate regarding contributions of K+ and/or glutamate
for SD induction (Somjen, 2001). However, Van Harreveld’s “dual hypothesis” which
incorporates both K+ and glutamate’s excitatory effects on neurotransmission to be main
contributors involved in SD initiation and propagation is now usually accepted (van Harreveld,
1978; Hartings et al., 2017; Pietrobon and Moskowitz, 2014). Thus, extracellular K+ elevations,
activation of voltage-gated Na+ and Ca2+ channels, presynaptic and regenerative glutamate
release, and NMDAR activation are all thought to participate in propagation of depolarizing
currents and feedforward extracellular accumulation of K+ and glutamate during SD (Zhou et
al., 2013). The relative contributions of K+ and glutamate likely depend on the physiological
or pathological inciting stimulus, as demonstrated by studies that pharmacologically
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manipulate extracellular levels of K+ or glutamate. For example, reducing action potential
dependent glutamate release (using TTX, described previously) as well as NMDAR
antagonists can prevent electrical stimulation induction of SD but are ineffective at blocking
SD induced by ischemia (modeled as oxygen-glucose deprivation, OGD in vitro).

While many studies have focused on elucidating cellular mechanisms involved in SD initiation,
reviewed in (Pietrobon and Moskowitz, 2014), it is likely that set of stimuli that converge on
the synchronous depolarization of a critical volume of excitable tissue (Tang et al., 2014) can
ignite SD. Propagation of SD is also likely influenced by the state of brain tissue and the
intrinsic (e.g. genetics) and extrinsic (e.g. injury) factors that govern cortical excitability.
Therefore, while the concentrations of extracellular K+ required to trigger SD are around ~1012 mM (Heinemann and Lux, 1977), tissue propensity for SD induction after ischemia is not
only species-dependent (Nakamura et al., 2010) but also may vary from one individual to the
next (as suggested by clinical data in (Dohmen et al., 2008; Woitzik et al., 2013)).

1.3.4 Ion changes during the DC shift
A hallmark of SD is the presence of a large shift in the extracellular slow direct current (DC;
< 0.1 Hz) or near-DC potential (< 0.5 Hz) and was first described by Leão in 1947 (LEAO,
1947). At the onset of SD, increases in membrane permeability outmatch ATP-dependent
processes involved in electrochemical gradient maintenance and results in net inward current
and depolarization of neurons (Dreier, 2011; Somjen, 2001). This breakdown of ionic gradients
combined with changes in tissue resistance changes give rise to the large (>2 mV) extracellular
DC potential shift that can last for minutes or longer (Somjen, 2001). The extent of
electrochemical gradient breakdown during SD is massive and results in near-complete
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depolarization of neurons and glia (Somjen, 2001, 2002). In comparison, electrochemical
gradients remain largely intact during normal synaptic communication where depolarization
lasts on the order of milliseconds.

Historical debates have existed regarding mechanisms (as mentioned previously) and the
relative time course of specific depolarizing currents during SD in different experimental
models (i.e.SD in healthy versus compromised CNS tissues) and is beyond the scope of this
dissertation work. However, there is consensus in the field that, regardless of the method used
to generate SD, there are fundamental (and massive) ionic changes that are largely time-locked
with the onset of the DC shift (but can outlast it) and variations in these mechanisms represent
characteristics of SD along a continuum (Hartings et al., 2017). While exact measurements of
ion concentrations are difficult due to technical limitations and the influence of intra- and
extracellular volume changes during SD, disruption in Ca2+, K+, Na+, H+, Cl-, HCO3- ion
homeostasis have all been observed during SD (Hartings et al., 2017; Somjen, 2001). In
general, SD is characterized by a sharp surge in extracellular [K+]e (from ~3 to 40-75mM), and
concomitant reductions in interstitial [Ca2+]e (from 1.3 to <0.1mM), [Cl]e (from ~150 to
95mM), and [Na+]e (from ~150 to ~60mM) (Hartings et al., 2017). The bulk changes in
extracellular (and intracellular) ion concentrations (Table 1.1) are enabled by substantial
increases in membrane permeability of neurons (and astrocytes) and thus contribute to
depolarization during the DC shift of SD.
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1.3.5 Metabolic demand of SD
Restoration of electrochemical gradients after SD requires tremendous ATP consumption, and
the effectiveness of recovery is strongly influenced by underlying tissue metabolic status.
Even in the well-perfused brain, activation of ATP-dependent pumps reset SD-induced ionic
disturbances and results in ~50 – 70 % reduction of tissue ATP levels (Mies and Paschen,
1984; Takano et al., 2007), in some studies. Based on experimental evidence, recent
calculations of Gibbs free energy release during electrochemical breakdown suggest that SD
is the “largest disruption of homeostasis that is possible in living neural tissue” (Dreier et al.,
2017; Dreier and Reiffurth, 2015), even more energetically demanding than seizures. This
energetic burden can be met by increased cellular metabolism and increased delivery of oxygen
and glucose (via cerebral perfusion in vivo) and thus does not cause permanent or overt
neuronal injury (Harreveld, 1958; Nedergaard and Hansen, 1988) inn otherwise uninjured
brain. On the contrary, in the injured human brain, spontaneous induction of SD (initiated by
trauma or ischemia) has been shown to cause step-wise reductions in tissue glucose levels
(indicative of increased metabolic demand) as well as corresponding increases in metabolic
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byproducts (i.e. lactate) and further disruption of extracellular ion concentrations (i.e. K+)
(Rogers et al., 2016). This indicates that SD consequences are greatly influenced by the ability
of brain tissue to meet energetic demands imposed by SD.

Previous work has demonstrated substantial changes in metabolic substrates and/or byproducts
are time-locked with SD – versus gradual changes over time; and include increased glucose
utilization (Mies and Paschen, 1984a; Takano et al., 2007). Protons (H+) and lactate production
(Kocher, 1989) and corresponding depletion of tissue O2 (Takano et al., 2007) and glycogen
stores (Seidel and Shuttleworth, 2011). These measurements indicate a high level of
metabolism which can lead to (in some studies) a massive drop in cellular ATP concentrations
(Mies and Paschen, 1984b). In the non-injured brain, these changes are transient and the only
noticeable consequence to neurotransmission is the long-lasting cessation of brain activity that
was originally described by Leão (Leao, 1944). Mechanisms of suppression during the large
depolarization of SD include collapse of ion gradients and Na+ - channel inactivation resulting
in depolarization blockade (Kager et al., 2000). However, suppression of activity lasts longer
(typically > 5 min) than the duration of depolarization and thus indicates the presence of other
mechanisms that limit neuronal activity. More recently, it was found that a major metabolite
of ATP breakdown, adenosine, is a key mediator of neuronal suppression after SD (Lindquist
and Shuttleworth, 2012, 2016).

The majority of ATP consumption during SD likely results from the pumping activity of
Na+/K+ ATPases that must rapidly hydrolyze ATP in order to counteract cation influx and
recover resting membrane potentials. However, ATP-dependent Ca2+ buffering processes and
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synaptic vesicle replenishment also add to ATP consumption after SD. All this ATP utilization
can be monitored downstream via the production of adenosine levels that increase in a similar
trajectory to other metabolic products, described above. During these processes ATP
breakdown results in the production adenosine monophosphate (AMP) that can be further
metabolized by 5’ nucelotidases to form adenosine (Frenguelli, 2017). Accumulation of
extracellular adenosine can then modulate neurotransmission via activation of adenosine 1
receptors (A1R) which are highly expressed in the rodent brain (Dixon et al., 1996) and are
located on both pre-and post-synaptic membranes (Boison et al., 2013). Coupling of A1Rs to
G-proteins inhibits the production of cyclic AMP (cAMP) which has downstream
consequences of reducing synaptic release of most neurotransmitters, including glutamate.
Evidence that A1Rs are activated in response to SD is provided by experiments using the
specific A1R antagonist (DPCPX) that was found to greatly accelerate postsynaptic responses
after SD in mouse brain slices and in vivo (Lindquist and Shuttleworth, 2012, 2014).

In metabolically compromised brain slices or after distal middle cerebral artery occlusion
(dMCAo) in mice, adenosine accumulation during SD is pronounced compared to levels
following SD in healthy brain tissue (Lindquist and Shuttleworth, 2014). In studies by
Lindquist and Shuttleworth, SD-induced adenosine signals were again correlated with the
duration of suppression of evoked and spontaneous cortical activity in vivo. Results from these
studies further indicated that real-time energy production via glycolysis and oxidative
phosphorylation greatly influenced the amount of adenosine that accumulates. Therefore, the
duration of A1R-mediated suppression of activity likely relates to the metabolic burden and the
amount of ATP consumed for tissue recovery after SD. This is also indicated in humans
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(discussed below) where worsening brain injury is characterized by progressively longer
recovery of times cortical activity monitored using electrocorticography (ECoG) techniques
(Hartings et al., 2017). Adenosine accumulation or the duration of A1R-mediated suppression
can thus serve as a read-out of SD metabolic burden.

1.3.6 SD in the human brain
As noted above, throughout Leão’s investigation of SD, he hypothesized that SD may play an
important role in human physiology including migraine, ischemia, and seizures (LEAO, 1947;
Leao, 1944; Leao and Morison, 1945). However, it was not until 1977 that SD was first
recorded in humans during stereotaxic brain surgery for focal epilepsy (amka et al., 1977). In
this study, Sramka and colleagues saw that SD could be induced by KCl infusion into the
caudate nucleus or hippocampus of humans, and the ensuing suppression of cortical activity
after SD was considered diagnostically useful for “functional ablation” during epilepsy
neurosurgery. Despite subsequent confirmation of SD in human brain slices, showing
properties apparently identical to those well described in rodent tissues (Avoli et al., 1991;
Petzold et al., 2005), the relevance to human physiology remained unclear until advancements
in imaging and recording techniques enable detection of SD in the 2000s.

Evidence that SD was involved in migraine came prior to Leão’s initial description by Karl
Lashley in 1941 (LASHLEY, 1941). In documenting the spread of his own migraine aura
across his visual cortex Lashley, unknowingly at the time, revealed a striking similarity to the
slow rate of spread of SD. However, it was not until 2001 that the propagating blood flow
response to SD was visualized using functional MRI (Hadjikhani et al., 2001). Today it is
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becoming more generally accepted that SD in the adequately perfused visual cortex of migraine
patients can manifest as a “scintillating scotoma” (LASHLEY, 1941) where excitatory
transmitter release at the SD wave front is followed by depression of activity, both of which
may contribute to visual acuity changes during aura.

It took 25 more years from its initial detection in humans, and close to 60 years from Leão’s
original description, to unequivocally electrically record spontaneous SDs in the injured human
cortex by Anthony Strong and colleagues (Strong et al., 2002). This report changed the
landscape for SD researchers and hinted that this phenomenon could play a large role in injury
progression. A year later, SD investigators joined forces and formed the Co-Operative Studies
on Brain Injury Depolarizations (COSBID) collaboration, with a mission to reveal the
relevance of SD to human brain injury. Over the next 15, large research efforts organized by
the COSID consortium have led to the identification of SD using subdural ECoG strip
electrodes in a range of acute neurological conditions. From these intraoperatively placed
strips, the SD hallmarks of a propagating shift in DC potential accompanied by suppression of
high frequency activity has been recorded in 70-80% of aneurysmal subarachnoid hemorrhage
patients (Dreier et al., 2006), 50-60% of severe traumatic brain injury (TBI) patients (Eriksen
et al., 2019), and 60-70% of patients with intracerebral hemorrhage (Fabricius et al., 2006).
Importantly, SD has been detected in nearly all patients with malignant hemispheric stroke
(Dohmen et al., 2008; Woitzik et al., 2013).

1.3.7 SD after ischemic stroke
A little over ten years ago, Dohmen et al. and the COSBID group demonstrated that 1) SD
occurs in high incidence in the human cortex after focal stroke and 2) SDs that occur in
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temporal clusters were associated with poor ECoG recovery and further tissue deterioration
(Dohmen et al., 2008). In the 16 patients included in this study, all had infarction of MCA that
required decompressive brain surgery to avoid further intracranial pressure (ICP)-related
injury. During surgery, investigators evaluated ECoG recordings from electrode strips placed
near the infarct in viable penumbral tissue. Recordings began anywhere from 13 to 109 hours
after individual stroke onset, and SD was detected in all patients that had ECoG strips located
over peri-infarct brain regions. In the two patients without detectable SDs, ECoG strip were
located over ischemic core regions and thus non-viable tissue. This indicates that SDs are
occurring primarily in metabolically vulnerable tissues for days after stroke onset and during
time periods of injury progression observed in CT scans.

1.3.8 SD incidence and relationship to injury progression
Prior to SD detection in the human stroke brain, it was generally assumed that spontaneous
SDs occurred only up to 6 hours after occlusion in animal stroke models which suggested that
the majority of cell death and infarct maturation manifesting at later time points (~24 hours)
was due to other mechanisms, suggested by (Hartings et al., 2003). However, foundational
work by Hartings et al. in 2003 revealed that, following permanent and transient MCAo,
spontaneous SDs persisted through 24 hours after injury in the rat cortex (Hartings et al., 2003).
Prolonged ECoG recordings further revealed that SD frequency increased in the acute hours
(~ 6 hrs.) and again ~12 hours after stroke onset. Importantly, SDs were detected throughout
lesion development (~24 hours) as measured by the loss of TTC staining over this same time
period. Not only did this study highlight the connection between SD and stroke injury
maturation, but also showed the ability of NMDAR-antagonists (Con-G; selective for NR2Bcontaining NMDAR subtypes) to limit infarct expansion when administered intrathecally
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during this phase of secondary SD frequency increases (1 bolus) hours after stroke injury
(administered ~8 hr. post MCAo).

1.4 Reevaluating mechanisms of the ischemic cascade in the context of SD
1.4.1 Rapid consequences at onset of ischemia
Early studies examining cell death processes at the initial onset of ischemia likely missed SD
due to the lack of physiological techniques capable of detecting SD at the time. In 1932 Edgar
Adrian and Sir Charles Sherrington shared the Nobel Prize for Physiology for the first
recordings of neuronal electrical discharges; and the first recordings of cortical activity during
cerebral anoxia in animals were being reported around this time (Sugar and Gerard, 1938). In
these early studies by Sugar and Gerard, they noted that cortical activity recorded in the cat
motor cortex was nearly absent within 10-20 seconds of bilateral carotid occlusion (Sugar and
Gerard, 1938). Later studies defined cortical potentials in terms of blood flow where
widespread suppression of cortical activity (observed in the 0.5-70Hz range of
electrocorticography) developed (again within ~10-20s) upon the reduction of CBF below the
threshold of 15-23 ml/100g/min (Hartings et al., 2017). If CBF is further limited to 510ml/100g/min, the suppression of cortical responses is inevitably followed (~2-5 min.) by
massive tissue depolarization (Hartings et al., 2017) that can only be electrically recorded in
the slow potential range. Importantly, these electrophysiologic consequences were noted in
Leão’s experiments in the rabbit cortex following global arrest of CBF (LEAO, 1947; Leao
and Morison, 1945) where he demonstrated that, if ischemia was continued beyond the
development of isoelectric cortical potentials, it was followed (~2-5 min. after occlusion) by
the large DC potential shift indicative of SD. In these experiments, the negative voltage shift
during SD lasted for the duration (up to 12 minutes) of circulation arrest (LEAO, 1947). This
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may indicate that the rapid and damaging cellular consequences of the ischemic cascade are
closely connected with SD, that erupts within minutes of stroke onset.

Whether or not injury results from SD in animal models is likely dependent on multiple related
factors, but low cerebral blood supply is an obvious contributor to vulnerability (Dreier et al.,
2018; Hartings et al., 2017). During the infamous Red Wing experiments in humans
(mentioned previously) there was rapid loss of consciousness (4-10s) following pressureinduced occlusion of CBF but there were no overt signs of injury— perhaps because CBF
arrest was not continued beyond 100s (Rossen et al., 1943) and thus likely did not trigger SD.
It is interesting to note however, that one patient with a clinical history of migraine, did
experience what he described as a migraine aura, perhaps due to increased SD susceptibility.
In the context of studies that were being conducted in dogs also during this time (see above),
the findings that only global CBF arrest lasting more than >8 minutes caused permanent
behavioral deficits (or death) and/or pathological changes in neurons (GRENELL, 1946; Kabat
et al., 1941); speculatively this could be due to the presence or absence of SD. In support this
idea (and the critical role of SD in the induction of injury in the injured brain), experiments
conducted in rats found that, in the absence of SD, severe focal ischemia (below 10% of
baseline) did not itself result in histological pathology (Kaminogo et al., 1998). These results
indicate that SD erupts following ischemia onset and the duration of electrochemical failure
during SD and the overall capacity for tissue to increase blood supply to the affected region
are main factors that contribute to brain death (Dreier et al., 2018; Hartings et al., 2017). These
factors are likely important during subsequent SDs that initiate during the secondary phase of
infarct maturation and increased SD frequency (Hartings et al., 2003). Such SDs have been
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shown to ignite along the penumbra-core border (Nakamura et al., 2010; Strong et al., 2006)
and can be due to pathological K+ elevations (Petzold et al., 2005) or in response to supplydemand-mismatches (von Bornstädt et al., 2015).

Key experiments that further linked SD to secondary injury after ischemia were conducted by
Busch and colleagues in 1996 (Busch et al., 1996). Here, SD was induced via repeated topical
application of K+ on the cortical surface after MCAO in rats and infarct expansion was
monitored using DWI-MRI over this time.

When compared to control animals, lesion

expansion occurred in a step-wise fashion, with each additional SD confirmed by DC shifts in
electrophysiological recordings.

Furthermore, administration of the NMDAR antagonist

MK801 blocked SD and prevented the expansion of ischemic injury. NMDAR antagonists can
(in some instances) prevent SD initiation (discussed below) and could indicate that the
ischemic cascade may be due primarily to excitotoxic mechanisms that are time-locked with,
and caused by SD.

1.4.2 Mechanisms of injury during SD
A. The role of glutamate
As discussed above, decades of work have made a clear connection between glutamate and the
induction of neuronal injury. In early work the ~ 8-fold increase in extracellular glutamate
measured within ~ 10 minutes of global anemia (Benveniste et al., 1984) could be due to
glutamate release during SD. Indeed, studies using micro-dialysis to measure interstitial
glutamate levels found that it was not increased immediately after cardiac arrest in rats and did
not increase until the onset of SD (confirmed by the presence of the DC shift) ~10 minutes
after CBF arrest (Fabricius et al., 1993). Recently, it was demonstrated that upon occlusion of
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the middle cerebral artery (MCA) there was an immediate ~60% decrease in extracellular
glutamate that corresponded to the non-spreading loss of spontaneous cortical activity (i.e. >
0.5Hz range) (Hinzman et al., 2015). In that study, use of microelectrode glutamate arrays
again tied glutamate with SD onset in the core region of the stroke.

Synaptic release appears to be a significant contributor to extracellular glutamate accumulation
during SD and was demonstrated using the Zn2+-sensitive fluorescent reporter (FluoZin3)
(Carter et al., 2011). Zn2+ imaging enables indirect monitoring of vesicular transmitter release,
as the cation Zn2+ is co-packaged into glutamatergic presynaptic vesicles via the ZNT3
transporter (Cole et al., 1999). Utilizing FluoZin3 fluorescence as a surrogate read-out of
synaptic glutamate release (Qian and Noebels, 2005), studies in brain slices (using K+
microinjection for SD initiation) demonstrated that episodic glutamate release occurred only
in tight relationship to SD (Carter et al., 2011). Additionally, oxygen-glucose deprivation
(OGD) triggering of SD in this study showed fluorescence increases only upon onset of
electrochemical failure (DC shift). These studies provide further evidence that glutamate
increases only in synchrony with SD in the aftermath of stroke.

In order to intervene with glutamate-mediated toxicity in ischemic core region, therapies would
need to be preventative and/or administered almost must begin immediately after infarction in
order to protect neurons, an approach likely not suitable for the vast majority of ischemic stroke
patients. While this may suggest that indeed glutamate-mediated excitotoxicity is over by the
time a patient reaches the hospital, animal and human studies have shown that SDs can still
occur days after initial ictus. SDs could theoretically explain why clinical testing of glutamate-
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targeting drugs were unsuccessful—i.e. interventions were administered too late to prevent
initial injury in the core and stopped prior to secondary infarct maturation during the delayed
phase of increased SD incidence. Therefore, studies are still needed to identify cellular
mechanisms that can be targeted in order to limit excitotoxic consequences during SD in the
injured brain.

Subsequent microelectrode recordings strongly support the idea of time-locked glutamate
accumulation, strictly matching SD. Enzyme-coated microelectrodes had a much higher time
resolution than previous microdialysis methods and allowed clear demonstration of glutamate
kinetics during single SDs after focal ischemia. In addition to examining SD onset in the first
minutes of occlusion, spontaneous SDs igniting from penumbral regions of the MCA
watershed are also temporally locked with increases in glutamate signals; the duration of
which positively correlate to the duration of nearby recorded DC shifts (Hinzman et al., 2015).
Moreover, brain regions proximal to the occlusion site exhibited prolonged and/or terminal
SDs that were associated with long-lasting glutamate signals (>300 seconds). These studies
provide a compelling link between glutamate toxicity and SD in animal stroke models and
suggest that these periods of excitotoxicity may also be important contributors to injury in
human ischemic stroke.

There is evidence that increased glutamate levels persist during infarct maturation in acute
ischemic stroke patients. Using micro-dialysis to measure CSF glutamate content over 24-48
hours after infarct onset, Davalos and colleagues identified elevations of transmitter in patients
with progressing, but not stable, ischemic stroke (Dávalos et al., 1997). However, likely due
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to unsuccessful clinical trials at the time of this study (mentioned previously), this report also
acknowledged that the ischemic cascade could still be “fully triggered” at the time points
monitored (Dávalos et al., 1997). Glutamate elevations could have thus been interpreted as a
reflection of more severe-grade lesions; as such, interventions pursuing glutamate release in
progressing stroke patients were not well justified. However, since SDs have been detected in
most patients with progressing infarction (using subdural electrodes placed during
neurosurgical procedures), SD could theoretically underlie CSF glutamate increases from prior
studies. This suggests that discrete and infrequent periods of ongoing SD-mediated glutamate
excitotoxicity mediate delayed lesion development after stroke. Studies that examine
mechanisms of extracellular glutamate accumulation are thus necessary in order to reduce
deleterious consequences of SD and widen therapeutic opportunities after ischemic stroke.

B. The role of NMDARs and Ca2+
Neuronal ion gradients remain largely intact during normal physiological activity and thus
intracellular Ca2+ levels are maintained in the low nanomolar range. During SD, altered ion
channel conductance and increased permeability to Ca2+ can lead to marked decreases in
extracellular Ca2+ concentrations, measured using ion-sensitive electrodes, and is presumably
due to substantial influx into neurons (Somjen, 2001). This was confirmed in brain slice
preparations using single cell loading of a low-affinity organic indicator (Fura-6F) to estimate
intracellular Ca2+ load in hippocampal pyramidal neurons (Dietz et al., 2008). In this study, it
was estimated that intracellular Ca2+ concentrations can reach ~10 – 25µM in neurons during
SD (initiated by K+ microinjection) but do not cause injury in healthy brain slices. However,
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irrecoverable neuronal Ca2+ loading was observed during SD induced by OGD (Dietz et al.,
2008).

Follow-up studies demonstrated that NMDAR-mediated cation influx during the late-phase of
the DC shift was a main contributor to irrecoverable Ca2+ loading and acute injury during SD
in metabolically compromised neurons (induced by brief dialysis of neurotoxic sodium azide)
(Aiba and Shuttleworth, 2012). As described previously, the voltage-dependence of NMDARs
is conferred by Mg2+ block within the ion channel pore that reduces open channel probability
until the presence of coincident depolarization and glutamate (and co-agonist D-serine or
glycine) binding (Retchless et al., 2012). Massive postsynaptic depolarization combined with
significant increases in presynaptic glutamate release during SD thus produce the ideal
conditions for sustained opening of NMDARs (Aiba and Shuttleworth, 2012). This late
component of SD-mediated Ca2+ dysregulation is an important contributor to acute injury as
focal application of the competitive NMDAR antagonist APV can alleviate intracellular Ca2+
accumulation during SD and prevent acute indicators of neuronal injury (Aiba and
Shuttleworth, 2012). These studies highlight that targeting intracellular Ca2+ loading is a
potential neuroprotective strategy for limiting deleterious consequences of SD in metabolically
compromised brain.

1.5 Potential beneficial outcomes of SD
While this section focuses largely on adaptive mechanisms in the brain that have been shown
to reduce injury after stroke, it is important to note that SD has been implicated in not only
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protective preconditioning (described below) but many other processes that may be beneficial
to functional recovery after stroke (Dreier, 2011; Nakamura et al., 2010).

1.5.1 Concept of conditioning
A well-studied strategy for eliciting protection or tolerance against ischemia-induced damage
is the concept of conditioning. Conditioning refers to protective mechanisms that occur in
response to the application of a detrimental stimulus that is below the threshold of initiating
cell death (Shen et al., 2016; Zhao, 2009). There are many stimuli capable of inducing tolerance
including hypoxia, ischemia, anesthetics, inflammatory mediators, hypo- and hyperthermia,
sleep deprivation, and SD (Dirnagl et al., 2003; Pincherle et al., 2018; Shen et al., 2017).
Additionally, since cell death signaling cascades can be similar in many cell types tolerance
can be induced by one trigger and provide protection against other insults (i.e. cross-tolerance)
(Dirnagl et al., 2003). In general, there are two main types of conditioning: pre- and postconditioning. Preconditioning refers to tolerance mechanisms initiated prior to injurious
stimulation, while postconditioning can be induced up to two days after prior insult (Burda et
al., 2009; Zhao, 2009).

1.5.2 Preconditioning
Experiments on conditioning began in the 1950’s and largely focused on ischemia-reperfusion
injury in the heart (SEWELL et al., 1955). Early studies in dogs identified that brief ischemic
events protected the myocardium from subsequent prolonged ischemia (Murry et al., 2018),
thus generating the concept of protection induced by preconditioning. In these studies,
ischemic preconditioning was found to delay cell death after myocardial infarction and
increase the volume of salvageable tissue during reperfusion therapies (Meldrum, 1997; Murry
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et al., 2018). Over the course of the next few decades, extensive research into the cellular
mechanisms that confer protection to the heart led to clinical trials applying ischemic
preconditioning for myocardial protection prior to planned cardiac surgical procedures or in
adjunct with reperfusion therapies (Dirnagl et al., 2003; Iliodromitis et al., 2007; Thijssen et
al., 2016; Yellon and Dana, 2000).

Preconditioning in the brain was reported as early as 1964 in a report by Dahl and colleagues.
In that study, pre-exposure to anoxia enhanced survival times during subsequent prolonged
anoxia in rats (Dahl and Balfour, 1964). It was also noted that cerebral ATP concentrations
decreased slower while lactate production was enhanced in pre-exposed animals; leading to
the hypothesis that preconditioning altered cellular metabolism to protect against subsequent
hypoxic injury (Dahl and Balfour, 1964). Hypoxia-induced tolerance was also confirmed ex
vivo in rat hippocampal slices, where brief (~5 minute) exposure to hypoxic conditions delayed
the loss of evoked synaptic activity during subsequent hypoxic conditions (loss at ~16 min.
compared to ~13 min. in slices without preconditioning (Schurr et al., 1986). Subsequent work
identified that ischemic preconditioning corresponded to an increase in proteins involved in
cellular tolerance (i.e. heat shock proteins (HSP)) and was associated with reduced infarct sizes
in rats following MCAo (48 hours later) (Simon et al., 1993). This was further examined in
more depth by Stenzel-Poore et al. using combined in vivo and in vitro approaches to evaluate
the genomic response to cerebral ischemia using DNA oligonucleotide microarrays (StenzelPoore et al., 2003). Here, prior preconditioning “reprogrammed” cellular responses to
damaging ischemia, where instead of upregulating gens involved in immune responses and
apoptosis, there was a downregulation of genes that overall shifted cellular profiles towards
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dampened cellular activity.

For example, genes involved in energy utilization were

downregulated including those for ion-channel activity (e.g. voltage-gated potassium
channels) and proteins involved in glucose oxidation (aldo-keto reductase and alcohol
dehydrogenase enzymes), which could reflect reduced or more efficient cellular metabolism
(Dirnagl et al., 2003; Pincherle et al., 2018; Stenzel-Poore et al., 2003). These transcriptional
responses are similarly observed in hypoxia-tolerant species and reduce energy expenditure to
adapt to environments with limited oxygen availability (Dirnagl et al., 2003; Stenzel-Poore et
al., 2003).

In addition to the shift in metabolic profiles and inflammatory mediators, other cellular
responses have been identified following ischemic preconditioning including restorative
mechanisms (neurogenesis (Lee et al., 2007) and angiogenesis (Gustavsson et al., 2006),
reductions in excitatory transmission (van Rensburg et al., 2009), and adenosine (specifically
activation of A1 receptors) (Dirnagl et al., 2003; Heurteaux et al., 1995; Pincherle et al., 2018).

1.5.3 Postconditioning
There is evidence in humans that transient ischemic events (such as transient ischemic attacks,
TIA) are associated with reduced infarct size (Wang et al., 2017; Weih et al., 1999) and
morbidity (Esposito et al., 2015) after subsequent ischemic stroke, and further support the
concept of preconditioning. However, translation of preconditioning to clinical practice is
likely not feasible for the general population due to the unpredictable nature of stroke injury.
Recent studies have shown that tolerance can be induced after injury (i.e. postconditioning)
and may be important for neuroprotection in the days after ischemic stroke (Dirnagl et al.,
2003; Pincherle et al., 2018; Zhao, 2009). This was first noted in the heart after coronary artery
35

occlusion and reperfusion in experiments by Sewell et al. in 1955 (SEWELL et al., 1955) but
has gained interest over the past 20 years as a novel approach for reducing brain injury after
stroke (Vetrovoy et al., 2017; Zhao, 2009). In animal stroke models, postconditioning can
reduce infarct sizes following focal and global ischemia (Zhao, 2009) and can also reduce cell
death in vitro in the aftermath of OGD exposure (Pignataro et al., 2009). Additionally,
postconditioning is effective using different stimuli including intermittent reperfusion (during
transient occlusions), ischemia or hypoxia, or administration of neurotoxic agents (Zhao,
2009). While more studies are needed to examine mechanisms of endogenous protection
elicited by postconditioning, evidence thus far suggests that cellular responses are similar to
those induced via preconditioning.

1.5.4 The role of SD in conditioning
As mentioned above, preconditioning can be induced by a number of triggers, including SD.
This was first demonstrated by Kobayashi et al. in 1995 where application of KCl (2hrs;
resulting in ~10 SDs) reduced the number of dead cells in the ipsilateral cortex (versus saline
on the opposite hemisphere) during subsequent (24hrs. later) bilateral forebrain ischemia in
rats (Kobayashi et al., 1995). This protection was further confirmed following MCAO
induction 3 days after SD preconditioning and was related to increases in brain-derived
neurotrophic factor (BDNF) mRNA after repetitive SDs (2hrs. of KCl (~10 SDs) without
subsequent MCAO) (Matsushima et al., 1998). SD-induced BDNF upregulation was further
shown to be an important contributor to protection as heterozygous mice with reduced BDNF
levels had no benefit of SD preconditioning on infarct size after focal ischemia (Yanamoto et
al., 2004).
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Interestingly, SD alone (without exposure to subsequent ischemia) can also induce many
similar changes observed in response to ischemic preconditioning (described previously) and
include genetic reprogramming (Shen et al., 2017, 2016), neurogenesis (Urbach et al., 2016),
adenosine accumulation and A1R activation (Lindquist and Shuttleworth, 2012), specific
reductions in excitatory transmission (Sawant-Pokam et al., 2017), and upregulation of
inflammatory pathways (Eising et al., 2017). This begs the question as to whether protective
effects of ischemic preconditioning are actually due to SD induced by another stimulus (i.e.
oxygen and/or glucose deprivation); and further suggest that not every SD is detrimental and,
on the other hand, might actual promote recovery and repair mechanisms in the aftermath of
injury.

Issues arise when it comes to SD and postconditioning mechanisms after stroke. To my
knowledge there have been no studies examining SD postconditioning after stroke which may
largely stem from decades of research that clearly show that exogenous induction of SD in the
injured brain leads to stepwise infarct progression in animal stroke models (Busch et al., 1996).

On the other side of the coin, the stimuli employed during postconditioning studies) to induce
endogenous protection after stroke (e.g. ischemia or hypoxia) are also likely to initiate SD. For
example, subtle mismatches in neurovascular coupling (e.g. transient dips in tissue oxygen or
increased cortical activity) can ignite SD in penumbral zones after MCAO in mice and may
predispose the onset of SD in human stroke patients (von Bornstädt et al., 2015). Studies are
thus needed to determine if tolerance to injury requires SD or if subthreshold stimuli are
sufficient.
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From SD preconditioning studies and other previous work (Nedergaard and Hansen, 1988) it
is clear that SD is not always detrimental to brain tissue.

Even in the injured brain,

confirmation of SD (via ECoG recordings) does not reliably guarantee injury progression. In
the foundational study conducted by Dohmen and colleagues (described previously) it was
noted that high SD incidences did not necessarily indicate injury progression in all malignant
ischemic stroke patients (Dohmen et al., 2008). Illustrating this point, the authors highlight one
patient case where 40 DC shifts were detected in the ICU but there was no corresponding
infarct growth detected in CT scans taken 4 months post stroke. Additionally, this patient
exhibited one of the better prognoses according to the extend Glasgow Outcome (eGOS) scale
at 6 months. On the other hand, another patient with 14 SDs exhibited progressively worse
ECoG recovery with each event that translated to lesion progression during CT follow-up
approximately one week later. While real caveats exist with regards to initial infarct severity,
age, location of the ECoG strip, etc., it remains unclear whether all SDs contribute to poor
outcomes after stroke, and importantly, whether pharmacologically blocking SDs will prevent
any possible neuroprotective benefits.

1.6 Rationale for targeting SD consequences
Prospective clinical studies are needed to demonstrate better patient prognoses when SD is
blocked. This poses a challenge as there are many obstacles which technical issues for
monitoring SD in humans; which is currently restricted to ECoG strips placed directly on the
brain during essential surgical procedures and thus limits studies to severely injured patients
that may not benefit from interventions). Moreover, ECoG recordings only provide
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information from tissue in the electrode proximity and elimination of SD from one recording
site may detect other SDs at different locations.

Accumulating evidence that recognizes potential benefits of SD make navigating the clinical
setting even more challenging and thus alternative approaches are needed that limit damaging
consequences of SD without preventing theoretical benefits of propagation into remote brain
regions. In 2012, the COSBID group published large retrospective study that explored the
effect of SD incidence with respect to the analgesics and sedatives administered to brain
injured patients in the ICU (Hertle et al., 2012). Out of 6 medications, the only drug found to
significantly reduce the odds ratio for SD occurrence was ketamine. Ketamine is a dissociative
anesthetic that antagonizes NMDARs and has been previously shown to inhibit SD in animal
models (Hernándéz-Cáceres et al., 1987; Marrannes et al., 1988; Sánchez-Porras et al., 2014)
and in case reports (Sakowitz et al., 2009; Schiefecker et al., 2015) and more recently in a
crossover prospective study in brain injured patients (Carlson et al., 2018).

The high doses of ketamine that are required to block SD are likely well above those that
prevent normal synaptic activation of NMDARs (Pietrobon and Moskowitz, 2014). This is
further augmented in brain injury where pathological elevations in extracellular K+ have been
shown to reduce efficacy of NMDAR blockade of SD (Petzold et al., 2005). Therefore, in
addition to not preventing any benefits of SD in remote brain regions, high dose ketamine may
further augment tissue injury after ischemia (as seen with previous NMDAR antagonists) by
preventing cell-survival cascades that depend on NMDAR activity. Whether ketamine can
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limit excitotoxic consequences of SD in vulnerable brain regions, without preventing remote
propagation, is unknown.

1.7 Goals of this study
This dissertation work examines mechanisms of neuronal injury associated with SD in brain
slices and in vivo after stroke.

The overall hypothesis is that extracellular glutamate

accumulation and NMDAR-mediated Ca2+ influx underlie neuronal injury processes in
vulnerable tissue after passage of the SD wave front. Therefore, the degree of basal tissue
metabolic compromise increases deleterious consequences of SD and thus determines whether
neurons will recover (Figure 1.1). Specifically, these key excitotoxic mediators of injury
(extracellular glutamate and intracellular neuronal Ca2+ loading via NMDARs) are expected to
be prolonged when neurons have impaired metabolism prior to SD. An additional goal of this
project is to test ketamine’s efficacy in reducing excitotoxic consequences, as opposed to
outright block, of SD. Completion of these studies will provide the first evidence that limiting
deleterious consequences of SD can be achieved using lower concentrations/doses of NMDAR
antagonists like ketamine. These findings could theoretically benefit ICU clinicians with
regards to intervention or sedation decision-making in patients at-risk for SDs and secondary
lesion progression.
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Figure 1.1

1.7.1 General experimental models
In the course of this work, a novel brain slice model was developed, which may better
recapitulate consequences of SD in penumbral brain regions, as opposed to current methods
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that rely on OGD. This model was then further characterized and used to answer questions
regarding how otherwise viable neurons may succumb to SD injury. After characterization in
brain slices, final studies evaluated SD-mediated excitotoxicity in vivo after dMCAo, and these
experiments included tests of whether the protective effects of ketamine seen in brain slices
were seen in penumbral brain regions in vivo while still enabling SD propagation in remote
locations.

1.7.2 Chapter 2: Does ketamine work to limit deleterious consequences in brain slices without
blocking SD?
In Chapter 2, experiments were designed to test the hypothesis that deleterious effects of SD
could be limited using concentrations of ketamine that do not prevent SD outright. A novel
brain slice model of metabolic compromise, electrophysiology, and imaging of neuronal Ca2+
loading were techniques utilized to study consequences of SD that occur in vulnerable neurons.
This model, referred to as a “vulnerable” recording conditions, was employed to more closely
examine processes in the wake of SD that promote the transition from viable to injured (or
impaired) neurons.

1.7.3 Chapter 3: Do brain slice models of stroke (OGD or hypoxia) adequately recapitulate SD
consequences that are observed in vulnerable brain regions? What factors increase SD
vulnerability?
The main goal of Chapter 3 studies was to examine in more detail the brain slice model of
compromise employed in studies from Chapter 2. The overall hypothesis of this study is that
vulnerable brain slices are mildly impaired at baseline prior to SD, but the additional hit of a
more metabolically burdensome SD is what causes neuronal demise.
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Experiments evaluated basal metabolic capacity of vulnerable brain slices using
electrophysiologically, oxygen measurements, and imaging read-outs. In addition to these
techniques, extracellular glutamate fluorescence imaging during SD was used to test the
hypothesis that neurons are exposed to excitotoxic levels of glutamate for prolonged durations
in vulnerable conditions—which suggests an increased burden of the SD.

Additional

techniques including immunohistochemistry and intrinsic optical imaging (IOS) were also
employed to evaluate structural changes that occur after SD in vulnerable conditions.

1.7.4 Chapter 4: Are low doses of ketamine effective at reducing excitotoxic consequences of
SD in vivo after stroke?
The main objective of Chapter 4 was to test mechanisms of SD-mediated consequences in vivo
after stroke in mice. Experiments tested the hypothesis that a low dose of ketamine, without
blocking SD, could limit deleterious effects of SD— especially in penumbral brain regions that
have been thought to gain the least protection from NMDAR antagonist administration.

Initial methods used in this chapter will employ electrophysiology (for monitoring of DC shifts
and spontaneous cortical activity (ECoG)) and laser speckle contrast imaging (LSCI)
monitoring of cerebral blood flow after surgical induction of a dMCAo. Follow-up studies
will utilize fluorescence imaging techniques of Ca2+ and glutamate during SD. The overall
hypothesis for this study brain regions more proximal to the occlusion site (i.e. penumbra) is
vulnerable to injury due to increased excitotoxic burden of SD and ketamine can reduce these
damaging consequences.
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2.1 Abstract
Recent work has implicated spreading depolarization (SD) as a key contributor the progression
of acute brain injuries, however development of interventions selectively targeting SDs has
lagged behind. Initial clinical intervention efforts have focused on observations that relatively
high doses of the sedative agent ketamine can completely suppress SD. However blocking
propagation of SD could theoretically prevent beneficial effects of SD in surrounding brain
regions. Selective targeting of deleterious consequences of SD (rather than abolition) could
be a useful adjunct approach, and be achieved with lower ketamine concentrations. We utilized
a brain slice model to test whether deleterious consequences of SD could be prevented by
ketamine, using concentrations that did not prevent the initiation and propagation of SD.
Studies were conducted using murine brain slices, with focal KCl as an SD stimulus.
Consequences of SD were assessed with electrophysiological and imaging measures of ionic
and synaptic recovery. Under control conditions, ketamine (up to 30µM) did not prevent SD,
but significantly reduced the duration of neuronal Ca2+ loading, and the duration of associated
extracellular potential shifts. Recovery of postsynaptic potentials after SD, was also
significantly accelerated. When SD was evoked on a background of mild metabolic
compromise, neuronal recovery was substantially impaired. Under compromised conditions,
the same concentrations of ketamine reduced ionic and metabolic loading during SD, sufficient
to preserve function after repetitive SDs. These results suggest that low concentrations of
ketamine could be utilized to prevent damaging consequences of SD, while not blocking them
outright and preserving potentially protective effects of SD.
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2.2 Introduction
Spreading depolarization (SD) is a slowly propagating wave (2- 4 mm min-1) of near-complete
neuronal and glial depolarization that has gained renewed interest as an important contributor
to the progression of acute brain injuries (Lauritzen et al., 2011, Dreier et al., 2017, Hartings
et al., 2017). SD can be initiated by stimuli that cause synchronous depolarization of a critical
volume of brain tissue (Tang et al., 2014), and SD propagation across the brain is propelled by
feed-forward release of glutamate and/or K+ (Somjen, 2001). In injured brain, the initiating
depolarization is caused by ischemia, trauma, or other energetic supply-demand mismatches
(von Bornstadt et al., 2015). The extent of ionic loading accompanying SD is extreme, with
intracellular Ca2+ loads continuously exceeding 10s of micromolar for more than a minute
(Somjen, 2001, Dietz et al., 2008). As such, the metabolic costs to recover from SD are much
more demanding than other brain phenomena, such as seizures (Dreier et al., 2013), and thus
are particularly challenging for the injured brain (Hartings et al., 2017).

Whether or not injury occurs after SD depends greatly on the capacity of tissues to re-establish
ionic gradients in the aftermath of SD. This capacity is governed by the degree of ionic loading
during SDs, the baseline metabolic capacity, and the ability of a region to profoundly increase
blood flow to match energy demands after SD (Dreier, 2011). This is exemplified during SD
in the healthy brain (e.g. migraine aura), where metabolic and vascular perfusion reserves are
adequate, and thus SD does not result in any permanent damage (Nedergaard and Hansen,
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1988). In contrast, SDs that spontaneously occur following stroke (Dohmen et al., 2008),
trauma (Hartings et al., 2011), or subarachnoid hemorrhage (Dreier et al., 2009) can underlie
stepwise progression of injury (Busch et al., 1996, Hartings et al., 2003, Hartings et al., 2017).

The development of clinical interventions for SD has lagged behind efforts to demonstrate
their incidence in different pathologic conditions. Initial efforts have concentrated on the
application of agents such as NMDA receptor (NMDAR) antagonists that block the initiation
and propagation of SD. The dissociative anesthetic ketamine is an NMDAR antagonist that
prevents SD in animal models (Hernandez-Caceres et al., 1987, Marrannes et al., 1988) and
shows effectiveness in case reports (Sakowitz et al., 2009, Schiefecker et al., 2015). A
retrospective review of medications used in the intensive care unit (ICU) also shows that
ketamine infusion can reduce the frequency of SDs in brain injured patients (Hertle et al.,
2012). Prospective studies of ketamine would be useful to determine whether a reduction in
SD frequency is associated with improved outcomes in the clinic. However, such studies are
complicated by two potential problems. First, the high ketamine concentrations used to
suppress SD also result in substantial sedation with attendant increases in risk of ICU
complications (Abou-Chebl et al., 2010, Nichols et al., 2010). Secondly, SDs propagate widely
in injured brain, including through tissue that may be distant from an injury core where intact
metabolic capacity is retained. It is possible that SDs invading these distant regions cause
protective preconditioning (Yanamoto et al., 2004, Viggiano et al., 2016), adaptive synaptic
plasticity (Faraguna et al., 2010), and/or neurogenesis (Urbach et al., 2017) that may be
beneficial to functional recovery (Nakamura et al., 2010, Dreier, 2011) These theoretical
issues require further study, but suggest that different approaches to selectively target the
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deleterious consequences of SD could be a useful adjunct to the current focus on global block
of SD events.

We tested here whether deleterious effects of SD could be limited by lower concentrations of
ketamine that do not prevent SD outright. Our findings with measurements of Ca2+ loading
and a model of metabolic vulnerability indicate that ketamine can be protective without
blocking SD, and support a possible significant modification of therapeutic strategies for SD,
based on blocking consequences of SD rather than incidence.

2.3 Materials and Methods
2.3.1. Animals and Preparations
All animal procedures were performed in accordance with protocols approved by the UNM
Health Sciences Center Institutional Animal Care and Use Committee. Adult (4-8 weeks) male
and female mice (C57Bl/6 and/or GCaMP5G) were used for all experiments. For Ca2+ imaging
experiments, homozygous mice expressing the floxxed calcium indicator GCaMP5G under the
CAG promoter (Gee et al., 2014) were purchased from The Jackson Laboratory (Stock No:
024477, B6;129S6-Polr2atm1(CAG-GCaMP5g,-tdTomato)Tvrd/J), and bred with homozygous mice
expressing Cre Recombinase under the CamK2a promoter (B6.Cg-Tg(Camk2a-cre)T291Stl/J, Jax Stock No: 005359). Offspring were utilized in experiments and had robust
GCaMP5G expression in hippocampal pyramidal neurons (Wang et al., 2013).

Acute brain slices were prepared as previously described (Shuttleworth et al., 2003). Briefly,
animals were deeply anaesthetized with 0.15mL (s.c.) injection of ketamine-xylazine (85 and
15 mg ml-1, respectively), decapitated, and brains were quickly removed into 150 mL
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oxygenated ice-cold cutting solution (in mM): sucrose, 220; NaHCO3, 26; KCl, 3; NaH2PO4,
1.5; MgSO4, 6; glucose, 10; CaCl2 0.2; equilibrated with 95% O2/5% CO2 supplemented with
0.2 ml ketamine (100 mg/ml, Putney Inc., Portland, ME), to limit excitotoxicity during the
slice preparation as described in (Aitken et al., 1995). Coronal cortico-hippocampal slices (350
µm) were prepared with a Pelco 102 Vibratome (Ted Pella, Inc., Redding, CA), hemisected,
and then allowed to recover in artificial cerebrospinal fluid (aCSF; containing (in mM): NaCl,
126; NaHCO3, 26; glucose, 10; KCl, 3; CaCl2, 2, NaH2PO4, 1.5; MgSO4, 1; equilibrated with
95% O2/ 5% CO2), at 35°C for 60 min. After 1h, the holding aCSF was replaced with chilled
(20°C) aCSF and slices were allowed to equilibrate to room temperature until the start of
recording sessions. These incubations and exchanges served to ensure effective wash out of
residual ketamine from slices, as previously established with responsiveness to glutamate and
NMDA (Shuttleworth et al., 2003, Hoskison and Shuttleworth, 2006, Vander Jagt et al., 2008).

2.3.2 Generation of SD
Individual brain slices were transferred to a submersion recording chamber with nylon slice
supports (RC-27L, Warner Instruments, Hamden, CT), and continuously super fused with
oxygenated (95% O2/95% CO2) aCSF at 2.2 ml min-1. Bath temperature was maintained at
32°C by an inline heater assembly (TC-344B, Warner Instruments).

After placement of

electrodes into the slice (See Electrophysiology methods) slices were allowed 20 minutes for
equilibration. As described below (Results), modified aCSF with elevated K+ (8mM) was used
for most experiments, in order to increase ability of single slices to support repetitive SDs and
enable rigorous testing of drug effects (Funke et al., 2009, Zhang et al., 2015).

SDs were

evoked by pressure microinjection (40ms, 30 psi; Picospritzer; Parker Hannifin, OH, USA) of
KCl (1M) via a glass micropipette ~3 MΩ) placed in hippocampal CA1 stratum radiatum.
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Repetitive SDs were initiated in each slice at 15 minute intervals to allow for full recovery
between events. In experiments assessing the effect of ketamine antagonism during repetitive
SDs (Figures 2.2-4 & Supplementary Figures), antagonist wash-in commenced following the
second of two control SDs, and the second control SD was used for analyses (Footitt and
Newberry, 1998). SD initiation and propagation, as well as slice viability (see Metabolic
Challenge below), were examined by monitoring intrinsic optical signals (IOS) of submerged
brain slices trans-illuminated with visible light (≥ 600nm) and collected using a 4X objective
(Olympus, 0.10 NA). IOS data were captured at 0.5 Hz using a cooled CCD camera (Imago,
Till Photonics) and analyzed with TillVision software (TillPhotonics, version 4.01). Data
analysis involved normalizing transmitted light to baseline and expressing IOS as percent
change in transmission (∆T/T0 × 100) (Anderson and Andrew, 2002).

2.3.3 Electrophysiology
Extracellular recordings were acquired (1-10kHz) with an Axon MultiClamp 700A amplifier,
digitized (Digidata 1332), and recorded using pCLAMP10.2 software (Molecular Devices,
Sunnyvale, CA, USA). Glass recording microelectrodes were filled with aCSF (tip resistance
~3MΩ) and positioned at a depth of 50–100 µm in the CA1 stratum radiatum ≥200 µm from
the KCl-filled glass ejection micropipettes. The durations of SDs were calculated from the
extracellular potential shift (“DC shift” (Somjen, 2001)), measured at 20% of the peak
maximum to 80% recovery. In experiments assessing synaptic recovery after SD, a concentric
bipolar electrode (FHC, Bowdoin, ME, USA) was placed on the slice surface ofCA1 stratum
radiatum, between the KCl ejection micropipette and recording electrode, for stimulation of
Schaffer collateral inputs. Excitatory postsynaptic potentials (EPSPs) were recorded using test
pulses (50 µs, 0.1Hz) delivered at intensities (80 – 400 µA) that gave 40 - 60% of the maximum
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EPSP amplitude. DC shifts and EPSPs were analyzed using Clampfit 10.2 software (Molecular
Devices, Sunnyvale, CA, USA).

Postsynaptic potentials were resolved from gap-free

recordings with a high-pass filter (1 Hz cut-off). The duration of EPSP suppression after a
single SD was measured from the time of the maximum negative potential of the DC shift to
the time at which postsynaptic potentials first reached ≥ 50% of baseline values.

2.3.4 Fluorescence Imaging
Neuronal Ca2+ dynamics during SD reported by GCaMP5G were imaged with a 20X waterimmersion objective (Olympus, 0.5 NA) and analyzed in TillPhotonics, version 4.01 software
(Till Photonics GmBH, NY). GCaMP5G was excited at 480nm using a monochromator
(Polychrome V, 2Hz); emission signals were passed through a dichroic mirror (515 DCLP)
and captured using a cooled CCD camera (Imago, Till Photonics). Total Ca2+ accumulation in
specific regions of interest during SD were calculated (GraphPad Prism 7.03) as the integral
of the signals for 120 seconds or 200s following the peak of the SD transient. The duration of
Ca2+ during SD was measured from the initial positive peak amplitude to the time point where
fluorescence returned to ≤ 5% of baseline levels.

Autofluorescence signals during SD that could contaminate Ca2+ signals were evaluated in
wild-type brain slices not expressing GCaMP5G. A small, but long-lasting (>200s)
fluorescence decrease was observed, as described previously and attributed to flavoprotein
autofluorescence (Shuttleworth, 2010). Autofluorescence decreases were similar in both
somatic and dendritic compartments (-3.0 ± 0.9 and -2.3 ± 0.9 ∆F/F0 (%) decrease at 160s after
SD for stratum pyramidale and stratum radiatum, respectively; n=3, Supplementary Figure
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2.2B). Ca2+ signals were therefore corrected for background and autofluorescence changes
during SD, and expressed as percent change from baseline values (∆F/F0 × 100).

2.3.5. Metabolic challenge
Under control conditions, slices are normally held 0.5mm above the coverslip floor of the
recording chamber to ensure continuous flow of aCSF on both sides of the slice. This is
considered a nominally-healthy condition for the current study (see discussion in Frenguelli,
2017). However, in some experiments, we reduced aCSF flow to the bottom side of the slice,
in order to intentionally reduce metabolic capacity and increase vulnerability to SD. This was
accomplished by inverting the slice support insert (SS-3, Warner Instruments), to remove the
flow channel under the slice. As opposed to complete oxygen-glucose deprivation, this partial
metabolic compromise did not spontaneously initiate SD in any preparation (n = 44). Slice
recovery after SD was evaluated from 1) intrinsic optical signals (Anderson and Andrew, 2002)
2) the ability of the tissue to generate a second SD (Koroleva and Bures, 1996) and 3)
electrophysiologically with evoked extracellular postsynaptic potentials (Lindquist and
Shuttleworth, 2012).

2.3.6 Drugs
Ketamine (100 mg/ml, racemic: R (-)/S (+)) was purchased from Putney, Inc. (Portland, ME),
and solutions containing ketamine were prepared daily. All other chemicals were obtained
from Sigma-Aldrich (St. Louis, MO, USA).

2.3.7 Statistical analysis
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Data are reported as mean ± SEM. Statistical analyses (repeated measure one-way analysis of
variance (ANOVA), paired and unpaired t-tests) were calculated using GraphPad Prism
(version 7.03; La Jolla, CA). Statistical significance was determined by P values < 0.05, with
Bonferroni correction during multiple comparisons.
Figure 2.1

Figure 1. Basal extracellular K+ influences sensitivity to ketamine.
A: Representative intrinsic optical signals showing SD propagation
through the hippocampal CA1 region of a brain slice. SD was triggered
by micro injection of KCl from a micropipette on the left (labeled “KCl”)
and SD is visualized as a slowly-propagating wave of increased light
transmission. The location of the advancing wavefront is marked by
white arrowheads and a second microelectrode (labeled “DC”) was
used to confirm electrical responses of SD coincident with arrival of the
optical signal (not shown). The upper right-hand values indicate time,
in seconds, relative to the triggering of the KCl stimulus pulse. B: Effect
of ketamine exposures on SD incidence under two different recording
conditions (3mM vs 8mM bathing K+). Ketamine more potently prevented SD incidence in the lower basal K+ recording conditions. Values in
parentheses indicate number of preparations.
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2.4 Results
2.4.1 Ketamine can reduce rate and duration of SD
We first examined the concentration-dependence of ketamine block of SD in brain slices
(Figure 2.1). Under standard recording conditions (3mM K+ aCSF, see Methods), 100µ
M ketamine invariably abolished SD. Consistent with previous observations using other
NMDAR antagonists, the effectiveness of SD block was reduced by moderate elevations of
baseline extracellular K+ that are similar to elevations in peri-infarct tissues in vivo (Petzold et
al., 2005). From these initial experiments, we selected the highest concentration of ketamine
that did not block SD for subsequent studies (30µM, 8mM K+ aCSF).

Figure 2.2 shows the time-dependent inhibition of SD propagation rate by ketamine. In these
experiments, ketamine (10 minutes pre-exposure, and maintained throughout the experiment)
immediately slowed SD propagation rate compared to that of control SDs initiated within the
same slice, but the maximum effect was observed by the second SD following drug exposure
(Figure 2.2B). In a separate set of experiments, brain slices were pre-exposed to ketamine for
extended incubation times (> 3hrs) prior to recording sessions. In these preparations, the
maximal slowing was achieved on the first SD trial in ketamine (3.4 ± 0.2 vs. 5.1 ± 0.3 mm
min-1 for the first SD in ketamine during acute exposures (shown in Figure 2.2B)) and was not
enhanced with successive stimulations (Supplementary Figure 2.1A; P = 0.27 for first vs.
third SD in ketamine
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Figure 2.2

Figure 2. Ketamine reduced SD propagation rate and DC shift duration.
A: Representative example of the effect of ketamine wash-in, during a series
of repetitive SDs. Top panels show intrinsic optical signal changes to track SD
propagation (as described in Figure 1) in control conditions (left), and during
the third SD evoked in the presence of 30µM ketamine (right). Note the
delayed propagation of the SD wavefront in ketamine. The traces show DC
potential recordings during this sequence of SDs in the same slice. Black
arrowheads indicate DC shift onset, and dashed lines represent 15 minutes
recovery between stimulations. The duration of the DC shift of SD was
progressively reduced, and then largely recovered after ketamine washout. B:
Summary data from 6 preparations as shown in A (white symbols), demonstrating progressive decreases in both propagation rate and DC duration with
partial recovery upon ketamine wash out (gray bar, n=3). Black symbols (n=3)
represent DC shift data and propagation rate from separate experiments
shown in Figure 4. *P<.05, **P<0.01, ***P<0.001, **** P<0.0001.

When recorded in the CA1 dendritic subfield, DC potential changes during SD have a
prominent “inverted saddle-like” shape with a slower secondary phase involving NMDAR
activation (Marrannes et al., 1988, Somjen, 2001, Aiba and Shuttleworth, 2012). SD duration
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was progressively reduced following acute ketamine exposures and reversed following wash
out (Figure 2.2). Similar to effects on propagation rate, DC durations following long ketamine
pre-exposures (> 3hrs, Supplementary Figure 2.1A), were maximally reduced upon the first
SD trial (27.1 ± 2.2 vs. 41.2 ± 3.0s for the first SD in ketamine during acute exposures (shown
in Figure 2.2B)), and were not enhanced by successive SDs in ketamine (Supplementary Figure
2.1A; P = 0.51 for first vs. third SD in ketamine).

Separate time-matched control studies verified that effects seen with ketamine on DC shift
duration were not due to spontaneous rundown over time (Supplementary Figure 2.1B).
Similarly, propagation rate showed no change during repetitive SDs in these control studies
(Supplementary Figure 2.1B). A small decrease (~13%) in the amplitude of DC potential shifts
was noted during repetitive SDs in ketamine (data not shown, control: 8.85 ± 0.43 mV vs. third
ketamine trial: 7.71 ± 0.33 mV, n=6, P=0.02). However, time-matched control experiments
(i.e. without ketamine) showed the same degree of run down, implying that this was not due to
ketamine itself (data not shown, ~13% decrease; durations of second vs. fifth SD: 7.65 ± 0.78
mV vs. 6.37 ± 0.70 mV, P=0.01, n=8).

2.4.2 Ketamine reduces neuronal Ca2+ accumulation and accelerates postsynaptic recovery
Ionic disruption is massive during SD, and NMDAR activation is largely responsible for
extended neuronal Ca2+ influx during the DC shift (See Introduction). We next tested whether
ketamine reduced neuronal Ca2+ accumulation following SD (Figure 2.3). Since the maximum
effect of ketamine was observed with successive SD stimulations, the 3rd SD following
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Figure 2.3

Figure 3. Ketamine reduces neuronal intracellular Ca 2+ accumulation during SD.
A: Top left panel: Transmitted light image, showing stratum oriens (so), stratum pyramidale (sp),
stratum radiatum (sr) in area CA1. Pseudo colored images show GCaMP5G fluorescence collected
during SD in control conditions. Numbers in each frame indicate time (in seconds) in relation to the
peak Ca2+ transient in regions of interest corresponding predominately to pyramidal cell somata
(ROIs) and CA1 dendritic regions (ROId). Scale bar = 100μm. B: Data extracted from ROIs and ROId
show that Ca2+ transients during SD in ketamine (blue) recover faster than control (black), and are
reversible after ketamine wash out (dashed). Gray traces in each plot represent autofluorescence
(AF) decreases in somata and dendrite regions during SD in a brain slice not expressing GCaMP5G.
Black arrowheads indicate SD onset. C: Summary data (n=5), show that ketamine reversibly and
reliably reduces total neuronal Ca2+ accumulation in both ROIs (integrals of 120s transients; see
Methods). *P<.05, **P<0.01, ***P<0.001.

ketamine was used for experiments in Figures 2.3 & 2.4. Figure 2.3A shows large intracellular
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neuronal Ca2+ (GCaMP5G) transients during a control SD. Ca2+ rapidly increases during the

SD wave front and returns to ≤5% baseline levels by ~2.5 minutes (Figure 2.3B). Ca2+
transients in pyramidal cell body regions (stratum pyramidale) had increased peak amplitudes
compared to signals in dendrites (stratum radiatum), however Ca2+ elevations in dendrites were
slightly longer in duration (Supplementary Figure 2.2A). This resulted in an overall increase
in total Ca2+ accumulation during control SDs in dendrites compared to cell bodies (black bars
in Figure 2.3C, P=0.04) Ketamine reduced the peak amplitude and duration of Ca2+ transients
(Supplementary Figure 2.2A). The rapid resolution of SD-induced Ca2+ transients in ketamine
(Figure 2.3B) reveals a small, reversible underlying fluorescence decrease. Since these signals
have been corrected for autofluorescence dynamics during SD (see Methods), residual
undershoots revealed in ketamine are likely contributed to by light scattering changes during
SD.

Ketamine attenuated total Ca2+ accumulation during SD in stratum pyramidale and

radiatum (Figure 2.3 B&C). These data support the hypothesis that ketamine reduces the DC
shift duration during SD, and thereby results in reduced intracellular Ca2+ dysregulation in
neurons.

One consequence of SD is a long-lasting suppression of spontaneous and evoked synaptic
transmission (Leao, 1944, Lindquist and Shuttleworth, 2012, 2017). We therefore determined
whether shorter DC shifts and reduced neuronal Ca2+ dysregulation in ketamine were
associated with accelerated synaptic recovery after SD. Figure 2.4 shows that ketamine
reliably accelerated the recovery of evoked excitatory postsynaptic potentials (EPSPs) by
~25% compared to within-slice controls. Separate time-matched control experiments
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confirmed that changes in EPSP recovery time were due to antagonist exposure, rather than
any other spontaneous changes. Together with Figures 2.2 & 2.3, these data suggest that
(without blocking SD), ketamine can reduce SD propagation, duration, and ionic dysregulation
thus enabling faster recovery of synaptic activity.

2.4.3 Ketamine improves recovery in metabolically vulnerable brain slices
We next examined whether ketamine, at a concentration that does not block the initiation or
propagation of SD (i.e. 30µM), can significantly protect against deleterious consequences of
Figure 2.4

Figure 4. Ketamine accelerates recovery
of evoked postsynaptic potentials after
SD.
A: Representative example of suppression
and recovery of evoked excitatory postsynaptic potentials (EPSPs) after SD. Control
EPSPs (a) were abolished after SD (b,c), and
slowly recovered to baseline amplitudes after
~12 min (d). The asterisk above control (a)
trace indicates the bipolar stimulus artifact.
The full time course of EPSP suppression
and recovery in this same slice is plotted
below (filled circles). SD onset indicated by
black arrowhead. Ketamine (30µM) did not
prevent EPSP suppression, but significantly
accelerated recovery rate (lower set of traces,
and empty circles in plot). B: Summary data
from 6 such experiments. The effect of
ketamine on DC shift duration in this data set
was consistent with prior observations in
Figure 2 (45.9 ± 2.3 vs. 35.7 ± 1.1 s for control
and ketamine, respectively; P = 0.0026). ***
P<0.001
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SD in metabolically vulnerable brain slices. As described above (Methods), partial reduction
in metabolic substrate availability was achieved by restriction of aCSF flow under brain slices.
As opposed to complete oxygen-glucose deprivation approaches, this partial metabolic
compromise did not spontaneously initiate SD in any preparation tested (n = 44), but greatly
impaired recovery after SD.

Figure 2.5 shows ketamine reduced excessive Ca2+ loading in vulnerable tissues, and was
associated with significantly improved functional recovery. SD-induced Ca2+ transients were
noticeably prolonged in vulnerable tissues, consistent with previous observations (Aiba and
Shuttleworth, 2012), with residual intracellular Ca2+ remaining ~20-30% above baseline ~3.5
minutes after SD (Supplementary Figure 2.2C). Ketamine pre-exposure significantly reduced
the integral of Ca2+ transients in both somatic and dendritic compartments (Figure 2.5B), and
enabled generation of a second SD in vulnerable slices (Figure 2.5C).

Likewise, recovery of

EPSPs was substantially delayed after SD in vulnerable tissues, and ketamine enabled EPSPs
to return to ~60% of baseline amplitude responses after SD (Figure 2.5D).
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Figure 2.5

Figure 5. Ketamine improves recovery of neuronal Ca2+ loading and promotes functional
recovery after SD in vulnerable brain slices. A: Top montage: GCaMP5G imaging in vulnerable
brain slices show considerably prolonged Ca2+ elevations compared to control conditions (compare
with Figure 4). Lower montage shows reduced intracellular Ca2+ 120s after SD in ketamine.Scale bar
=100μm. B: Plots show Ca2+ transients from somatic and dendritic ROIs (white circles in A) during SD
in control (black), vulnerable (red), and vulnerable + ketamine (dashed). Summary data of Ca2+ transient integrals from a set of such experiments confirm beneficial effects of ketamine (control, n=9;
vulnerable, n=6; vulnerable + ketamine, n=6).C: Data from experiments in B, showing vulnerable
slices exposed to ketamine recovered the ability to generate a second SD. Values in parentheses
indicate number of preparations. D: Summary data of EPSP amplitude suppression and recovery
after SD in control (black, n=5), vulnerable (red, n=10), and vulnerable with ketamine (white, n=9).
Black arrowhead indicates SD onset and loss of postsynaptic responses. **P<0.01,***P<0.001,
****P<0.0001.
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Figure 2.6

Figure 6. Ketamine protects against structural disruption after SD in vulnerable slices.
A: Left hand panel shows the arrangement of recording electrodes on a transmitted light
image. The white box outlines the imaging area shown in panels on the right; so, stratum
oriens; sp, stratum pyramidale; sr, stratum radiatum; LM, stratum lacunosum moleculare; M,
molecular layer of dentate gyrus. The set of images on the right show representative light
transmittance (intrinsic optical) changes at baseline, during SD, and 10 minutes after SD in
brain slices recorded under three different conditions; control, vulnerable, and vulnerable +
ketamine. Note the difference in light transmission seen at the 10-minute time point after SD.
White arrowheads indicate the wave front of SD. Scale bar = 250 μm. B: Signals extracted
from the three representative examples shown in A (traces on left), and summary data (n= 6-7,
right hand panel) at 10 minutes after SD in these studies. These population data confirm substantially decreased light transmittance after SD vulnerable slices, and prevention by ketamine.
****P<0.0001.

Figure 2.6 shows the effects of metabolic compromise on intrinsic optical signals (IOS) during
SD, and optical signals associated with ketamine protection. Under control conditions, a
prominent light transmission increase is observed that recovers towards baseline. In contrast,
SD in metabolically compromised conditions was invariably followed by a sustained decrease
in IOS signals (~45% ∆T/T0; Figure 2.6A&B). Previous reports have attributed IOS decreases
in metabolically compromised conditions to a combination of factors, including dendritic

62

disruption and swelling of intracellular organelles (Obeidat and Andrew, 1998, Fayuk et al.,
2002), and persistent astrocyte swelling observed in vulnerable tissues could also contribute
(Risher et al., 2012). In the present study, ketamine effectively prevented decreased IOS
signals associated with lack of functional recovery in vulnerable slices (see Figure 2.5). Thus,
prolonged IOS decreases were prevented in almost all vulnerable preparations (Figure 2.6B).
Together these findings support a role for extended NMDAR-dependent Ca2+ influx into
neurons during SD in vulnerable tissues (Aiba and Shuttleworth, 2012), and suggest that submaximal concentrations of NMDAR antagonists can target this process to enable better
functional recovery.

2.5 Discussion
2.5.1 General
The main new finding of the study is the demonstration that ketamine can be protective against
SD-induced injury, even at concentrations that are insufficient to block the initiation or
propagation of the SD event itself. Ketamine was able to significantly improve recovery from
ionic loading of SD and was shown to be sufficient to protect tissues from SDs in a model of
metabolic vulnerability. These beneficial effects provide support for the notion that targeting
consequences of SD could be effective in injured brain, as an adjunct or alternative to
interventions intended to completely abolish SD events.

2.5.2 Mechanisms of ketamine actions
We focused on the NMDAR antagonist ketamine because of its current use in clinical settings
and because of reports that ketamine sedation in the ICU was associated with reduced
frequency of SD events (Sakowitz et al., 2009, Hertle et al., 2012, Schiefecker et al., 2015). In
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order to preserve NMDAR availability and potential beneficial outcomes of SD (see
Introduction), we determined concentrations of ketamine that kept SD intact in healthy brain
slices (Figure 2.1). Ketamine’s ability to block SD, even with high concentrations, was reduced
when basal extracellular K+ was moderately increased. As previously discussed (Petzold et al.,
2005), these K+ elevations may be similar to pathological ionic disturbances in peri-infarct
tissues in animals (Nedergaard and Hansen, 1993) and in brain injured patients (Rogers et al.,
2017). The ketamine concentration selected for most studies here (30µM, Figures 2.2-6)
allowed for repetitive SD initiation, while presumably leaving a portion of NMDARs available
(Izumi and Zorumski, 2014, Khlestova et al., 2016). Since ketamine competes with Mg2+ for
binding within the NMDAR channel pore, NMDAR subtypes with weaker Mg2+ block (i.e.
GluN2C and GluN2D) are preferentially inhibited, whereas GluN2B and GluN2A-mediated
currents are less sensitive to ketamine (Khlestova et al., 2016). If GluN2B and GluN2A
NMDARs underlie residual NMDAR current in 30µM ketamine, availability of these channel
subtypes may be helpful for preserving synaptic plasticity in the recovering brain (Khlestova
et al., 2016).

It is difficult to directly compare the ketamine concentration used here with prior clinical
observations, in part because of species-dependent differences of in vivo ketamine distribution
and metabolism, and brain concentrations following intravenous infusions were not
determined in the ICU studies. Furthermore, while both the racemic mixture and the S (+)isomer of ketamine are in clinical use, the racemic ketamine mixture used in the present study
is approximately half as potent as the S-ketamine isomer (Peltoniemi et al., 2016) used in
published clinical work with SD. The present results imply that brain concentrations effective

64

at blocking SD clinically are higher than 30μM (for racemic ketamine, or ~15μM for Sketamine), but more detailed studies are needed to resolve whether infusions used for clinical
sedation far exceed this value. Non-sedative concentrations that effectively prevent deleterious
consequences of SD could be clinically valuable.

Ketamine’s efficacy was progressively enhanced during a series of repetitive SDs (Figure 2.2),
or by prolonged (~3hr) ketamine pre-incubations (Supplementary Figure 2.1A). The time
course of effects may be due in part to ketamine’s use-dependent mechanism of action at the
Mg2+ - site of NMDARs (Johnson et al., 2015) and/or drug diffusion into brain slices. Timedependent effects of ketamine have been noted previously in in vivo recordings in pigs
(Sanchez-Porras et al., 2014). In the present study, the progressive decrease in the DC shift
duration of SD was particularly notable (Figure 2.2). NMDAR activation is prominent during
the secondary phase of the “inverted-saddle” - shaped DC shift. During the late-phase of SD,
glutamate release probability is substantially enhanced for ~ 1 minute, at a time when
postsynaptic neurons remain persistently depolarized. These conditions favor relief of Mg2+
from its binding site within the NMDAR pore, and lead to massive cationic influx. As such,
targeted application of NMDAR antagonists (i.e. AP5) during the late-phase, can abolish the
secondary component of the DC shift and reduce extended Ca2+ loading (Aiba and
Shuttleworth, 2012). Use-dependency of block with ketamine may be particularly useful for
targeting excessive glutamate accumulation during SD in injured tissues.

Our GCaMP5G imaging of neuronal Ca2+ accumulation showed significant reductions in total
Ca2+ loading after ketamine (Figure 2.3 & Supplementary Figure 2A), associated with reduced
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DC shift durations. In addition, recovery of synaptic potentials after SD was significantly
accelerated by ketamine exposures (Figure 2.4). The long-lasting suppression of evoked
EPSPs in brain slice after SD (≥ 5 minutes) is largely a result of extracellular adenosine
accumulation and activation of presynaptic adenosine-1-receptors (A-1R) and provides a
measure of the metabolic burden imposed by SD (Lindquist and Shuttleworth, 2012, 2014).
Taken together, these data show that a concentration of ketamine that does not block SD in
nominally healthy tissues, decreases NMDAR- mediated Ca2+ influx during the late phase of
the DC shift, reduces the metabolic burden of SD and enables faster recovery of EPSPs.

2.5.3 Protective effects of ketamine in vulnerable tissues
We used a novel brain slice model of metabolic insufficiency, in order to recapitulate the
deleterious consequences that peri-infarct SDs have on viable, but vulnerable brain regions.
By limiting aCSF superfusion to one side of the slice, metabolic capacity was sufficient for
slices to remain viable for hours in the recording chamber. However, on this compromised
baseline, an SD generated by focal KCl microinjection led to severely impaired 1) recovery of
neuronal Ca2+ elevations, 2) recovery of synaptic potentials, 3) ability to generate a second SD,
as well as signs of structural disruption (suggested from intrinsic optical signals) (Figures
2.5&6). This model of vulnerability to SD is fundamentally different from the oxygen-glucose
deprivation (OGD) or hypoxia induced SD (HSD) paradigm that we and others have used to
generate SD in brain slices (Somjen, 2001, Dietz et al., 2008). In the standard OGD or HSD
models, severe oxygen and/or glucose reductions are used as the inciting stimulus for SD, as
Na/K+/ATPase failure produces progressive loss of membrane potential and extracellular K+
accumulation. SD is usually triggered within ~10 minutes, and even if SD can be delayed or
prevented by antagonists, cell damage invariably occurs if substrate removal is continued. The
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OGD or HSD paradigms are therefore useful for understanding initiation of events in infarct
cores, but are not as well suited for understanding how at-risk penumbral tissue suddenly
succumbs to injury when it is invaded by an SD. The partial inhibition model here addresses
this concern and is straightforward and reproducible. It is also noted that the recording
configuration tested here (with slices superfused on a single side) is common for many
neurophysiology studies.

Ketamine exposures (30μM) provided substantial protection against the deleterious
consequences of SD under these conditions of metabolic compromise. As described above for
nominally healthy tissues, SD was not prevented by this concentration of ketamine, but the
total Ca2+ loading after SD was significantly reduced, and both optical signals and functional
recovery after SD in vulnerable conditions were significantly improved (Figures 2.5&6).

2.5.4 Potential beneficial effects of targeting consequences (rather than initiation/propagation)
of SD
We expect the degree of NMDAR block in our experiments to leave a significant portion of
the NMDAR pool available for plasticity and Ca2+-dependent synaptic signaling that is
presumably beneficial for recovery and repair mechanisms required in the immediate aftermath
of an injury (Shohami and Biegon, 2014). In addition to NMDAR availability, the fact that
SDs still propagate may be directly beneficial effects to recovering brain. This is because SDs
can travel long distances throughout the cortex, including to relatively healthy tissue that is
remote from an injury site. While SDs can clearly cause damage when they propagate through
metabolically compromised tissue, there is good evidence for protective effects of SD, when
it is allowed to propagate through otherwise healthy brain regions (see Introduction). Whether
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or not substantial benefit could be derived from targeting the consequences of SD in vivo, could
be tested by assessing SDs at different locations from an injury site and relating to outcome.
In this scenario long-term functional outcomes, rather than lesion volume alone would be
valuable to assess the importance of potential beneficial effects of SD on cortical plasticity
remote from the infarct core.

2.6 Conclusions
Results from the current study suggest that SDs that occur in the presence of ketamine could
be shorter in duration and less metabolically demanding. By reducing intracellular Ca2+ influx
during SD, ketamine may minimize the amount of energy needed for recovery (exemplified by
accelerated recovery of evoked synaptic activity). These results raise the possibility that
ketamine may be effective clinically, even at lower concentrations that do not prevent SD, but
may shorten the duration of ECoG suppression and minimize lesion development in patients
with acute brain injuries. Our study focused on ketamine but the main pre-clinical findings
here could be generalized to other interventions that improve recovery of neurons after the
passage of SD. This includes other use-dependent NMDAR antagonists such as memantine,
which are clinically well tolerated and may lack some of the negative side effects of ketamine
(Johnson et al., 2015). Alternative approaches that improve neurovascular coupling after SD
propagates through vulnerable tissues (Dreier, 2011) would be expected to be complementary
or additive with ketamine effects.
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3.1 Introduction
Spreading depolarization (SD) is a slowly propagating wave (2- 4 mm min-1) likely fueled by
feedforward release of potassium and/or glutamate (Somjen, 2001) and characterized by nearcomplete depolarization of neuroglia (Leao, 1944; Somjen, 2001). These “brain tsunamis”
have been detected in humans with acute brain injuries (Hartings, 2017, Dreier et al., 2017;
Eriksen et al., 2019) including ischemic stroke (Dohmen et al., 2008, Woitzik, 2013). After
stroke, SDs have been detected in ICU patients up to a week after the initial ictus and repetitive
SDs are associated with poor clinical prognoses (Dohmen et al., 2008). This suggests that
targeting SD may extend the therapeutic window for stroke as there are currently no treatment
options beyond 24 hours after the initial insult (Powers, 2018).

SD can be initiated by ischemia or other stimuli that induce supply-demand mismatches in
tissues surrounding the infarct core (e.g. penumbra) (von Bornstädt et al., 2015) that is
comprised of metabolically vulnerable, but salvageable brain. Due to its massive energetic
burden, greater even than seizures (Dreier, 2015), SD may be responsible for the recruitment
of otherwise viable neurons into the necrotic infarct core. Here we describe a brain slice model
of moderate metabolic impairment in order to study cellular mechanisms relating to injurious
consequences of SD in penumbral tissues.

Brain slices are an important tool for studying neuronal mechanisms of SD injury (and
neuroprotective drugs targeting SD), as profound blood flow responses to SD in vivo (Ayata
and Lauritzen, 2015), provide further complexity to an already complicated physiology. To
create a stroke-like environment in vitro most brain slice studies employ complete metabolic
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substrate removal (i.e. hypoxia, oxygen and glucose deprivation (OGD)), conditions that
initiate SD within ~10 minutes (Andrew, 1999). These models are important for evaluating
cellular mechanisms of SD that occur at the onset of ischemia, during the initial development
of the infarct core; however, they may be less applicable to metabolically vulnerable
penumbral brain that is viable for hours or days following ictus, and only later succumbs to
deleterious consequences of SD. This aligns with a recent consensus in the field that SD, and
its consequences, occur along a continuum in relation to brain metabolic capacity (Hartings et
al., 2017). Therefore, in addition to OGD studies, in vitro models examining SD consequences
under a less severe degree of metabolic stress may be useful. Such studies could be relevant to
mechanisms of injury that occur during SD in peri-infarct brain regions after stroke that contain
functionally intact but metabolically vulnerable neurons (Nakamura et al., 2010; Strong et al.,
2006).

To increase neuron vulnerability to the deleterious consequences of SD we altered the
configuration of the brain slice recording chamber to reduce metabolic substrate availability.
We recently employed this model (Reinhart, 2018) and here we sought to further characterize
changes using electrophysiology, imaging, and histology techniques. We found a minor impact
of substrate restriction on synaptic efficacy and metabolic parameters in this configuration
indicating slices were viable but with reduced metabolic capacity. However, SD consequences
were more deleterious as indicated by reduced pO2 availability, increased NADH fluorescence,
prolonged glutamate release, and impaired structural and functional recovery. These findings
support the use of this model to study consequences of SD in brain slices resembling periinfarct tissues that are otherwise viable in the absence of SD.
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3.2 Materials and methods
3.2.1 Animals
All animal procedures were performed in accordance with protocols approved by the UNM
Health Sciences Center Institutional Animal Care and Use Committee. Adult (1−4 months
old) male and female mice (C57Bl/6) maintained in standard group housing were used for all
experiments. Homozygous mouse strains were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA).

3.2.2. AAV injections
The fluorescent reporter iGluSnFR (Marvin et al., 2013) was delivered via intracortical
injection of the adeno associated virus (AAV; pAAV1.hSyn. iGluSnFr.WPRE.SV40;
Addgene, Cambridge, MA, USA) to enable imaging of extracellular glutamate on hippocampal
neurons in the CA1 subregion of C57Bl/6 mice. Animals were anesthetized with isoflurane
(4-5% induction, 1-2% maintenance) and head fixed into a stereotaxic frame (Kopf
Instruments). After sanitization using Betadine and alcohol wipes, a scalp incision was made
for burr hole preparation (0.295” drill diameter). A total volume of ~ 0.5 µl of iGluSnFRcontaining AAV (6.52 x 1012 GC/mL) was infused bilaterally (1 injection per hemisphere) at a
depth of 150 µm using coordinates AP: -1.75 mm and ML: ± 1.25 mm, relative to bregma.
Slow infusion (~0.1µl min-1) was achieved using a 5.0 µl gastight syringe (Hamilton Company
Inc., Reno, NV, USA) connected via polyethylene tubing to a 33G diameter infusion cannula
(C315I/SPC; Plastics One Inc., Roanoke, VA, USA). The scalp was sutured to close and
topical lidocaine and antibiotic ointment were applied to the incision site. Mice recovered on
a heating pad and 40% buprenorphine (0.1 mg kg-1) saline solution was delivered (i.p.) for

74

postoperative pain.

Animals were returned to their home cages with littermates and

experiments were performed ~2-4 weeks post injection to enable adequate iGluSnFR
expression (Marvin et al., 2018).

3.2.3 Brain slice preparation
Acute brain slices were prepared as previously described (Shuttleworth et al., 2003). Briefly,
mice were deeply anaesthetized with 0.15mL (s.c.) ketamine-xylazine mixture (85 and 15 mg
ml-1, respectively) and decapitated. Brains were quickly removed into 150 mL ice-cold cutting
solution (in mM): sucrose, 220; NaHCO3, 26; KCl, 3; NaH2PO4, 1.5; MgSO4, 6; glucose, 10;
CaCl2 0.2; equilibrated with 95% O2/5% CO2 and supplemented with 0.2 ml ketamine (100
mg/ml, Putney Inc., Portland, ME) to minimize excitotoxicity during slice preparation as
described previously (Shuttleworth et al., 2003). Coronal cortico-hippocampal slices (350 µm)
were prepared using a Pelco 102 Vibratome (Ted Pella, Inc., Redding, CA), hemisected, and
then transferred to 35°C artificial cerebrospinal fluid (aCSF; containing (in mM): NaCl, 126;
NaHCO3, 26; glucose, 10; KCl, 3; CaCl2, 2, NaH2PO4, 1.5; MgSO4, 1; equilibrated with 95%
O2/ 5% CO2) for recovery. After 60 min recovery, holding aCSF was replaced with chilled
(20°C) aCSF and slices equilibrated to room temperature until the start of recordings.

3.2.4 Generation of SD and brain slice metabolic compromise
Individual brain slices were transferred to a submersion recording chamber (RC-27L, Warner
Instruments, Hamden, CT, USA) maintained at 32°C via an inline heater assembly (TC-344B,
Warner Instruments) and continuously super-fused at 2.2 ml min-1 with oxygenated (95%
O2/95% CO2) aCSF. SD was evoked by pressure microinjection (40ms, 30 psi; Picospritzer;
Parker Hannifin, OH, USA) of KCl (1M) via a glass micropipette ~3 MΩ placed in

75

hippocampal CA1 stratum radiatum. In control conditions, slices were elevated ~0.5 mm above
the coverslip floor using a nylon slice support (SS-3, Warner Instruments) enabling continuous
flow of aCSF on both sides of the slice.

To reduce metabolic capacity and increase

vulnerability to SD, the slice support was inverted and aCSF flow under the slice was reduced.
After placement of electrodes into the slice (See Electrophysiology methods) wash in of
modified aCSF with elevated K+ (8mM) commenced and slices were allowed 20 minutes for
equilibration prior to SD initiation. This exchange with elevated K+ aCSF was made to reflect
similar pathological ionic disturbances observed in peri-infarct tissues in animals (Nedergaard
and Hansen, 1993) and (Petzold, 2005) and brain injured patients (Rogers et al., 2016). In this
configuration, SD did not initiate spontaneously in any preparation, but slices were rendered
functionally and structurally impaired after SD, as described previously (Reinhart and
Shuttleworth, 2018).

3.2.5 Electrophysiology
Extracellular analog recordings were amplified and digitized using Axon Instruments’
MultiClamp 700A amplifier (CV-7A headstage) and Digidata 1332A for acquisition (1-10
kHz) by pCLAMP10.2 software (Molecular Devices, Sunnyvale, CA, USA). Glass recording
microelectrodes were filled with aCSF (tip resistance ~3MΩ) and positioned ≥ 200 µm from
the glass pipette containing KCl (See Generation of SD, above) at a depth of 50 –100 µm in
CA1 stratum radiatum. Excitatory postsynaptic potentials (EPSPs) were evoked using a
concentric bipolar electrode (CBAPC74, FHC, Bowdoin, NE, USA) driven by a current
controller (A.M.P.I., Jerusalem, Israel) and positioned for stimulation of Schaffer Collateral
inputs using a paired-pulse protocol (2 x 70 µs; interpulse interval of 50ms). After placement
of electrodes, input-output curves were generated during the equilibration period (See
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Generation of SD, above) and current pulses (25-150 µA) that evoked 40-60% of maximum
EPSP amplitude responses were delivered at 0.1 Hz during recording sessions.

Postsynaptic potentials were resolved from gap-free recordings with a high-pass filter (1 Hz
cut-off) and the duration of EPSP suppression after a single SD was measured from the time
of the maximum negative potential of the DC shift to the time at which postsynaptic potentials
first returned to ≥ 50% of baseline values. The paired-pulse ratio (PPR) of EPSP responses
evoked with brief interpulse intervals (50ms) was calculated as the ratio of EPSP amplitudes
(amplitudeEPSP2 / amplitudeEPSP1) and was used to assess changes in presynaptic release
probability as a form of short-term synaptic plasticity (Lindquist and Shuttleworth, 2012).

3.2.6 Fluorescence imaging in brain slices
Neuronal extracellular glutamate fluorescence reported by iGluSnFR or endogenous
nicotinamide adenine (phosphate) dinucleotide (NAD(P)H) autofluorescence were examined
using a fiber optic/monochromator system (TILL Polychrome V, Till Photonics, GmBH,
Graefelfing, Germany). After focusing onto the slice surface with 10X / 0.30W (for iGluSnFR)
or 20X / 0.50W (for NAD(P)H) water-immersion objectives (UMPlanFL N, Olympus
Corporation, Shinjuku, Tokyo, Japan), 480 nm or 360 nm wavelengths were used to excite
iGluSnFR or NAD(P)H, respectively. An acquisition rate of 4Hz was used to monitor longpass filtered (515 nm DCLP) iGluSnFR emission; and, in separate experiments, NAD(P)H
signals were acquired at 1 Hz and emitted light was filtered using a 458 nm dichroic mirror
(Semrock, Rochester, NY, USA). All fluorescence signals were captured using a cooled
interline transfer CCD camera (Imago, Till Photonics) for image analysis in TILL Photonics
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Imaging System Software (TILLvisION v.4.01), and GraphPad Prism 8.1.0 (GraphPad
Software, San Diego, CA, USA) was used for statistical analyses.

Image analysis involved background subtraction and calculation of the change in pixel
intensity relative to pre-SD values. Fluorescence data is thus expressed as ∆F/F0 (F0 = 3
frames). For glutamate imaging experiments, brain slices inevitably had varying degrees of
basal iGluSnFR expression in relation to the injection site, likely resulting from diffusion
constraints of AAV-gene delivery. In order to evaluate glutamate accumulation across different
preparations and metabolic conditions, fluorescence transients were normalized to the peak of
the iGluSnFR signal during SD in specific regions of interest. Therefore, iGluSnFR
fluorescence is expressed as the change from baseline as a percent of the peak amplitude during
SD ((∆F/F0)/Fmax) x 100; where the value of 100 = peak amplitude at t = 0s). The integral of
iGluSnFR transients from ≥ 5% of peak to 160s post-SD was used to evaluate total glutamate
accumulation during SD. Nonlinear regression curves for glutamate transients were generated
using GraphPad’s algorithm for exponential one phase decay and ROUT’s method of
identifying outliers (Q = 1%) was used to exclude data points based on R2 values. From bestfit curves, the time constant (tau) of decay from 5s to 120s (t5 – t120 seconds) after the peak
glutamate response (t = 0 seconds) were determined.

3.2.7 Oxygen measurements
In some studies, the partial pressure of oxygen (pO2) was measured (~1.5 Hz) in CA1 stratum
radiatum using an oxygen microsensor (50 µm diameter) connected to a PC-controlled fiber
optic oxygen meter with temperature compensation (OXY MICRO, World Precision
Instruments, Inc., Sarasota, FL, USA). Prior to experiments, a two-point calibration of O2
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probes was performed using water-saturated air and O2-free water solution (sodium sulfite 1%
w/v) and the local barometric pressure was used to convert sensor outputs into mmHg.

3.2.8 MAP2 Immunohistochemistry
Microtubule associated protein (MAP2) immunohistochemistry was used to evaluate dendrite
disruption in non-resected brain slices (350µm) as described previously (Hoskison et al., 2007;
Hoskison and Shuttleworth, 2006) with minor modifications. After electrophysiology and
imaging sessions, brain slices were carefully removed from the recording chamber at 15
minutes following the DC shift of SD and fixed in freshly prepared 4% paraformaldehyde
solution. Each section was rinsed (3 x 15 min) with phosphate buffered saline containing 0.1%
Tween-20 (PBS-T) and permeabilized in PBS containing 0.4% Triton X-100 for 40 min with
gentle rotation. Slices were then gently rotated for 120 min in a blocking solution of PBS-T
containing 10% normal donkey serum (NDS) and 1% bovine serum albumin (BSA). After
blocking, preparations were exposed to primary antibody (mouse monoclonal anti-MAP2
1:500 (M-1406; Sigma-Aldrich, St. Louis, MO) for a total of 48h (solution was exchanged at
24h and incubated again for 24h) and then extensively washed in PBS-T (1 x 60 min and 4 x
30 min). After an additional blocking step (120 min, 10% NDS, 1% BSA in PBS-T solution),
samples were incubated for 180 min with Cy3 goat anti-mouse serum and rinsed with PBS-T
(3 x 30 min) prior to overnight wash in PBS at 4°C. Final rinses in PBS (3 x 30 min) and PBST (2 x 30 min) were preformed prior to preparation mounting using Fluromount-G.

3.2.9 Confocal imaging and analysis
A Leica TCS SP8 inverted confocal microscope equipped with a Galvo-Z-stage and resonance
scanner was used for acquisition of z-stacks (0.6µm steps) in preparations with adequate MAP-
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2 antibody penetration at a depth up to ~20µm from the slice surface. A white light laser was
tuned for excitation of Cy3 (590-643nm) at low power settings (<6%) and emission was
detected with a Hybrid Spectral Detector (HyD) at a gain set below 20% of maximum. Each
z-stack image acquired was deconvoluted using Huygens Deconvolution software (Scientific
Volume Imaging, Hilversum, Netherlands) and maximum intensity projections of 3µm in
depth beginning ~5µm below the slice surface was used for subsequent analysis using opensourced Fiji software.

3.2.10 Drugs and solutions
Ketamine (100 mg/ml, racemic: R (-)/S (+)) used during brain slice preparation was prepared
daily and purchased from Putney, Inc. (Portland, ME, USA). All other chemicals including
antibodies, as well as salts and glucose for aCSF solutions were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The selective A1 adenosine receptor antagonist, 8-cyclopentyl-1,3dipropylxanthine (DPCPX), was prepared as a 10 mM stock in dimethyl sulfoxide (DMSO)
and aliquots were stored at -20°C until daily use at a final concentration of 300 nM in aCSF.
As mentioned in prior studies (Lindquist and Shuttleworth, 2012) extensive chamber washout
and use of separate tubing was employed to minimize drug carryover effects of DPCPX
between experiments.

3.2.11 Statistical analysis
Data are reported as mean ± SEM. Statistics were performed using GraphPad Prism and
included: ROUT’s method of identifying outliers, one- and two-way analysis of variance
(ANOVA) with repeated measures for examining drug wash-in effects compared to baseline,
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and unpaired t-tests. Statistical significance was determined by P values < 0.05, with
Bonferroni correction during multiple comparisons.
3.3. Results
3.3.1 Brain slice metabolic impairment
Figure 3.1
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Figure 3.1A, shows a significant reduction in the amplitude of evoked postsynaptic potentials
(EPSP) recorded in CA1 dendrites in metabolically impaired brain slices. Panels in Figure 3.1B
show that wash-in of the A1 adenosine receptor antagonist DPCPX increased EPSP amplitudes
in vulnerable, but not control, brain slices. We further examined paired-pulse ratios (PPR), as
an indirect measure of initial glutamate release probability. Figure 3.1C shows increased PPR
in impaired preparations that was again normalized by the application of DPCPX (Figure
3.1C). Taken together, these data suggest that initial release probability is reduced at baseline
in vulnerable brain slices and is mediated by A1 receptor activation.

We next evaluated endogenous NAD(P)H fluorescence and tissue pO2 in CA1 stratum
radiatum after brain slice equilibration and prior to SD induction. Consistent with metabolic
compromise, we observed a slight increase in NAD(P)H signal prior to SD in vulnerable slices
(103.6 ± 3.5 counts) compared to controls (90.1 ± 4.4 counts, P = 0.04, n = 5,5 slices from 3
animals). While these findings suggest increases in NAD(P)H primed for mitochondrial
oxidation, there was not a significant effect of baseline metabolic status on pO2 values
monitored at ~50 µm increments from the surface (0 µm) to center (~175 µm) of brain slices
(range of pO2 measured at slice depths of 0 – 175 µm: 165.1 ± 7.4 – 60.5 ± 11.5 mmHg in
control (n=7) versus 166.5 ± 9.1 – 61.3 ± 8.1 mmHg in vulnerable (n=8), P = 0.34; also See
Figure 3.2A). These data show that increased NAD(P)H autofluorescence does not correspond
to significantly decreased pO2 availability in vulnerable brain slices, under baseline conditions.

3.3.2 Metabolic vulnerability increases deleterious consequences of SD
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In agreement with our prior findings (Reinhart and Shuttleworth, 2018) this model of mild
metabolic impairment did not result in spontaneous SD initiation in any preparation. However,
Figure 3.2
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SD initiated by K+ microinjection resulted in poor recovery of EPSPs and failure of slices to
propagate a subsequent SD 15 minutes later. Traces in Figure 3.2A show continuous pO2
measurements during SD. The initial drop in pO2 during SD was similar in control and
vulnerable brain slices (-46.1 ± 3.8 versus -41.7 ± 4.9 % change pO2 in mmHg, for control and
vulnerable slices, respectively; P = 0.46, n = 6,7). 15 minutes after SD tissue pO2 gradients
across all measured depths had recovered to baseline levels in control tissues (Figure 3.2A).
However, vulnerable brain slices had significantly less available pO2 at all depths during this
same time point (Figure 3.2A).

Throughout the CA1 region NAD(P)H signals have a typical biphasic transient in response to
neuronal depolarization (Foster et al., 2005; Hall et al., 2012; Shuttleworth, 2010) and during
SD in adequately oxygenated brain slices (Foster et al., 2005; Lindquist and Shuttleworth,
2014). Figure 3.2B shows biphasic responses (traces) with larger oxidative transients indicated
by the dip in NAD(P)H fluorescence in control compared to vulnerable slices. This dip was
followed by a prolonged increase in NADH fluorescence and was reliably longer in duration
after SD in vulnerable conditions (Figure 3.2B). After NADH increases, a long-lasting
reduction below baseline was noted in all experiments and appeared to slowly return to
baseline in control slices (see traces over extended time scale in Figure 3.2B). These changes
were not further investigated in this study as they have the potential of arising as artifacts due
to tissue optical changes during SD (Shuttleworth, 2011). However, it is possible that the
impaired return to baseline in vulnerable slices is due to extensive oxygen utilization at this
time point (Figure 3.2A). In a subset of experiments, brain slice hypoxia was induced by
replacement of carboxygenated with 95% N2 / 5% CO2 supplemented aCSF. Figure 3.2B shows
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substantial near-linear increases in the NADH signal during hypoxia that 1) indicate that
elevated basal fluorescence in vulnerable slices did not blunt NADH signals during SD due to
ceiling effects and 2) emphasize the differences between this model of metabolic vulnerability
compared to complete substrate removal. Taken together these data indicate that brain slices
have mild metabolic impairment at baseline that is augmented in the wake of SD.
Figure 3.3

85

3.3.3 Extracellular glutamate accumulation is prolonged in vulnerable brain slices
To examine the excitotoxic burden of SD in vulnerable brain slices we monitored extracellular
glutamate accumulation during SD using iGluSnFR fluorescence imaging. Figure 3.3A shows
a representative iGluSnFR transient and image montage during SD. In ROIs taken from CA1
stratum oriens (pyramidal cell bodies) and stratum radiatum (largely dendrites from pyramidal
neurons) in Figure 3.3 B &C, demonstrate that glutamate transients are significantly prolonged
across the hippocampus in vulnerable brain slices. The inset traces show examples of the
curves generated via nonlinear regression used for determining decay constants (tau), where
the R2 goodness of fit parameter was used to determine data set outliers. Results from the entire
data set reveal that the time course of glutamate recovery as well as total accumulation is
impaired during SD in vulnerable slices.

3.3.5 Structural and functional recovery is impaired after SD in vulnerable slices

We have previously reported that EPSP recovery is significantly impaired after SD in
vulnerable preparations (Reinhart and Shuttleworth, 2018). Prior work has shown that action
of adenosine at presynaptic A1 receptors is a main contributor to the prolonged suppression of
neuronal activity that outlasts action-potential blockade during the DC shift (Lindquist and
Shuttleworth, 2012). We thus examined whether A1 receptor activation contributes to the lack
of recovery of EPSPs in vulnerable preparations. Figure 3.4A confirms previous findings and
demonstrate that in vulnerable conditions EPSPs only recovered to ~25% of baseline
amplitudes after SD (Figure 3.4A). In these experiments, DPCPX incubation (500nM, ~10
min.) prior to SD improved recovery of responses and suggest that adenosine’s actions at A1
receptors could mask, in part, the synaptic potential of neurons after SD. However, even
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though neurons were able to respond to their presynaptic inputs, IOS read-outs of brain slice
structural integrity were not improved by DPCPX (Figure 3.4C).

Figure 3.4
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3.4 Discussion
3.4.1 General Findings
Here we further characterized a previously used brain slice model of metabolic impairment
and assessed baseline changes in evoked synaptic transmission, slice oxygenation, and
fluorescence metabolic read-outs before and after SD. Based on our findings, we propose the
use of moderately compromised tissues in order to study mechanisms that contribute to the
damaging consequences of SD. Such studies could promote our understanding of how
vulnerable brain succumbs to SD-mediated injury and also elucidate potential targets for
intervention at delayed time points after focal ischemia.

3.4.2 Metabolic compromise in brain slices
At baseline in control brain slices we observed almost no effect of the specific A1 receptor
antagonist DPCPX on the amplitude and PPR of EPSPs (Figure 3.1). This suggests that basal
adenosine production is minimal in these preparations. On the contrary, in vulnerable
conditions, DPCPX wash-in significantly increased the amplitude (Figure 3.1B) of initially
attenuated (Figure 3.1A) postsynaptic responses while normalizing elevated PPR to control
levels. Though extracellular adenosine concentrations were not measured in these slices,
results with DPCPX indicate that A1 receptors are important mediators of depressed EPSPs
and elevated PPR in vulnerable brain slices prior to SD stimulation. Since both pre- and
postsynaptic processes for glutamate neurotransmission rely on substantial ATP production
via oxidative phosphorylation (Hall et al., 2012), adenosine production may serve as protective
feedback mechanism for limiting neuronal ATP expenditure when metabolic capacity is low.
Activation of presynaptic A1 receptors by adenosine can reduce energy expensive vesicular
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release while postsynaptic actions of adenosine mediate neuronal hyperpolarization to reduce
postsynaptic currents.

The reduction of synaptic activity may in part explain the similar rates of basal pO2
consumption (or availability) measured in vulnerable compared to control preparations (Figure
3.2A). However, since the redox state of NAD+/NAD(P)H influences tissue autofluorescence
intensity – the reduced form (i.e. NAD(P)H) is fluorescent compared to the oxidized and nonfluorescent NAD+ – increased NAD(P)H fluorescence in vulnerable brain slices may still
implicate mitochondrial dysfunction and reduced oxygen availability for the final stages of
oxidative phosphorylation in neurons.

3.4.3 Vulnerability to deleterious consequences of SD
Drastic differences between the two recording configurations was most apparent upon SD
stimulation (Figures 3.2-3.4). Consistent with previous studies, we observed a precipitous drop
in tissue pO2 levels (Figure 3.2 traces) that coincided with the DC shift of SD. This likely is
due to increased oxidative phosphorylation and O2 consumption in response to sizeable ATP
demands necessary for ion gradient reestablishment. The magnitude of the O2 transients was
not significantly larger in vulnerable slices compared to controls; however, 15 min. after SD
O2 measurements remained low in vulnerable preparations while controls had fully recovered.
Further evidence of SD-induced metabolic stress is shown via prolonged fluorescence
increases and buildup of NAD(P)H in vulnerable slices (Figure 3.2).

The increased burden of SD in compromised slices is also shown in studies employing
iGluSnFR (Figure 3.3). During SD, massive amounts of glutamate accumulate extracellularly
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likely due to extended depolarization and Ca2+-mediated vesicular release and/or transporter
reversal mechanisms that normally rely on electrochemical gradients for the clearance of
glutamate. Disturbances in either of these processes could thus be in part responsible for
extended glutamate transients measured in vulnerable metabolic conditions. Prolonged action
at postsynaptic glutamate receptors (especially NMDA receptors) after the SD wave front can
thus result in lengthy durations of intracellular neuronal Ca2+ loading; as observed previously
using this brain slice model of compromise (Reinhart, 2018).

Basal elevations in NAD(P)H autofluorescence are positively correlated to adenosine
accumulation in response to SD in thick hippocampal brain slices (>350 µm); tissues that are
also metabolically strained due to steep reductions in O2 delivery within the depths of the slice
(Lindquist and Shuttleworth, 2014). Furthermore, adenosine A1R activation after SD is largely
responsible for the period (>5 min. in slice experiments) of synaptic depression that extends
beyond action potential failure during the DC shift (Lindquist and Shuttleworth, 2012). The
duration of A1R mediated suppression of activity serves as a read-out of the metabolic demand
of SD, where extended depression durations are a consequence of elevated adenosine–likely a
result of augmented ATP consumption. Enhanced metabolic burden of SD in vulnerable slices
is further supported by our results where DPCPX enabled virtually complete recovery of
postsynaptic responses after SD in vulnerable slices (Figure 3.4). However, this did not change
optical indicators of structural integrity disruption (i.e. dendritic beading, swelling and/or cell
shrinkage, etc.) that have been previously evaluated in submerged brain slices using IOS
imaging (Andrew, 1999)
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3.5 Conclusions
For decades, researchers have been divided regarding mechanisms of SD that are induced in
healthy brain compared to SD initiated in response to ischemia (or OGD in vitro); which has
led to confusion regarding the relevance of SD in different conditions (e.g. migraine and
ischemic stroke) (Hartings et al., 2017). While classical techniques of complete substrate
removal are important for studying injury at the core of infarction or mechanisms of cell death
during global cerebral ischemia (e.g. cardiac arrest, hypoglycemia, or altitude sickness) they
may be less applicable to injury mechanisms in penumbral regions after stroke. Here we
provide additional findings from a novel model of metabolic compromise that confers
increased vulnerability to deleterious consequences of SD. This model could be used to
examine mechanisms of injury during SD and/or therapeutic interventions.
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4.1. Abstract
Spreading depolarization (SD) has emerged as an important contributor to enlargement of
acute brain injuries. We recently showed that the NMDA receptor antagonist ketamine was
able to prevent deleterious consequences of SD in brain slices, under conditions of metabolic
compromise. The current study aimed to extend these observations into an in vivo stroke
model, to test whether gradients of metabolic capacity leads to demonstrable differences in
glutamate and calcium accumulation following SD. In addition, we tested whether ketamine
protects vulnerable tissue while allowing SD to propagate through surrounding undamaged
tissue. Focal lesions were generated using a distal middle cerebral artery occlusion in mice,
and clusters of SD were generated at 20 min intervals with a remote microinjection of KCl.
SDs invading into peri-infarct regions had significantly different consequences, depending on
distance from the infarct core. Close to the lesion, calcium and glutamate transients were
extended, as compared with responses in better-perfused tissue more remote from the lesion.
Extracellular potential shifts were also longer in regions proximal to lesions, and hyperemia
following SDs were reduced. Consistent with in vitro studies, ketamine, at concentrations that
did not abolish the propagation of SD, reduced severity of excitotoxic signaling in vulnerable
peri-infarct regions without preventing spread of SD waves through more remote regions.
These findings suggest that deleterious consequences of SD can be targeted in vivo, without
preventing the spread of waves into tissue that may benefit from preconditioning or other
potentially beneficial effects of SD.
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4.2 Introduction
Spreading depolarization (SD) is a slowly propagating wave of near-complete neuroglia
depolarization (~0 mV) that has been detected in intensive care unit (ICU) patients suffering
from acute brain injuries including trauma (Eriksen et al., 2019; Hartings et al., 2011),
subarachnoid hemorrhage (Dreier et al., 2006), and ischemic stroke (Dohmen et al., 2008).
Repetitive SDs and/or SDs with prolonged depolarizations are particularly challenging to
metabolically compromised brain and are associated with secondary lesion expansion and poor
neurological outcomes (Dreier et al., 2017; Hartings et al., 2017, 2003). After stroke, SDs have
been detected for days after ischemia onset (Dohmen et al., 2008; Nakamura et al., 2010;
Woitzik et al., 2013) and during this time there are currently no clinically approved
interventions (Powers, 2018). This suggests that therapeutics targeting SD mechanisms of
injury may be neuroprotective after ischemic stroke.

A retrospective review of ICU medications showed that the NMDAR-antagonist ketamine can
reduce SD frequency when used for sedation in brain injured patients (Hertle et al., 2012;
Sakowitz et al., 2009). A recent prospective study demonstrated that ketamine infusion dosedependently prevented SD over a range of clinically sedative doses after acute brain injury
(Carlson et al., 2018). While these findings demonstrate SD can be prevented with ketamine,
there is the theoretical possibility that SD propagating into non-ischemic brain regions can
induce ischemic tolerance and/or preconditioning (Dreier, 2011; Pincherle et al., 2018,
Shuttleworth et al., 2019). Therefore, doses of ketamine that block SD may also prevent any
theoretical benefits of SD in tissues with adequate cerebral perfusion outside of the ischemic
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penumbra (Hartings, 2017). Thus, it remains to be determined whether approaches that limit
deleterious consequences without outright blocking SD may be clinically useful.

Extracellular recordings of SD reveal a large shift in the extracellular slow potential (DC shift)
(Leao, 1947, Somjen, 2001). The duration of the DC shift is an indicator of underlying ionic
loading that can be particularly deleterious to metabolically compromised neurons. Thus,
prolonged or irrecoverable Ca2+ accumulation mediated by glutamate release and activation of
NMDARs is prominent during the late phase of SD (Aiba, 2012). In brain slices, a
concentration of ketamine that did not block SD reduced the duration of the late-phase of DC
shifts (Reinhart, 2018). Additionally, ketamine attenuated intracellular neuronal Ca2+ loading
during SD and improved functional recovery of evoked synaptic potentials in metabolically
vulnerable slices (Reinhart, 2018). This indicates that ketamine, in the absence of vascular
effects, can reduce the ionic burden of SD in vitro and mitigate neuronal injury without
blocking SD. Whether ketamine can attenuate deleterious consequences in vulnerable neurons
within the ischemic penumbra without preventing SD in more intact brain regions after in vivo
stroke had not previously been examined. Here we studied SD clusters initiated in vivo after
distal middle cerebral artery occlusion in mice and tested whether a ketamine in mice could
reduce deleterious consequences without blocking SD outright.
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4.3 Materials and Methods
4.3.1 Animals
All animal procedures were performed in accordance with protocols approved by the UNM
Health Sciences Center Institutional Animal Care and Use Committee. Adult (10-20 weeks)
male and female mice and maintained in standard group housing were used for all experiments.
C57Bl/6 mice and homozygous breeding pairs for generation of neuronal GCaMP5G
expressing mice were purchased from The Jackson Laboratory (Bar Harbor, ME). For Ca2+
imaging experiments, mice expressing the floxxed calcium indicator GCaMP5G under the
CAG promoter (B6;129S6-Polr2atm1(CAG-GCaMP5g,-tdTomato)Tvrd/J; from (Gee et al., 2014)) were
bred with mice expressing Cre Recombinase under the CamK2a promoter (B6.CgTg(Camk2a-cre)T29-1Stl/J). Offspring had robust GCaMP5G expression throughout the
hippocampus and cortex (Wang et al., 2013) and were thus utilized for experiments.

4.3.2. AAV injections
Neuronal expression of the fluorescent glutamate reporter iGluSnFR was achieved via
intracortical

injection

of

the

adeno

associated

virus

(AAV;

pAAV1.hSyn.

iGluSnFr.WPRE.SV40; Addgene, Cambridge, MA, USA)(Marvin et al., 2013) in C57Bl/6
mice. Animals were anesthetized with isoflurane (4-5% induction, 1-2% maintenance) and
head fixed into a digital stereotaxic alignment system (Model 1900, David Kopf Instruments,
Tujunga, CA, USA). After sanitization using Betadine and alcohol wipes, a scalp incision was
made for burr hole preparation (0.295” diameter). In each burr hole, a total volume of ~0.5 µl
of AAV (3.8 x 1013 GC ml-1) was slowly delivered at ~0.1µl min-1 using a 5.0 µl Hamilton
gastight syringe (Hamilton Company Inc., Reno, NV, USA) connected via polyethylene tubing
to a 33G diameter infusion cannula (C315I/SPC; Plastics One Inc., Roanoke, VA, USA). After
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infusions, the scalp was closed with silk sutures and topical lidocaine applied over the incision
site. A 40% buprenorphine (0.1 mg kg-1) saline solution was administered intraperitoneally
(i.p.) for postoperative pain and animals recovered from surgery on a heating pad. Mice were
returned to their home cages with littermates and experiments were performed ~2-4 weeks post
injection to enable adequate iGluSnFR expression (Marvin et al., 2013).

4.3.3. Surgical preparation and distal middle cerebral artery occlusion
Mice were anesthetized with urethane (1.5 mg g-1 induction dose with ≤ 0.75 mg g-1 for
maintenance, if needed), placed in a small animal stereotaxic frame assembly (David Kopf
Instruments, Tujunga, CA, USA) and body temperatures were maintained at 37°C using a
feedback-controlled heating pad system (Kent Scientific Corporation, Torrington, CT, USA).
Urethane-anesthetized mice undergoing prolonged in vivo experiments have increased
mortality rates when combined with airway obstruction by stereotaxic frames (Moldestad et
al., 2009). We thus provided continuous O2 supplementation via the stereotaxic frame gas inlet
port throughout recording sessions as an alternative to additional invasive procedures (i.e.
tracheotomy). An incision was made, and the exposed skull was kept moist with saline (0.9%
NaCl) and mineral oil-soaked cotton to improve image quality (Chung et al., 2018). Burr holes
were drilled (1 mm diameter) and the dura was carefully removed by microdissection for
subsequent SD induction (initiated from bilateral burr holes in the frontal bone (ML: ± 1.0 mm,
AP: + 3.0 mm, relative to bregma) and electrophysiological recordings. Burr holes above the
motor cortex (AP: - 2.0 mm, ML: 1.0 and 2.0 mm) were used for simultaneous
electrophysiological recordings from these two locations within the right hemisphere.
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After burr hole preparation, focal stroke was induced by occluding the right distal middle
cerebral artery (dMCAo) via cauterization, as described previously (KURAOKA et al., 2009;
Lindquist and Shuttleworth, 2014). Briefly, an incision in the skin was made between the
lateral part of the orbit and external auditory meatus and the temporalis muscle was removed.
A small craniotomy (~2 mm) was drilled on the frontal bone just rostral to the zygomatic and
squamosal bone union to allow transtemporal exposure of the MCA for coagulation (see Figure
4.1A). In sham-operated animals, the MCA was exposed but not cauterized. After occlusion
or sham procedures, animals stabilized for 60 min prior to SD induction; during this time
recording electrodes were placed in burr holes over the motor cortex (see Electrophysiology).

4.3.4 SD generation
It is likely that an initial SD occurred shortly after onset of occlusion in all animals but were
not detected as this was prior to establishment of electrode recordings.

After waiting

approximately one hour for recovery from initial occlusion, SDs were initiated by
microinjection of 1M KCl, to provide reproducible sets of SDs that propagated through regions
of different metabolic capacity. KCl-evoked SDs were generated as previously described
(Aiba et al., 2011) at a rostral location, distant from the MCA territory (see Surgical Preparation
and Figure 4.1A). After visual confirmation of SD propagation (using imaging techniques,
described below), any residual KCl was quickly removed (absorbed with cotton-tip applicator).
The first induced SD was evoked 60 min. following dMCAo or sham surgeries and there were
no significant differences in the onset time of KCl-induced SDs between groups (64.4 ± 2.0
min. versus 66.5 ± 3.1 min. for sham and dMCAo animals, respectively). We examined tissue
consequences during repetitive SDs (a total of 3) separated by ~20-minute intervals (Figure
4.1B), as SDs that occur in clusters are particularly challenging for the injured brain. Under
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these conditions of repetitive induction of SDs with focal KCl microinjection, Spontaneous
SDs, were infrequently recorded, with clusters of KCl-induced SDs generated before
spontaneous events were established (von Bornstädt et al., 2015). The experimental strategy
employed here was designed similar to early work by Busch et al., that demonstrated step-wise
lesion expansion with each SD evoked in 15 min. intervals after MCA occlusion (Busch, 1996).

4.3.5. Imaging
Laser speckle contrast imaging (LSCI) experiments were conducted in a subset of C57Bl/6 and
GCaMP5G expressing mice (n = 4 male, 4 female for C57Bl/6 and n = 3 male, 3 female
GCaMP5G mice). LSCI acquisition began shortly after dMCAo or sham surgeries (~5−10
minutes) and was used to monitor blood flow changes during SD, as previously described
(Lindquist and Shuttleworth, 2014). Briefly, the intact exposed skull was illuminated by a 785
nm laser diode (Thorlabs, Newton, NJ, USA) and reflected backscattered light was longpassfiltered (720 nm) and focused with an SLR camera lens (55 mm; Nikon, Tokyo, Japan). Images
were collected at ~ 6 Hz using a digital CCD camera (Stingray F-504B, Allied Vision
Technologies, Stadtroda, Germany) and cerebral perfusion maps were calculated and displayed
in real time by LabVIEW software modified from Bernard Choi, UCI (Yang et al., 2011).
Offline calculations in Fiji (Schindelin et al., 2012) were used to normalize blood flow in
ipsilateral regions of interest (ROIs) to corresponding ROIs on the contralateral hemisphere.
ROIs were ~750µm in diameter (avoiding major blood vessels) and created in cortical areas
close to (“proximal”) and more distant from (“remote”) the ischemic MCA territory (see
schematic in Figure 4.1A). ROI coordinates were similar in sham and dMCAo groups for
remote (ML: 1.4 ± 0.05 & AP: -1.3 ± 0.09 mm in sham versus ML: 1.5 ± 0.06 & AP: - 1.3 ±
0.08 mm in stroke, P > 0.9 for both ML and AP, relative to bregma, n = 7 animals/group) and
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proximal locations (ML: 3.5 ± 0.04 & AP: -1.3 ± 0.08 mm in sham versus ML: 3.5 ± 0.06 &
AP: -1.2 ± 0.07 mm in stroke, P > 0.9 for both ML and AP, relative to bregma, n = 7
animals/group).

For Ca2+ and glutamate imaging, a custom LED-based system was built to monitor wide-field
fluorescence through the intact skull. LEDs and associated optical components were purchased
from Thorlabs (Newton, NJ, USA). A 470 nm LED was collimated and mounted to a cage
cube containing a 505 nm dichroic long pass (DCLP) beam splitter and incident light was
orthogonal to the dorsal surface of the exposed skull. Fluorescent signals were long pass (505
nm DCLP) and bandpass filtered (510/40nm). Images (1280 x 960 pix, 1 x 1 binning) were
collected at 4 Hz using a CCD camera controlled by Micro-Manager open source microscopy
software (Edelstein et al., 2010). ROIs (500 µm diameter) on dMCAo or sham ipsilateral
(right) hemispheres were normalized to corresponding contralateral ROIs and values were then
transformed to reflect change in fluorescence from baseline (∆F/F0; F0: average intensity of 10
baseline frames prior to each SD). GCaMP5G and iGluSnFR signals during SD had
contaminating signals ~30s after the peak and during the secondary phase of the transient (see
Supplementary Figure 4.2 for an example from an individual GCaMP5G sham experiment).
These are likely artifacts due to blood flow changes and/or intrinsic optical signals arising from
parenchyma tissue undergoing SD (see Discussion). In order to exclude these contributions
from both GCaMP5G and iGluSnFR analyses and examine neuronal kinetics of recovery from
SD, the peak amplitude of transients were aligned, and curves were fit using nonlinear
regression algorithms (from the peak to 30s after peak). From these curves, recovery of
fluorescence to 50% of mean baseline signals was calculated and reported as the half-life of
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recovery (t50). Due to variations in iGluSnFR signals with respect to the injection site,
glutamate signals were normalized to the peak amplitude during individual SDs, to enable
comparisons of the duration of transients. While this prevented quantitative analysis of peak
amplitudes during SD, previous reports suggest that the absolute magnitude of glutamate
accumulation during SD does not correlate with DC shift duration and/or lesion progression
after ischemia in animals (Hinzman et al., 2015; Iijima et al., 1998). In contrast, the duration
of depolarization does correlate with the duration of glutamate increases (Hinzman et al., 2015)
and suggests that the time course of recovery is likely a better indicator of potential neuronal
damage during SD versus the amplitude of the glutamate response.

4.3.6 Electrophysiology
Glass micropipettes containing Ag/Cl wires were filled with artificial cerebral spinal fluid
(aCSF; containing (in mM): NaCl, 126; NaHCO3, 26; glucose, 10; KCl, 3; CaCl2, 2, NaH2PO4,
1.5; MgSO4, 1) or normal saline (0.9% NaCl) and carefully placed in the two burr holes over
the motor cortex (see surgical preparation, above) at a depth of ~500µm for continuous
recording of DC and electrocorticographic (ECoG) potentials. Recordings were referenced to
a Ag/Cl ground wire placed under the skin through a small incision in the neck. Signals were
amplified using an Axoclamp-2B amplifier (Molecular Devices, Sunnyvale, CA, USA) and
1X or 100X (for ECoG signals) gain outputs were A/D- converted and displayed using a
PowerLab 8/35 digitizer and LabChart 7 software, respectively (AD Instruments, Dunedin,
New Zealand). A lowpass filter (0.5 Hz) was used for DC recordings and DC potential shift
durations were calculated from onset (drop below baseline voltage) to 80% recovery. ECoG
signals were bandpass filtered (0.5 – 45 Hz) and depression was evaluated according to
established clinical guidelines in LabChart 7 software, with minor modifications (Dreier et al.,
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2017b; Hartings et al., 2003, 2017) and performed by an individual who was blinded to the
experimental group. Briefly, a standard integral (20s tau of decay) was calculated from the
total ECoG power and depression durations were evaluated as the initial decrease in the
integral to the time of first recovery.

4.3.7. Drugs
Urethane was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and
dissolved daily in normal saline (0.9% NaCl). Ketamine (100 mg/ml, racemic: R (-)/S (+),
Putney, Inc., Portland, ME), was diluted in saline and administered (i.p.) at a dose of 5 mgkg1

. This dose was chosen based on pilot experiments (data not shown) and did not block SD

initiation. Ketamine or saline vehicle control was administered (i.p.) 30−45 minutes after
dMCAo or sham surgery based on recent reports showing maximum plasma concentrations of
ketamine are achieved within ~30 minutes after injection (i.p.) (Toki et al., 2018) and closely
resemble CSF concentrations (Khlestova et al., 2016; Toki et al., 2018). All other chemicals
were obtained from Sigma-Aldrich (St. Louis, MO, USA).

4.3.8 Statistical analysis
Data are reported as mean ± SEM.

Statistical analyses (one-way analysis of variance

(ANOVA), unpaired t-tests, nonlinear regressions) were calculated using GraphPad Prism
(version 8.1.0, San Diego, CA, USA) and Statistical significance was determined by P values
< 0.05, with Bonferroni correction during multiple comparisons.
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4.4 Results
4.4.1 Regional heterogeneity of cerebral perfusion responses to SD after dMCAo
After stroke, brain tissue surrounding the infarcted region is often viable but at risk for
succumbing to SD-mediated injury. To better understand mechanisms that lead to injury
progression in vulnerable tissue during SD we performed dMCAo in mice. In this model,
transtemporal access of a distal branch of the MCA allowed for occlusion under direct
visualization (representative image of MCA shown in Figure 4.1A) and resulted in perfusion
gradients across cortical areas supplied by the MCA watershed; including a necrotic core,
penumbra, and intact/undamaged brain regions (KURAOKA et al., 2009). Images created
using LSCI are shown in Figure 4.1C and show blood flow maps normalized to the
contralateral hemisphere at approximately 50 – 60 minutes post sham and dMCAo surgeries.
Group data in Figure 4.1C show cerebral perfusion deficits after dMCAo are moderately
exacerbated in regions of interest (ROIs) proximal to the infarction compared to more remote
ROIs and confirms regional differences in metabolic capacity across the cortex (Figure 4.1A).
In ROIs even closer to the site of MCA infarction, but still within the imaging field on the
surface of the cortex, relative perfusion deficits tended to be further reduced (~32 ± 1.6%
decrease from the contralateral hemisphere) compared to remote and proximal ROIs (~19 ±
3.2% and ~27 ± 2.0% for remote and proximal, respectively and also shown in Figure 4.1C).
This was a significant decrease in cerebral perfusion compared to remote (P<0.01, n=7), but
not proximal, ROI locations (P=0.11, n=7).
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Figure 4.1
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To evaluate whether modest perfusion deficits in proximal ROIs made these cortical regions
vulnerable to injury during SDs, we generated repetitive SDs at ~20 min intervals. Focal
microinjection of KCl into a rostral burr hole distant from the immediate MCA territory was
used to initiate SDs (see Methods; Figure 4.1A). In line with previous work (Ayata and
Lauritzen, 2015), relative perfusion changes during the first evoked SD (initiated 60 min. postsurgery) were predominately characterized by profound hypoperfusion with minimal
hyperperfusion in proximal ROIs, compared to more biphasic transients in less ischemic
(remote) ROIs in dMCAo mice (Figure 4.1D). Results in Figure 4.1D show that SD-induced
hyperperfusion responses during the first SD were reliably blunted only in proximal locations
in dMCAo animals. More remote regions after stroke were initially no different than respective
remote ROIs in sham animals (Figure 4.1D), however hyperemic responses were less
prominent during repetitive SD events (Figure S4.1).

The magnitude of hypoperfusion responses to SD was larger in proximal locations than in
remote areas from both sham and dMCAo animals, indicating a smaller impact of ischemia on
this parameter (Figure 4.1D). However, only dMCAo animals showed less pronounced
perfusion responses during repetitive SDs in proximal ROIs (Figure S 4.1). This could be due
to lesion expansion or other mechanisms that inhibit SD propagation in these regions. In sham
animals, successive SDs (Figure S4.1) were initiated on an already oligemic background
(resulting from the first SD stimulation, as reviewed by (Ayata and Lauritzen, 2015) and thus
hypoperfusion transients may be underestimated under this imaging paradigm (i.e. macroscale, intact skull with no thinning). This suggests that CBF measurements of hypoperfusion
during SD may be less diagnostic for determining the metabolic capacity of underlying tissue
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as it could reflect either ischemic injury progression or normal vascular responses during SD
clusters. Collectively, these data show that brain tissues proximal to the MCA occlusion are
Figure 4.2
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less able to mount hyperemic responses after SD and reflects vulnerability to further injury in
these regions (Feuerstein et al., 2014).

DC shift durations are prolonged in penumbral regions
SDs characterized by prolonged durations of depolarization can be indicative of underlying
tissue metabolic failure (Dreier et al., 2017a). We therefore monitored DC shift durations
during repetitive SDs using electrodes placed near remote and proximal LSCI ROIs (diagram
in Figure 4.2A). Representative DC shifts during SD in dMCAo and sham mice in Figure
4.2A and group data in Figure 4.2B show DC shift durations are significantly longer only in
proximal recording locations after dMCAo. In 2 mice from the dMCAo group, the DC
potential did not recover to baseline prior to the next SD stimulation in proximal tissues (Figure
4.2A, points above 15 minutes) and DC shifts were less distinguishable in recordings during
subsequent SDs. In total ~80% of all SD attempts successfully propagated (confirmed via
LSCI and/or DC recordings) into proximal tissues (17 confirmed SDs / 21 stimulations)
compared to 100% in respective remote ROIs (21 confirmed SDs / 21 stimulations; n=7 mice)
from dMCAo animals. In sham experiments 100% of stimulations evoked SD that was
detected in both recording locations (21/21 for both remote and proximal; n=7 mice).
Comparisons of hyperemia responses (shown in Figure 4.1) during SD and respective DC shift
durations in these same animals are plotted in Figure 4.2B and demonstrate that prolonged
depolarizations are accompanied by reduced tissue ability to increase blood flow (i.e. supply
demand mismatch).
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4.4.3 Extracellular glutamate recovery is delayed in Figure 4.3
proximal brain regions after dMCAo
Employing

glutamate-sensitive

microelectrode

arrays, it was recently reported that extracellular
glutamate increases are tightly time-locked with
spontaneously occurring SDs after MCAo, and also
that the duration of glutamate elevations positively
correlates with DC shift durations (Hinzman et al.,
2015). We thus evaluated the influence of dMCAo
metabolic gradients on the extent of extracellular
glutamate

accumulation

during

SD

in

our

experiments. Figure 4.3 shows representative traces
and group data of fluorescence signals during SD and
indicate that neurons in proximal zones experience
prolonged exposure to extracellular glutamate. These
data indicate that regions in proximal areas after
dMCAo are vulnerable to glutamate-mediated excitotoxicity during the DC shift of SD.

4.4.4. Ketamine reduces neuronal Ca2+ and DC shift durations after dMCAo
In brain slice models of metabolic compromise SD induces irrecoverable neuronal Ca2+
loading that can be reduced by NMDAR antagonists (Aiba and Shuttleworth, 2012) including
ketamine (Reinhart and Shuttleworth, 2018) to improve neuronal recovery. We thus monitored
cortical neuron Ca2+ accumulation during SD through the intact skull of GCaMP5G-expressing
mice (Figure 4.4). Ca2+ signal half-lives from best-fit curves show a marked delay of Ca2+
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recovery during SD in proximal ROIs in dMCAo animals (Figure 4.4B). In these experiments,
SD intervals were not different between groups, however in vehicle-treated dMCAo mice,
~83% of SD initiation attempts (15/18) resulted in Ca2+ transients observed in proximal ROIs
compared to 100% (18/18) success within remote regions. Traces in Figure 4.4C from one of
these experiments show irrecoverable Ca2+ signals during the first SD that become
significantly lost during subsequent SDs. Additionally, remote ROIs show step-wise increases
in the duration of neuronal Ca2+ that resemble more proximal areas by the final SD in the
cluster. In ketamine treated animals, SD-induced Ca2+ signals were confirmed in both remote
and proximal ROIs during all SD attempts (18/18). Results in Figure 4.4B show the time course
of recovery was accelerated in penumbral regions in the presence of ketamine compared to
delayed recoveries in proximal locations in vehicle-treated mice. However, the Ca2+ load was
still elevated compared to proximal regions in non-ischemic animals (Figure 4.4B). Traces in
Figure 4.4C show that Ca2+ dysregulation is still observed in proximal locations after ketaminetreatment likely due to the immense challenge that SD clusters pose to vulnerable brain.
Additionally, ketamine prevented the progression of irrecoverable Ca2+ accumulation in
remote regions during SD. DC recordings during SD showed that ketamine treatment could
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Figure 4.4

reduce the duration of depolarization in proximal locations (Figure 4.5) during repetitive SDs.
Comparisons of Ca2+ recovery half-life to the duration of DC shifts showed that ketamine could
reduce damaging consequences of neuronal Ca2+ loading in part by reducing the DC shift
duration after dMCAo.

4.5 Discussion
4.5.1General Findings
In this study we examined mechanisms of neuronal injury that occur during repetitive SDs in
the ischemic brain and tested whether the clinically-approved NMDAR antagonist ketamine
could reduce these damaging consequences. Using LSCI to monitor CBF, we identified brain
regions with reduced perfusion and poor neurovascular responses to SD which are implicated
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in tissue deterioration and expansion of injury after stroke. In vulnerable brain regions
(proximal to the infarction), we observed prolonged DC shift durations and impaired recovery
of extracellular glutamate and intracellular neuronal Ca2+ accumulation during SD. A dose of
ketamine that did not block SD reduced the duration of DC shifts and was accompanied by
improved neuronal recovery of intracellular Ca2+ loading during SD. Collectively, these results
indicate that excitotoxic mechanisms can be targeted to reduce deleterious consequences of
SD in vivo after stroke.

4.5.2 Experimental design
We induced focal ischemia in mice by occluding the MCA, as this approach is thought to
resemble the most common type of insult experienced in stroke patients (Alessandra et al.,
2014). MCA occlusion has the advantage over global ischemia or bilateral common carotid
artery (CCA) intraluminal filament approaches as it promotes the development of collateral
flow and thus readily-discernable regions of metabolic differences (i.e. necrotic core,
salvageable penumbra, and healthy tissue) (KURAOKA et al., 2009) and (Xi et al., 2004). We
chose to occlude a distal branch of the MCA (dMCAo) as other methods, including
intraluminal approaches, occlude the MCA at more proximal locations which can also interrupt
perfusion along bifurcations within the Circle of Willis as the suture ascends the internal
carotid artery (ICA) (Alessandra et al, 2014). As such, although the intraluminal MCAo is less
invasive during stroke induction, it results in larger ischemic lesions beyond the MCA territory
that includes neuronal death in subcortical structures including the caudate and hippocampus.
These larger stroke models are useful for examining functional deficits as there are no obvious
functional impairments elicited by the surgical dMCAo model in mice (KURAOKA et al.,
2009, Xi et al., 2004).
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We took advantage of the resultant metabolic heterogeneity of the focal dMCAo stroke model
to examine SD mechanisms that contribute to neuronal injury and lesion expansion. This was
also useful for examining the effect of ketamine as prior work has demonstrated that NMDAR
antagonists are less effective in tissues that are closer to the infarction due to pathological
elevations in extracellular K+ in these regions (Petzold et al., 2005). Since the delayed phase
of injury progression occurs in the hours to days after stroke onset (Hartings et al., 2003), we
initiated a cluster of 3 SDs using local application of K+ in order to image excitotoxic
mechanisms during SD over a shorter time-scale. This experimental design is according to
similar protocols employed in earlier work by Busch et al. that provided a causal role of SD in
stepwise injury expansion monitored via diffusion-weighted MRI (Busch et al., 1996).

4.5.3 SD-induced cerebral perfusion responses reflect regional heterogeneity in brain
metabolic capacity
Using LSCI to monitor CBF throughout the entire cortex, we confirmed regional differences
in perfusion (prior to SD stimulations) in dMCAo animals (Figure 4.1). Due to technical
limitations (i.e. repositioning of animals for imaging and electrophysiology after surgery) we
did not collect baseline perfusion maps prior to dMCAo or sham surgeries. Therefore, residual
blood flow compared to baseline levels was not used to determine stroke core and penumbra
areas based on previous literature. Instead, ROIs were normalized to their respective locations
in the intact contralateral hemisphere during analyses and cortical areas with mild (remote) and
moderate (proximal) levels of perfusion deficits were identified. ROIs placed as close as
possible to the site of surgical occlusion and still within the imaging field showed a slight but
not significant decrement in perfusion compared to proximal ROIs (i.e. ~32% vs. ~27%). This
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could indicate that more severe perfusion deficits exist outside of our field of view and
represent the true infarct core.

After identifying remote and proximal ROIs with reduced vascular supply, we examined CBF
responses to SD in sham and dMCAo animals (Figure 4.1). In the naïve otherwise healthy
cortex in mice, intact neurovascular coupling in response to a single SD is most often
characterized by profound initial hypoperfusion which is followed by transient hyperperfusion
and long-lasting oligemia (as shown Figure S4.1. traces during the first SD in a sham animal).
On this oligemic background, we saw that subsequent SDs did not exacerbate blood flow
decreases, and hemodynamic responses to SD were predominately hyperemic, as previously
described (Ayata and Lauritzen, 2015). Though dMCAo did not drastically alter the magnitude
of hypoperfusion, we did observe a marked reduction in the degree of hyperperfusion
responses to SD in proximal ROIs closer to the infarct (Figure 4.1D) that was consistent during
repetitive SDs (Figure S4.1). Initially, hyperperfusion responses in remote ROIs after dMCAo
were similar to sham experiments (Figure 4.1D). However, there was progressive loss of SDinduced hyperperfusion in these regions during repetitive SDs, that was not observed in control
animals (Figure S4.1). This transition of SD hemodynamics relates to tissue metabolic capacity
and has been observed after ischemia in animals (Feuerstein et al., 2014; Shin et al., 2005;
Sukhotinsky et al., 2008; Strong et al., 2006) and in humans after malignant middle cerebral
artery infarction (Woitzik et al., 2013) and may be attributed to pathological mechanisms
preventing hyperemia (Dreier, 2011; Dreier et al., 1997), and/or the inability of maximally
dilated vessels to increase local CBF (Feuerstein et al., 2014).
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Our findings further emphasize the continuum of consequences of SD in the injured brain
(Ayata and Lauritzen, 2015; Dreier, 2011). In combination with poor vascular supply, impaired
neurovascular coupling during SD (especially in more proximal areas), likely signifies that a
brain region is compromised (Ayata and Lauritzen, 2015) and at risk for tissue deterioration
during SD (Feuerstein et al., 2014). We therefore sought to examine cellular mechanisms that
contribute to deleterious neuronal consequences of SD and test whether ketamine could
interfere with these injury processes.

4.5.4 DC shift duration
The breakdown of electrochemical gradients during the DC shift of SD (Somjen, 2001) is
estimated to be the largest disruption of homeostasis in living neural tissue and is thus
energetically costly, even in non-injured brain (Dreier and Reiffurth, 2015). After MCAo in
rats, spontaneous and repeated SDs with prolonged DC shifts correlate with histological
neuronal damage (Mies, 1993). Injurious consequences of SD are also implicated in brain
trauma patients where poor neurological outcomes are associated with prolonged DC shift
durations (Hartings et al., 2011).

In our experiments, we saw a range of DC shift durations (Figure 4.2) after dMCAo in
proximal locations that became significantly prolonged with repetitive SDs. However, there
were many DC shifts that had similar durations to sham controls and remote recording
locations. Across studies there seems to be no concrete time period of depolarization required
for injury but prolonged DC shifts and accompanying low perfusion appear to be main
contributors (Dreier et al., 2018). In support of these findings, we observed that SDs in
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proximal dMCAo regions have longer DC shift durations and reduced hyperemia, and further
suggest these regions are vulnerable to injury (Figure 4.1 & 4.2).

4.5.5. Glutamate
Brain slice studies have demonstrated that substantial glutamate release and NMDARmediated Ca2+ influx into fully depolarized neurons during the late-phase of the DC shift are
important mediators of deleterious SD consequences (Aiba and Shuttleworth, 2012; Dietz et
al., 2008). To examine neuronal mechanisms of injury during SD, we used viral delivery of
the glutamate sensitive reporter iGluSnFR that is expressed on the extracellular surface of
neurons (Marvin et al., 2013). In a recent report, glutamate transients following K+- induction
of SD were monitored with two-photon imaging of iGluSnFR in the healthy cortex and
demonstrated relatively rapid recovery of extracellular signals returning to baseline levels
within ~20 seconds (Enger et al., 2015). In nominally healthy brain slices, we have observed
similar recovery time courses of glutamate during SD (data not shown). Here, we examined
iGluSnFR transients during SD initiated from a less ischemic brain region after dMCAo and
saw that SD-mediated glutamate increases were prolonged (> 30 seconds, based on t50
calculations). While the use of different imaging modalities prevents direct comparison to
published findings (Enger et al., 2015; Iijima et al., 1998), it is likely that neuronal compromise
contributes to enhanced glutamate accumulation that occurs only in synchrony with SD after
dMCAo (Fabricius et al., 1993; ijima et al., 1998). This is also supported by glutamate
microelectrode array findings where glutamate durations, but not absolute magnitudes of
increases, correlated to prolonged DC shift durations during SD (Hinzman et al., 2015).
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Our data confirms these findings and provides further evidence that damaging consequences
of SD are in part mediated by extended exposure of penumbral neurons to the excitotoxic
effects of glutamate (Figure 4.3). In addition to contributing to regenerative presynaptic
glutamate release (Zhou et al., 2013) and ionic disruption during SD (Somjen, 2001), clearance
of extracellular glutamate is metabolically costly; consuming ~1 ATP per molecule of
glutamate (Danbolt, 2001). These results suggest that gradients of glutamate accumulation
during SD can exist simultaneously across different brain regions after focal ischemia and
further support the notion of a continuum of SD consequences with respect to tissue metabolic
capacity (Hartings et al., 2017).

4.5.6 Calcium
Extracellular glutamate concentrations (>10 µM) (Hinzman et al., 2015; Iijima et al., 1998)
and near-complete depolarization of neurons (Somjen, 2001) are sufficient to activate all
receptor subtypes of NMDARs (EC50: ~0.5- 2µM) (Nakanishi et al., 1992). It is thus likely that
prolonged glutamate signals observed during SD in metabolically compromised brain regions
results in excitotoxic intracellular Ca2+ accumulation. Using GCaMP5G-expressing mice, we
observed relatively uniform basal Ca2+ fluorescence in the parenchyma through the intact skull
(Figure 4.4).

During SD, profound perfusion artifacts likely contribute to the intensity of Ca2+-bound
GCaMP5G fluorescence as both oxy- and deoxyhemoglobin (HBO2 and HBR, respectively)
have absorption at the GCaMP wavelength (470nm, used here) (Ma et al., 2016). Prior to SD
in the healthy cortex, molar extinction coefficients of HBO2 and HBR are relatively
comparable and thus similarly absorb excitation light. During SD in the naïve brain,
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hypoperfusion and vasoconstriction will cause a decrease in both HBO2 and HBR (likely at the
SD-wave front) while subsequent hyperemia will increase delivery of HBO2. During the
prolonged phase of oligemia, CBF can be decreased by ~60% (Shin et al., 2005) and coincides
with increases in oxygen metabolism and hemoglobin desaturation (Yuzawa et al., 2011).
Corresponding to this phase, we observed a substantial increase in Ca2+ fluorescence intensity
after the first SD in sham animals (Supplementary Figure 4.2) and is likely due to less
absorption of both HBO2 and HBR compared to pre-SD levels. Thus, in order to compare
GCaMP5G dynamics during SD, we used the initial time course of fluorescence recovery from
peak (aligned to 0s) to 30s as an indicator of the capacity of neurons to recover from
intracellular Ca2+ accumulation during SD (Figure 4.4).

We observed slower recovery of Ca2+ in proximal regions after SD that failed to return to
baseline in 3/6 mice during imaging. When SD-induced Ca2+ transients failed to recover, SDs
did not propagate into the same ROI during subsequent stimulations. Traces in Figure 4.4C
show that failure of SD to propagate into proximal locations was coincident with progressively
delayed time courses of Ca2+ recovery in remote ROIs and could indicate expansion of the
injury into these brain areas.

4.5.7 Ketamine
Based on prior animal studies and recent findings in humans, we tested whether ketamine could
reduce neuronal Ca2+ load in metabolically vulnerable brain regions without preventing SD in
remote regions. In rodents, intraperitoneal injection of up to 30 mgkg-1 are considered
subanesthetic ketamine doses and are used in many animal models examining ketamine’s rapid
anti-depressive effects (Zanos et al., 2016; Zanos and Gould, 2018). Additionally, the potency
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of ketamine blockade of NMDARs depends not only on receptor subunit composition but also
ketamine stereospecificity (Glasgow et al., 2017; Khlestova et al., 2016). Both stereoisomers
of ketamine S (+) and R (−) are clinically used however the S (+) isomer is ~ 2-times more
potent at NMDARs (Peltoniemi et al., 2016). Here we used a 5 mgkg-1 dose of racemic
ketamine which is thus expected to correspond to subanesthetic doses in humans (~0.5 mg/kg;
(Khlestova et al., 2016)).

Ketamine (5 mgkg-1) reduced intracellular Ca2+ loading in neurons and the duration of
depolarization during SD (Figures 4.4&4.5). Here, we detected DC shifts and/or Ca2+
transients in all animals undergoing repetitive SD challenge (in sham and ketamine-treated
dMCAo groups) and thus suggests that underlying tissue is viable as it can sustain subsequent
SDs (Koroleva and Bures, 1996). Since SDs that occur in clusters are particularly challenging
for compromised tissues, ketamine did not completely prevent the development of
irrecoverable Ca2+ transients during SD in more ischemic regions.

However, ketamine

exposure did delay the progression of injury into remote regions (Figure 4.4). These data are
consistent with our prior findings using ketamine in metabolically vulnerable brain slices
challenged by SD (initiated by K+); where neuronal Ca2+ influx was attenuated by ketamine
(30µM) without preventing SD propagation (Reinhart and Shuttleworth, 2018). In those
studies, ketamine improved recovery of evoked neurotransmission and brain slices were
capable of propagating subsequent SD waves and is indicative of viable neurons (Koroleva
and Bures, 1996).

4.5.8 Conclusions and Implications
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In this study, we saw increased vulnerability of neurons to excitotoxic injury during SD in vivo
that was based on proximity to the infarction. In these proximal regions, insufficient blood
supply and prolonged DC shift durations can contribute to neuronal injury during SD. We
additionally found that accumulation of extracellular glutamate and intracellular neuronal Ca2+
are enhanced in vulnerable brain regions and serve as potential cellular targets for limiting
excitotoxicity during SD. This is supported by our findings that ketamine could reduce the
duration of DC shifts and neuronal Ca2+ loading during SD.

Doses of ketamine and other NMDAR antagonists required to suppress SD are greater than
those needed to prevent NMDAR activation under normal physiological conditions (Pietrobon
and Moskowitz, 2014). NMDAR activation is likely important for brain recovery after injury,
and blockade of downstream cell survival mechanisms is thought to contribute to the
unsuccessful clinical trials of NMDAR-antagonists in acute ischemic stroke patients (Wu and
Tymianski, 2018). Additionally, NMDAR antagonists are less effective at preventing SD after
brain injury likely due to pathological increases in extracellular K+ concentrations (Petzold et
al., 2005). Together, the high doses of ketamine capable of blocking SD in the injured brain
might do so at the expense of important NMDAR-dependent repair processes. While work is
needed to determine whether SD itself contributes to cellular repair and/or other processes (i.e.
preconditioning) in remote tissues in the aftermath of stroke, these findings support the clinical
use of ketamine to reduce SD-mediated injury after ischemic stroke.
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4.6 Supplementary Figures
Figure 4.5
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Figure 4.6

.
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5.1 Summary

5. DISCUSSION

Initial studies in this dissertation project were designed in brain slices using fluorescent
glutamate and Ca2+ reporters in order to exclude complex vascular responses to SD (as seen in
Chapter 4 experiments) and evaluate consequences specific to neurons. Early during the
pursuit of this work, it became clear that current models for examining SD consequences in
metabolically impaired tissues were limited and relied on mostly complete substrate removal
(hypoxia or OGD). A novel brain slice model of metabolic compromise that conferred
neuronal vulnerability to SD was thus initially employed in Chapter 2 and subsequently
characterized in Chapter 3. In these studies, extracellular glutamate (Chapter 3) and
intracellular neuronal Ca2+ (Chapter 2) accumulation in response to SD were both prolonged
by metabolic compromise and associated with poor recovery of synaptic responses—revealing
an opportunity for therapeutic intervention. Brain slice studies with ketamine (Chapter 2)
provided proof of concept data that mediators of injury can be reduced (i.e. Ca2+ loading via
NMDAR opening) to improve neuronal recovery without preventing SD outright.

Prolonged accumulation of glutamate and Ca2+ during SD was confirmed in Chapter 4 studies
that translated brain slice findings to in vivo experiments after dMCAo. Findings that glutamate
and neuronal Ca2+ levels are enhanced during SD in peri-infarct tissue are consistent with the
role of these mediators in lesion expansion. Chapter 4 studies also demonstrated the protective
nature of ketamine where reduced DC shift durations and NMDAR-mediated Ca2+ loading
made neurons less vulnerable to SD consequences. Importantly even though mechanisms and
interventions were first characterized in brain slices, they remained prominent in the presence
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of massive cerebrovascular responses to SD; responses that involve elevations in virtually all
vasoactive substances– including NO, adenosine, K+ (Ayata and Lauritzen, 2015). Also
important is the efficacy of ketamine on SD consequences in penumbral tissue– regions where
NMDAR antagonists have been previously shown to have little effect on SD (determined as
the ability of blockade) due to pathological elevations in interstitial K+ concentration (Petzold
et al., 2005). While information regarding the best effective dose for reducing SD
consequences were not examined in this dissertation (largely due to substantial speciesdependent differences in effective ketamine doses, discussed in Chapter 2), this work provides
evidence that ketamine or even related (e.g. memantine (Emnett et al., 2013)) medications may
be repurposed to limit deleterious consequences of SD after stroke (see Appendix A for initial
brain slice studies with memantine). The figure below summarizes mechanisms involved in
deleterious consequences of SD that will be considered throughout the discussion of this
dissertation work (Figure 5.1).
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Figure 5.1
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5.2 Brain slice model of metabolic compromise
5.2.1 SD consequences and the relationship to tissue metabolic capacity
Brain slice techniques are important in basic neuroscience, as experiments can be wellcontrolled and enable separation of neuronal from confounding in vivo vascular responses.
However, in vitro tools present a challenge for stroke researchers as the complexities of brain
ischemia are hard to achieve outside of the intact animal. Current in vitro techniques for
examining neuronal injury after ischemia are thus largely limited to OGD or hypoxia models
that induce injury and thus complete substrate removal. While these methods are important
for understanding tissue and cellular responses to energy depletion, findings from such studies
may only be directly applicable to the core of the injury that is established shortly after
infarction (Dirnagl et al., 1999) As such, complete deprivation models may offer little
information about injury development in vulnerable tissues surrounding an infarct core—i.e.
in tissues that are viable until the additional burdensome hit of SD.

Pharmacological studies indicate that no single ion channel or receptor can be targeted to
reliably prevent SD during OGD in brain slices or in vivo following CBF arrest (and if there
was, perhaps this would be the key for immortality). In support of this idea, early studies in
this dissertation found no effect of ketamine (up to 100µM, data not shown), and the related
less-potent antagonist memantine (up to 300µM), in delaying or preventing SD induced by
OGD in brain slices (discussed in more detail in Appendix A) Prior to this work, similar
findings were observed in vivo where ketamine had no effect on blocking terminal
depolarization in rats exposed to anoxia (via inhalation of N2) or asphyxiation (Amemori and
Bures, 1990; Hernándéz-Cáceres et al., 1987; Marrannes et al., 1988b). This is further
supported by the failure of more potent antagonists than ketamine (e.g. MK801) or competitive
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NMDAR antagonists (e.g. APV) in preventing SD initiated by OGD (Jarvis et al., 2001;
Obeidat et al., 1999) or circulatory arrest in rats (Lauritzen and Hansen, 1992). These studies
collectively indicate that extensive ion loading and the absence of metabolic substrates during
SD are sufficient to kill neurons in the ischemic core– even when NMDARs are inhibited
(Hartings et al., 2017).

The above studies emphasize the overt inability of NMDAR antagonists to prevent SD (or
neuronal injury) in situations of complete metabolism arrest. However, in light of our
understanding that SD is not always detrimental to tissue, perhaps our models for examining
SD simply need adjustment in order to better test both interventions and mechanisms in a
variety of metabolic conditions. The development of the brain slice model of SD vulnerability
(Chapters 2 & 3) in this dissertation thus adds another step along our progress in understanding
consequences that fall along the ‘continuum’ of SD. This continuum can be inspected in vivo,
especially after a focal occlusion (as employed in Chapter 4 studies) that greatly augments
regional heterogeneity in cerebral perfusion and tissue metabolic requirements. In vitro studies,
on the other hand, have largely been limited to the two extremes along the continuum–SD in
nominally healthy conditions (generated via K+ or electrical stimuli) or SD in severely
compromised brain (induced by hypoxia/OGD).
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From this dissertation work and the description of

Figure 5.2

a new model of compromise, we are now able to
reliably assess mechanisms by which otherwise
viable neurons succumb to the excitotoxic
consequences initiated by SD. Moderate metabolic
compromise was used to increase neuronal
vulnerability to deleterious consequences of SD
without complete substrate removal (Chapters 2 &
3). This was achieved using modified artificial
cerebral spinal fluid (aCSF) containing elevated K+
(8mM) and by reducing super-fusion of aCSF (i.e.
oxygen and glucose delivery) to one only side of
the preparation. This reduction was achieved via a
slight modification in the recording chamber
configuration, as described in Chapter 3 and shown in Figure 5.2.

As opposed to OGD, SD did not spontaneously develop in these conditions and thus SD was
initiated using focal K+ microinjection. This type of focal SD induction, on top of mild
metabolic compromise and moderate extracellular K+ increases, is likely related to SDs
generated in response to fluctuations in tissue pO2, depolarization and K+ efflux, or other
stimuli that create supply-demand-mismatches in penumbral zones after stroke (von Bornstädt
et al., 2015).
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5.2.2 In vitro models of moderate metabolic impairment
Additional techniques exist for limiting brain slice substrate, without total deprivation;
although the impact of compromise is sparsely evaluated in the context of SD (except see
Canals et al., 2008; Lindquist and Shuttleworth, 2014). In submerged slices, the rate of aCSF
super-fusion can drastically alter tissue oxygenation levels which in turn influences evoked
and spontaneous network activity, short-term plasticity, and other processes that rely on
oxidative metabolism (Ivanov et al., 2011; Frengulli, 2017). However, perfusion rates of aCSF
not only increase delivery of substrates but also influence normal clearance of metabolites and
neurotransmitters which makes results more difficult to interpret and compare to control slices.
Brain slices of varying thicknesses have also been utilized to mimic ischemic environments in
vitro (Newman et al., 1990; Lindquist and Shuttleworth, 2014). The lack of capillary support
makes brain slices completely reliant on aCSF delivery of oxygen and glucose substrates; as
such, pO2 measurements at the well-perfused slice surface are often drastically higher than pO2
levels buried in the depths of the tissue (Chapter 3, Figure 3.2) and in Hall et al., 2012;
Lindquist and Shuttleworth, 2014) . This steep gradient is even more pronounced in thicker
brain slices and additional evidence of diminished metabolism is suggested by elevated lactate
concentrations, increased basal NAD(P)H, and impaired oxidative transients following
synaptic stimulation (Lindquist and Shuttleworth 2014; Ivanov et al., 2011). Other models,
still, have employed gliotoxins (Canals et al., 2008) or chemical anoxia (ouabain, (Rosen,
1993; Dietz et al, 2008)) that also induce SD and subsequent neuronal injury (Obeidat and
Andrew, 1998), but do not require complete metabolic restriction.

While chemical toxicity can provide useful information about the involvement of certain cell
types and receptors theoretically involved in ischemia/SD-induced injury, the vulnerable
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model (developed in this dissertation) has an advantage of not requiring poisoning of the tissue
and related off-target effects. While thicker brain slices are indeed impaired and likely
resemble vulnerable tissues after ischemia, proper comparisons to healthy (control) slices must
be corrected for tissue size which could augment perceived contributions of metabolic
byproducts (e.g., lactate, adenosine, etc.) (Lindquist and Shuttleworth, 2014) in addition to
influencing the accumulation of neuroactive substances, differences in slice volume could also
affect fluorescence signals (i.e. glutamate, Ca2+, NAD(P)H) and SD-induced IOS read-outs of
slice integrity that were used heavily throughout this dissertation The experimental model of
tissue vulnerability to SD (Figure 5.2) requires further characterization studies; however, aCSF
perfusion and slice thickness were held constant (~2 mL min-1, 350µm) and thus potentially
circumvented the above limitations of alternative experimental conditions.

5.2.3 Relationship between complete substrate removal and brain death
Classical OGD or hypoxia models of ischemia create a gradual run-down of ATP
concentrations causing impairment of Na+/K+ ATPases and other ATP-dependent pumps or
channels. In hippocampal slices exposed to hypoxia, a brief phase of hyperpolarization (Czeh
et al., 1993) is followed by the failure of action potential-dependent presynaptic
neurotransmitter release (Hershkowitz et al., 1993; Pietrobon and Moskowitz, 2014).
However, spontaneous (largely TTX-insensitive) synaptic potentials (excitatory and
inhibitory) are not prevented by hypoxia and actually may increase very early on (within
seconds) along the progression of ATP depletion in hippocampal (Hershkowitz et al., 1993;
Pietrobon and Moskowitz, 2014) and neocortical slices (Fleidervish et al., 2001). These swift
disturbances in neurotransmission during hypoxia (prior to SD onset) could underlie the rapid
and reversible alterations of cortical activity during global ischemia experiments in vivo (see
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Introduction). Perhaps this sequence of perturbed integration of presynaptic inputs with
postsynaptic responses (Fleidervish et al., 2001; Revah et al., 2016) underlies the loss of
consciousness seen in Red Wing experiments (Rossen et al., 1943) (or perhaps in patients with
orthostatic hypotension, for example) that was coincident with cortical EEG slowing and
occurred within ~20s after the critical drop in cerebral perfusion (Lennox et al., 1938). The
decline of postsynaptic evoked activity could be an attempt to preserve ATP, as active synapses
are high consumers of energy, and thus neuronal hyperpolarization would attenuate
postsynaptic currents and thus truncate ATP consumption (Dreier and Reiffurth, 2015; Revah
et al., 2016). This is supported by recent work (mentioned in Introduction) showing
extracellular glutamate levels decrease by ~60% at the onset of ischemia prior to terminal SD
near the core of infarcted tissue after MCAO (Hinzman et al., 2015). While potentially
protective in the early stages, if substrate removal is sustained neurons and their mitochondria
will continue to depolarize and extracellular K+ will progressively increase. Once the net
current flow across the cell membrane turns inward, SD erupts and the electrochemical
gradient collapses (Table 1.1., in Introduction) (Dreier, 2011).

Along the progression of persistent ischemia (as in experiments performed by Leão) SD
develops shortly after (~2-5 min.) the decline of evoked cortical activity— which now becomes
irrecoverable in the absence of reperfusion (LEAO, 1947). As mentioned previously, in these
metabolically desolate environments no single channel or receptor can be targeted to
completely prevent SD and the subsequent neuronal injury in either in vitro or in vivo
experiments. This pathophysiological sequence was also confirmed in severely brain injured
patients where, upon withdrawal of life-sustaining treatment, cortical activity deteriorated
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(Norton et al., 2017) and according to recent findings, was followed (~13 – 14.5 min. later) by
terminal SD (Dreier et al., 2018). It is important to note this order of events as they diverge
from tissues that are viable until the additional hit of SD, described in more detail below.

5.2.4 Vulnerable slices are similar to outer penumbral regions after stroke
Some characteristics of tissue heterogeneity after focal ischemia were described by Lindsay
Simon and colleagues in the late 1970s and early 1980s (Astrup et al., 2018; Branston et al.,
1977; Hartings et al., 2017). In general, the ischemic core of the infarct (i.e. the initiation site
of the first terminal SD) is characterized by electrical silence and very low residual perfusion
(<5-10ml/100g/min); the inner penumbra has slightly improved residual flow due to collateral
circulation (>5-10 and <15-23ml/100g/min) and is structurally intact though remains
functionally inactive. The outer penumbra is oligemic (>15-23 and <35ml/100g/min), but
neurons show only moderate signs of distress (Canals et al., 2008) while electrical activity is
largely intact. In the course of hours to even days after stroke onset, SDs can initiate in either
inner or outer penumbral regions (Hartings et al., 2017) and hot spots for SD induction may be
more likely in the outer penumbral due to intact neuronal activity and mismatched vascular
coupling (von Bornstädt et al., 2015). This may be especially augmented owing to pathological
elevations in extracellular K+ levels that transform steeply across the different flow thresholds,
described above (Branston et al., 1982). The extracellular ionic environment (namely K+
increases) have been shown to reduce the ability of NMDAR-antagonist blockade of SD
leading to dominant assumption in the field that the most vulnerable brain regions will benefit
the least from drugs targeting NMDARs (Petzold et al., 2005). This is particularly important
for studies in this dissertation and thus will be discussed in upcoming sections for both brain
slice and in vivo stroke experiments.
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Based on these broad definitions (and work in Chapter 3, described below), the brain slice
model of metabolic compromise developed during experiments in this dissertation is proposed
to be a model of outer penumbral tissues after ischemic stroke. It is noteworthy that the
recording configuration used here to model tissue at-risk (i.e. slice resting at the level of the
glass coverslip) is commonly employed by slice electrophysiologists, albeit with minor
changes in superfusion rate and/or slice thickness.

5.2.5 Cellular changes prior to SD
Chapter 3 in this dissertation focused on characterizing differences between vulnerable and
nominally healthy brain slices (i.e. slices perfused on both surfaces) and the most significant
effect was found on synaptic responses (described in more detail below). Signs of metabolic
stress did not prevent extended EPSP recordings (up to 60 min) or synaptic plasticity (i.e. longterm potentiation) in vulnerable slices, thus confirming the presence of intact hippocampal
circuitry (data not shown). This again contrasts to complete neuronal suppression observed
shortly after OGD/hypoxia introduction.

Postsynaptic responses in vulnerable preparations were consistently decreased compared to
controls (Chapter 3, Figure 3.1) in part due to a reduction in initial release probability of
glutamate from schaffer collateral inputs (i.e. increased PPR). These changes could be
attributed to an increase in A1R activation (as shown in experiments using the selective
antagonist DPCPX), which strongly suggests a rise in extracellular adenosine in vulnerable
slices. Increases in adenosine in vulnerable slices could reflect changes in energy metabolism
and mitochondrial bioenergetics in neuronal and nonneuronal cells (Boison et al., 2013).
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In the healthy brain, extracellular adenosine levels are typically in the sub micromolar range
(Frenguelli, 2017) and thus A1R activation is relatively low, resulting in lower paired-pulse
ratios and larger evoked synaptic responses, as shown in adequately perfused brain slices
(Figure 3.1). Minor decreases in intracellular ATP concentrations can cause not only
significant increases in adenosine levels (Boison et al., 2013) but also promote the opening of
ATP-sensitive potassium (KATP) channels (Heurteaux et al., 1995); processes that both
contribute to reduced neuronal excitability. Reduced synaptic efficacy and increased PPR
could thus reflect mild metabolic stress and declining intracellular ATP concentrations in
vulnerable brain slices.
In addition to presynaptic dampening of neuronal activity, adenosine can activate postsynaptic
A1Rs which can provoke downstream opening of inwardly rectifying K+ channels (Boison et
al., 2013) and result in membrane hyperpolarization. This would further reduce synaptic
efficacy when ATP concentrations are diminished. Interestingly, adenosine itself can modulate
(KATP) channels by inducing their internalization in metabolically stressed hippocampal CA1
neurons (Hu et al., 2003). Perhaps this provides insight with regards to mechanisms involved
in hypoxia/ischemia-induced early hyperpolarization (KATP activation) versus subsequent
action potential failure prior to the development of SD—i.e. perhaps adenosine’s actions
outweigh other mechanisms to overall illicit presynaptic inhibition and KATP internalization.

Together, actions of adenosine may be theoretically protective (or compensatory) and
minimize metabolically costly neuronal activities (i.e. vesicular release and postsynaptic
depolarization) in times of energy crisis (Boison et al., 2013). This concept of protection and/or
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compensation will be further discussed in later sections regarding evolutionary responses of
SD but may help explain why tissue pO2 levels were unchanged in vulnerable slices at baseline.
The changes observed in vulnerable slices seem to be intermediate between nominally healthy
and severely compromised tissues (hypoxia/OGD). Therefore, findings from Chapter 3 further
support the use of this model as a tool for studying consequences along the SD continuum.

5.2.6 Vulnerability to SD injury
A main concern for ICU patients and clinicians in the aftermath of stroke is progressive infarct
expansion into previously viable brain tissue. This deterioration is usually only detected at
infrequent snapshots in time (i.e. during neurological exams or brain imaging) and thus
pinpointing the underlying pathophysiology related to SD remains very challenging today.
This is especially difficult in the most severe cases of acute brain injury, where substantial
sedation and attendant ICU complications are additional obstacles to patient stability and
adequate assessment of brain physiology. While scalp-EEG has been employed in the ICU
brain injury setting, current technical limitations prevent the identification of SD via these
methods. As such, substantial efforts were made by COSBID investigators to record from
subdural ECoG strips placed during neurosurgical procedures in patients after acute brain
injury. In 2008, the first study in ischemic stroke patients was published showing SD can occur
in patients up to a week after occlusion onset (Dohmen et al., 2008). In that report the authors
highlighted an instance where functional brain activity was suddenly and irreversibly
suppressed immediately after SD propagated through series of channels located within the
ECoG recording strip. This emphasizes that brain tissue in the outer penumbra can be viable
until faced with an insurmountable energy crisis produced by an SD.
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In the present dissertation study, neurons in metabolically compromised brain slices were
specifically vulnerable to the massive energetic demands imposed by SD, and these
observations support the hypothesis that the additional hit of SD, on the backdrop of metabolic
compromise (and not compromise alone), elicits acute neuronal impairment (Obeidat and
Andrew, 1998). This was shown in Chapters 2 & 3 where synaptic potentials were intact,
though reduced in amplitude (discussed above), prior to SD and were only lost or impaired
after SD. Interestingly, pre-exposure to the A1R antagonist DPCPX could almost fully restore
postsynaptic responses in vulnerable slices (Chapter 3, Figure 3.1 and described below) which
raises important questions as to the true viability of silent neurons in the wake of SD. While
again further studies are needed, these experiments support prior findings (Lindquist and
Shuttleworth, 2012, 2014) that extracellular adenosine is partially responsible for the
prolonged synaptic depression after SD in vulnerable conditions. However, the indication that
neurons can respond to stimuli contrasts with optical read-outs of slice heath (i.e. intrinsic
optical signals, IOS) that were unaffected during DPCPX exposures (Chapter 3, Figure 3.4).

Intrinsic optical signals (IOS) have been well-characterized in the hippocampus of brain slices
following OGD/hypoxia (Andrew et al., 1999; Jarvis et al., 2001) where substantial decreases
in transmitted light through stratum radiatum dendrites (like those seen in Chapters 2 & 3
experiments, Figures 2.6 and 3.4) accompany acute signs of neuronal damage including
dendritic beading. SD-induced dendritic beading can be observed in vivo where recovery can
be rapid (<3 min.) in tissues with adequate CBF; however, when perfusion responses no longer
meet the energetic demand of SD (i.e. in metabolically compromised brain), beading is
irreversible (Risher et al., 2010). Experiments in vulnerable brain slices also demonstrated
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profound decreases in light transmittance in stratum radiatum after passage of the SD wave
front; changes that appear consistent with IOS signs of neuronal injury after SD (Andrew et
al., 1999).

In that previous work, Obeidat and colleagues noted that when slices did not undergo SD (i.e.
OGD was stopped prior to SD onset), that dendrites (visualized histologically or via bulk
fluorescent dye loading) were smoothly contoured, as opposed to SD slices that had beaded
processes that were more difficult to resolve. Interestingly, morphological changes in neurons
were mentioned in early results by Grenell (described in Introduction) where he denotes the
presence of pathological changes and increased “tortuosity” of neuronal processes in brains
from seemingly different causes of death in animals (GRENELL, 1946; HOFF et al., 1945).
Perhaps tortuosity is simply another word used to describe dendritic beading—which also
deforms dendritic processes, making them more difficult to resolve. Additional work in brain
slices has shown that acute pyramidal cell injury (resulting from NMDA exposure) is
associated with dendritic beading and the relocation of microtubule-associated protein (MAP2)
immunoreactivity from CA1 processes to somata compartments (Hoskison et al., 2007;
Hoskison and Shuttleworth, 2006). Based on these descriptions, MAP2 immunohistochemistry
was used to examine pyramidal cell changes after SD in vulnerable slices (Figure 3.4) at the
same time-point that IOS changes were quantified (Figures 2.6 and 3.4).

At this time point (~10 min. post SD), vulnerable slices had variability in the extent of both
MAP2 redistribution and obvious structural deformations; though pyramidal cell processes
after SD did look more “tortuous” according to descriptions by (GRENELL, 1946; HOFF et
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al., 1945). In retrospect, images immediately following toxic NMDA exposure also have a
more tortuous appearance in (Hoskison et al., 2007); however, striking changes in MAP2
fluorescence were evident much later (> 20 min.) following NMDA in these experiments. It is
thus possible that diminished MAP2 in processes (and corresponding somata increases) had
not fully developed by this chosen time after SD in vulnerable slices. Additionally, since aCSF
superfusion is predominately reduced below the slice (in the vulnerable configuration), there
could be gradients of neuronal injury with respect to the extent of compromise throughout the
thickness of the tissue. This is also supported by pO2 measurements in Chapter 3 as well as
previously described data by (Lindquist and Shuttleworth, 2014). In those results, gradients in
pO2 availability diminished along the depth of the slice and disruptions in oxidative
metabolism (i.e. NAD(P)H transients) was also observed during SD (initiated by K+). In
metabolically vulnerable preparations pO2 availability was also markedly attenuated at all
depths after SD (Chapter 3), and thus additional studies would be useful to quantify MAP2 (or
other markers of neuronal integrity) throughout the full thickness of the tissue. Due to
challenges with antibody penetration throughout the full thickness of the slice (350µm), an indepth characterization of MAP2 changes was not attempted in these dissertation experiments.
However, overall findings elude to the presence of deep structural changes within vulnerable
brain slices (and perhaps even well-perfused preparations) that alter light scattering properties
of tissue after SD to contribute to IOS.

As mentioned earlier, antagonizing adenosine’s inhibitory action at A1Rs (with DPCPX)
enabled detection of EPSP responses (collected at a slice depth of ~50-100 µm) after SD in
vulnerable brain slices (Figure 3.4) but did not correct IOS decreases in these same slices

137

(Figure 3.4). This suggests that DPCPX is not protective against the possible morphological
changes associated with neuronal deterioration that are perhaps ongoing at the most
compromised depths of the slice (>100 µm). Furthermore, DPCPX has been shown to
accelerate SD onset and decrease protective effects of adenosine in brain slices exposed to
gliotoxins (Canals et al., 2008a), suggesting that lengthier electrophysiological recordings or
other markers of slice health are needed to further evaluate DPCPX treated slices. Findings
from Chapter 3 in vulnerable slices (i.e. DPCPX effects on EPSPs but not IOS after SD) may
also indicate that some neurons succumb to injury while others are functionally intact, although
suppressed by adenosine, after SD. If true, a potentially mixed population of viable and dead
neurons could exist within a volume of compromised tissue.

Along these lines, early animal studies that employed histology (GRENELL, 1946) or
electrophysiology (Sugar and Gerard, 1938) independently reported that certain cell types or
brain regions are more sensitive (i.e. pyramidal cells, Purkinje cells, and higher cortical
centers) to oxygen deprivation compared to others (life-supporting brainstem centers). This
could be due to the propensity of different brain regions and cell types to participate in SD
initiation and or propagation. In a review by Somjen it was noted that some neurons “refused”
to participate in depolarization during SD even though recordings also confirmed the presence
of mass depolarization in the extracellular slow potential (Somjen, 2001). More recent wholecell recordings also demonstrated that neurons in higher gray matter centers are more inclined
to propagating SD versus lower gray matter centers of the brainstem (Andrew et al., 2016). In
this study it was noted that cytoarchitectural differences and do not seem to account for
threshold differences and that perhaps the milieu of excitatory amino acid transporters or
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Na+/K+ ATPases and their interaction may play an important role. A new publication by
Andrew and colleagues is further evidence that a mixed population of neurons can exist even
within the necrotic core after MCAo in mice (Petrin et al., 2019). In this study, structurally
intact pyramidal cells were found within the lesion core after infarction (12 hr.); and although
appropriate presynaptic inputs were absent, these neurons retained the ability to respond in the
presence of external stimuli. While these ideas may further complicate our understanding of
lesions in human brain, there is much to be learned from the heterogenous neurons that either
survive or succumb to SD during focal ischemia. Per the discussion above, the vulnerable brain
slice model could be an additional tool for understanding the complexity of SD mechanisms
as they relate to tissue metabolic status.

5.3 Experimental design to evaluate injury mechanisms during SD after in vivo stroke
Distal locations along the middle cerebral artery (MCA) are a relatively common site of
occlusion in human ischemic stroke. As such, there are many rodent stroke models that target
the MCA by different avenues including intraluminal suture, embolic, endothelin-1,
photochemical (i.e. photothrombosis), and craniotomy (as used in this dissertation) occlusion
models. While preclinical stroke models have ranging advantages in their resemble to the
human condition; various disadvantages make them suitable for different types of studies (e.g.
infarct size determination, behavioral deficits, studies on thrombolytic agents) (Kleinschnitz et
al., 2015). The craniotomy / dMCAo model (Chapter 4) is more invasive and requires fine
surgical skills than other techniques, however it is highly reproducible (Kuraoka et al., 2009)
with low mortality rates, likely due to the direct visualization of the MCA and its occlusion
(Kleinschnitz et al., 2015). Functional deficits and infarct sizes are smaller in dMCAo models
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compared to proximal MCAO and intraluminal approaches that also interrupt other large
cerebral vessels (i.e. internal carotid artery) and concomitant damage to subcortical structures
(KURAOKA et al., 2009). However, the main rationale behind employing dMCAo in this
dissertation work was due to the development of metabolic heterogeneity (i.e. presence of
healthy, penumbral, and necrotic tissue) with respect tissue to distance from the occlusion site
(KURAOKA et al., 2009). This characteristic was important for examining 1) excitotoxic
mechanisms during SD in relation to the infarct and 2) for testing ketamine’s efficacy in tissues
with varying metabolism— especially in the peri-infarct region where NMDAR antagonists
are believed less protective.

As mentioned previously (Introduction), studies by Hartings, et al. in 2003 revealed that infarct
expansion occurs alongside the second or delayed phase of increased SD frequency (Hartings
et al., 2003). In order to employ fluorescent-based imaging modalities to examine SD
mechanisms involved in the recruitment of penumbral tissue into the ischemic core,
experiments were designed in alignment with previous work by Busch and colleagues in 1996
(Busch et al., 1996). That foundational study provided the first link between SD and infarct
expansion in vivo by showing that recurrent SD induction (using exogenous K+ application in
a non-infarcted region) caused stepwise injury expansion in animals. As such, experiments in
Chapter 4 examined exogenously evoked SDs initiated at ~20 min. intervals after 60 min.
recovery from dMCAo or sham surgeries. It is important to emphasize that SDs generated
experimentally in this work are different from “spontaneously” occurring SDs that have been
reported in mouse stroke models. In the current study, sets of KCl-induced SDs originate a
long distance from the recording sites, and this allows clear evaluation of the consequences of
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SDs, as they propagate through tissues of different metabolic capacity. This is quite different
from examining conditions that influence the initiation of SDs in peri-infarct regions, which is
likely due to other factors as previous described (see Ayta and Lauritzen, 2015).

5.3.1 Impaired vascular responses and prolonged DC shifts indicate tissue vulnerability to SD
Leão was again the first to describe perfusion responses during SD as he denoted dramatic
changes in pial vessel diameters and blood flow changes (Leao, 1944). Over the course of
decades of research, vascular responses to SD have been characterized across different species
and in relationship to various metabolic brain states, reviewed in depth by (Ayata and
Lauritzen, 2015). In this dissertation work, laser speckle contrast imaging (LSCI) was used to
monitor perfusion responses elicited by SD and responses were compared to previous literature
for the identification of brain regions that had reduced capacity to recover from SD (Chapter
4). Imaging techniques used here (and during subsequent in vivo experiments) were designed
to monitor both hemispheres which enabled simultaneous monitoring of SD in remote and
proximal brain locations while providing internal normalization to the contralateral
hemisphere.

Experiments confirmed prior reports (Feuerstein et al., 2014) that metabolically impaired brain
tissue (i.e. proximal) has diminished capacity to mount hyperemic responses during SD (Figure
4.1). Furthermore, DC shift durations were greatly extended in peri-infarct regions (Figure
4.2). Combined with prolonged DC shift durations, experiments using LSCI demonstrated that
prolonged electrochemical breakdown during the DC shift was not matched with adequate
vasodilatory/hyperperfusion responses thus indicating increased vulnerability to SD-injury in
these regions (Dreier et al., 2018a).
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5.3.2 Wide-field fluorescence imaging in vivo
Based on the above pilot experiments, studies were next designed to evaluate contributions of
glutamate (iGluSnFR) and Ca2+ (GCaMP5G-expressing mice) provoked by SD and used a
custom-built wide field fluorescence imaging set up (discussed in Chapter 4). Fluorescence
was monitored through the intact skull and was minimally invasive (skin removal and burr
holes for SD induction and electrophysiology were created) compared to open skull
craniotomies that have been used for glutamate-sensitive electrode arrays (Hinzman et al.,
2015) or two-photon imaging of glutamate (Enger, 2015) and Ca2+ during SD (Murphy et al.,
2008) .

In vivo, use of different wavelengths (250nm – 1000nm) can carry diverse information
regarding concentrations of oxy- and deoxyhemoglobin (HbO2 and HbR, respectively) and
thus have been employed to study physiological parameters in the cortex (Ma et al., 2016).
These intrinsic optical changes have been used in studies of SD revealing unique information
about propagation patterns (Santos et al., 2014) and hemodynamic responses (Schöll et al.,
2016) in the gyrencephalic brain of pigs. However, this can also create obstacles for
determining fluorophore contributions during SD. The fluorophores employed in this
dissertation work (i.e. iGluSnFR and GCaMP5G) were excited using a 470 nm LED and
emitted fluorescence was collected in the green spectrum (510-550 nm). At 470 nm, both HbO2
and HbR have relatively high tissue molar extinction coefficients (Ma et al., 2016) and thus
absorb iGluSnFR or GCaMP5G excitation light. The impact of hemoglobin concentrations are
further pronounced after SD and is even more complicated in the context of stroke due to
heterogenous residual CBF in the ipsilateral cortex.
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In order to best eliminate these

confounding perfusion artifacts, multispectral LED assembly could be employed to excite
tissue fluorophores (470 nm) and successive illumination of HbO2 and HbR at wavelengths
that reveal a) total hemoglobin (i.e. at the isosbestic point 530nm; where absorption qualities
are roughly equivalent) and b) predominately HbO2 contributions (~650-700nm). Post-hoc
analyses could then be used separate hemodynamic responses from fluorescent reporter
emission during SD (as in (Bouchard et al., 2009)).

To reduce the contributions of these artifacts during in vivo analyses in Chapter 4, only the
initial recovery from Ca2+ or glutamate accumulation during SD were examined, and curves
were fit to estimate the half-life of signals as a surrogate for measuring the duration of
responses that would be underestimated due to remaining confounds, per the discussion above.
In future studies, multispectral fluorescence imaging would be important, but do not change
the overall findings from in vivo studies conducted in Chapter 4 of this dissertation work.
Additionally, findings in brain slices from Chapters 2 & 3 corroborate in vivo experiments, and
further emphasize the value of brain slice studies to separate cellular mechanisms.

5.4 Excitotoxic consequences of SD
Experiments conducted throughout this dissertation tested the hypothesis that extended
glutamate and NMDAR-mediated Ca2+ accumulation mediate neuronal dysfunction in
compromised but viable tissue. During the late phase of the DC shift, prolonged extracellular
glutamate release combined with neuronal depolarization promote Mg2+ release from within
the NMDAR pore which increases membrane permeability to cations including Ca2+ (Aiba and
Shuttleworth, 2012). Furthermore, when individual neurons were chemically compromised
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(via patch pipette sodium azide) activation of NMDARs during late-SD led to irrecoverable
Ca2+ loading and dendritic signs of damage (Aiba and Shuttleworth, 2012); effects that were
prevented by competitive blockade of NMDARs (using APV). This dissertation sought to
extend these findings beyond single cells to both slice and intact animal experimental designs.
Additionally, studies tested the non-competitive NMDAR antagonist ketamine, as competitive
NMDARs have failed in previous clinical stroke trials, have undesirable side-effect, and also
interrupt essential NMDAR-dependent cellular processes (discussed previously).

5.4.1 Fluorescent sensors used in this study
Studies were initially designed in mouse brain slices using fluorescent reporters of extracellular
glutamate and intracellular Ca2+ to evaluated consequences of SD that were specific to neurons.
These sensors had not been utilized in prior studies within Dr. Shuttleworth’s lab, and thus in
vitro studies in brain slices also provided feasibility for subsequent in vivo experiments.

Chapters 3 & 4 examined glutamate dynamics during SD using the recently developed
intensity-based glutamate sensitive fluorescent reporter iGluSnFR (Marvin et al., 2013)
delivered ~2 weeks prior to experiments via AAV injection into the hippocampus or cortex for
brain slice or in vivo recording sessions, respectively. iGluSnFR is controlled under the
synapsin promoter for expression in neurons with additional constructs that guides protein
trafficking to the plasma membrane (Marvin et al., 2013). Upon binding of extracellular
glutamate, a conformational change enables detection of fluorescence and thus provides a more
direct indication (compared to microdialysis or glutamate-sensitive electrodes) that glutamate
is in direct contact with neuronal membranes. Additionally, microdialysis and amphoteric
techniques do not have single cell resolution which makes fluorescence imaging of iGluSnFR
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a useful new tool for monitoring glutamate levels, not only during SD but in other neuroscience
fields as well.

An overall limitation of the iGluSnFR variant used in this dissertation work, is that it cannot
resolve fast or sparse glutamate release likely due to its relatively high affinity (~5µM, for
glutamate) and slow off kinetics when expressed on neuronal surfaces (Helassa et al., 2018;
Marvin et al., 2018). While this limitation did not play a major role in this dissertation work
(due to massive and prolonged glutamate release during SD) it does prevent accurate
calculations of glutamate concentrations as the indicator was most likely saturated during SD.
These challenges may be overcome with new iGluSnFR variants that have higher or lower
affinities due to slower or faster off-rates, respectively. The faster off-rate variants were
designed for more accurate quantification of quantal glutamate release and thus higher
dissociation constants (Kd 30-600 µM; (Helassa et al., 2018; Marvin et al., 2018) increase
fluorescent range.

Experiments in Chapter 2 & 4 also utilized mice expressing the Ca2+- sensitive fluorescent
reporter GCaMP5G expressed in a Cre-dependent fashion under the CaMKIIa promoter (Gee
et al., 2014). This enabled robust expression of GCaMP5G in hippocampal and cortical
neurons without requiring bulk loading of fluorescent dyes and/or dialyzing neurons. Similar
to limitations described for iGluSnFR, advancements in fluorescent Ca2+ reporters (with higher
or lower affinities) could provide more information with regards to intracellular Ca2+ loading
during SD in neurons (or in other cell types using different promoters). Additionally, future
brain slices utilizing dual-band dichroic mirrors for fluorescence imaging of both glutamate
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and Ca2+ (red and green, which are now available for glutamate detection via iGluSnFR
variants (Marvin et al., 2018)) as well as transgenic mice designed with red-shifted Ca2+reporters (Dana et al., 2016)) would be interesting for the simultaneous detection of both
excitotoxic mediators during SD.

5.4.2 Glutamate accumulation during SD
iGluSnFR for two-photon monitoring of glutamate dynamics during SD were recently reported
in vivo (Enger et al., 2015), however studies in this dissertation are the first to utilize iGluSnFR
to examine SD in brain slices and in vivo after focal ischemia. Vulnerable brain slices (Chapter
3) and peri-infarct cortex after dMCAo (Chapter 4) both exhibited prolonged glutamate
fluorescence increases during SD. This advocates for lengthy presence of ligand within direct
proximity to both pre- and post-synaptic glutamate receptors in neurons that are most
vulnerable to excitotoxic SD consequences. Long-lasting glutamate increases could help
explain why DC shifts and the ionic burden of SD are more pronounced during metabolic
compromise. Furthermore, SD-induced glutamate increases were irrecoverable in both brain
slices exposed to OGD (Appendix C) and during terminal SD in vivo (i.e. during euthanasia at
the end of experimentation in Chapter 4, not shown). Notably, irreparable glutamate elevations
were never observed during SD in vulnerable slices or in peri-infarct regions with recoverable
DC shifts.

As formerly mentioned (Introduction), synaptic glutamate can significantly contribute to
extracellular transmitter levels during SD, as proposed in earlier studies that employed Zn2+indicators. Preliminary studies in this dissertation work examined vesicular glutamate release
using FluoZin3 and data showed strikingly similar kinetics as iGluSnFR transients when both
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were evaluated during SD in healthy brain slices (not shown). These comparisons are
preliminary due to limitations of both iGluSnFR and Zn2+ imaging techniques and thus future
work is needed to examine sources of glutamate accompanying SD in healthy slices impart
insight into mechanisms that go awry in compromising environments. While sources of
glutamate formerly identified using OGD experimental models (described in Introduction)
could be comparable to those here, it is possible that these mechanisms may play important
roles (or can actually be targeted) in vulnerable brain tissue. This statement is supported by
preliminary experiments in this dissertation work showing that glutamate accumulation during
SD is vastly different in vulnerable compared to OGD conditions (Appendix C).

Newer iGluSnFR constructs (discussed above) could also be used to examine more dynamic
fluctuations in glutamate (or its downstream read-outs) that sometimes overlap or occur shortly
after the DC shift, for example. This is suggested due to recent unpublished data that, during
the decay of glutamate transients during SD, small increases in iGluSnFR fluorescence called
“glutamate plumes” can be detected (A previous brain slice study that employed glutamate
sensitive electrodes (Zhou et al., 2013) also showed glutamate transients during SD that, in
some instances, were contaminated with “plume-like” fluctuations during this same decay
phase, although this was not discussed.

Plumes are perhaps further confirmation that

presynaptic release is enhanced during the late phase of the DC shift or theoretically
responsible for the rapid voltage fluctuations that can be occasionally observed shortly after
DC shift recovery, also noted but not specifically examined by (Aiba and Shuttleworth, 2012).
If these plumes contribute to glutamate-mediated consequences of SD, experiments could be
designed to evaluate the frequency of these events during SD in vulnerable brain slices or in
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peri-infarct regions in vivo after dMCAo. Additionally, monitoring of Zn2+ could provide
insight as to whether vesicular machinery is involved in plume induction.

In addition to eliciting depolarization, glutamate is a central mediator of astrocyte-dependent
vasodilation in response to neuronal activity (i.e. neurovascular coupling) including during
normal physiological responses. Glutamate-mediated neuronal depolarization, along with
many other cellular and vascular factors (reviewed in (Ayata and Lauritzen, 2015)), should
thus necessitate profound dilation during SD. However, hyperemic responses to SD were only
observed in the cortex of non-injured animals or in remote regions after dMCAo (Chapter 4
and described above); supporting literature in the field that SD in metabolically impaired
tissues is accompanied by impaired vasodilation and/or inverse-neurovascular coupling
mechanisms (Dreier, 2011; Feuerstein et al., 2014).

This dissertation work extends our understanding of glutamate dysfunction that occurs after
passage of the SD wave front in vulnerable tissue that is at-risk for neuronal injury. Compared
to the irrecoverable increases observed during SD in environments of complete substrate
deprivation (OGD or the infarct core), excitotoxic transmitter increases in vulnerable brain can
recover back to baseline levels. These findings provide rationale behind reexamining the
pharmacology of such SDs in a new light—perhaps revisiting interventions that were
abandoned due to lack of efficacy in OGD/hypoxia in vitro models. For in vivo studies,
evidence that glutamate increases are time-locked with SD may be important for controlling
the time course of drug administration; specifically, interventions could be delivered when
damage is most likely to occur (i.e. during or after passage of the SD wave front).
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5.4.3 Calcium and NMDARs
Experiments in brain slices (Chapter 2) confirmed prior reports (Aiba and Shuttleworth, 2012;
Dietz et al., 2008) that dendrites are particularly vulnerable to SD, as indicated by prolonged
accumulation of intracellular Ca2+ in dense dendritic regions of stratum radiatum even in
healthy brain slices. Ca2+ loading was further exacerbated during SD in vulnerable brain slices
in both somata and dendrites and corresponded to poor functional recovery of synaptic
responses. Prolonged Ca2+ durations (calculated from nonlinear regression half-lives) were also
observed during SD in proximal locations after dMCAo and were associated with extended
DC shifts; supporting evidence that metabolically impaired regions are faced with amplified
energetic requirements during SD.

This work provides more information regarding

mechanisms that promote neuronal injury during SD and likely subsidize stepwise injury
expansion—as suggested by the progressive impairment of intracellular Ca2+ buffering
mechanisms that infiltrated remote regions during sets of SD in stroke animals. In these areas,
neuronal Ca2+ responses were extended with each subsequent SD, and regions of irrecoverable
Ca2+ loading could not propagate subsequent events. Based on brain slice studies, this could
implicate either neuronal demise or adenosine-mediated suppression (Lindquist and
Shuttleworth, 2012)—both of which oppose SD initiation and/or propagation (Koroleva and
Bures, 1996; Canals et al., 2008). These findings provide evidence that extended glutamate
observed during SD is likely sufficient to activate all NMDAR-subtypes (described below)
enabling Ca2+ influx into metabolically vulnerable neurons. as glut likely sufficient to activate
all NMDARs.
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Unlike non-NMDA receptors, NMDARs are obligatory hetrotetramers based on various
combinations of GluN1, GluN2A-D, and GluN3A-B; although requiring GluN1 and GluN2
subunits as prerequisites. Open channel conductance occurs upon neuronal depolarization and
release of Mg2+ from within the pore in the presence of glycine or D-serine (interaction with
GluN1) and L-glutamate (binding to GluN2 subunits) (Burnashev et al., 1992). The
transmembrane domain of the NMDAR is responsible for the functional differences from other
ionotropic glutamate receptors and confers this channel with voltage-sensing capacity, Mg2+
blockade, and substantial permeability to the Ca2+ cation (Karakas and Furukawa, 2014). While
permeable to Ca2+, NMDARs are nonselective cation channels and the majority NMDARmediated currents are actually carried by the influx of Na+. NMDARs are involved in a variety
of neuronal processes that include pro-survival and cell death mechanisms and are even located
on presynaptic membranes where they participate in neuronal signaling and plasticity
mechanisms (Bouvier et al., 2015). In addition to largely postsynaptic roles of NMDARs
during SD, discussed previously, recent work has implicated presynaptic NMDARs in
regenerative glutamate release during SD (Zhou et al., 2013). Theoretically, this could mean
that blockade of presynaptic NMDARs (e.g. with ketamine) could further decrease vesicular
release of glutamate but also may opposingly elevate release via disinhibition of GABAergic
interneurons. Therefore, depending on presynaptic NMDAR (as well as subunit subtypes)
expression levels, ketamine efficacy could have varying effects on SD in different brain
structures. However, the disinhibitory effect of NMDAR antagonists may play a lesser role
during SD, as suggested by studies performed in (Aiba and Shuttleworth, 2014).

150

The mixing of subunit compositions further confers varying degrees of cation permeability and
relative strength of Mg2+ -blockade from within the pore of different NMDAR subtypes
(Retchless et al., 2012). Influences of NMDAR combinations and localization could therefore
confer variability in NMDAR roles and responses. For example, recent studies show that
activation of GluN2A-containing subtypes localized at the synapse can be essential for the
induction of pro-survival cascades important for neuronal survival and perhaps recovery and
repair mechanisms after stroke injuries, reviewed in (Lai et al., 2014; Wu and Tymianski,
2018). As opposed to GluN2A subtypes, GluN2B-containing NMDARs have gained renewed
interest for future stroke treatments due to their conductance properties and extrasynaptic
location on neurons (Tu et al., 2010; Wu and Tymianski, 2018). Since it is largely believed
that glutamate released after focal ischemia occurs only during the acute period (min-hrs after
stroke onset) it is thought that targeting excitotoxic GluN2B-containing NMDARs would need
to be early on. However, in knowing that SDs can occur for days after the initial ictus—and
are major sources of glutamate—this could extend the utility of these drugs beyond the acute
phase. This is proposed with the caveats that SD is unpredictable (even when recording from
subdural electrodes) and glutamate levels are massive (>10µM) even in healthy brain.
Therefore, it would be important to elucidate if certain NMDAR subtypes contribute more to
the damaging Ca2+ accumulation observed in vulnerable neurons undergoing SD, as
corresponding glutamate increases are likely sufficient to activate all NMDAR subtypes (EC50:
~2µM (Nakanishi et al., 1992)).

5.5 Ketamine reduces excitotoxic consequences of SD
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Studies prior to this dissertation work elucidated the role of NMDARs in not only SD initiation
and propagation (Somjen, 2001) but also in Ca2+ loading and neuronal demise following SD
in vulnerable neurons, discussed in Introduction and (Aiba and Shuttleworth, 2012). While
decades of work suggest that blocking SD can reduce infarct sizes, the most reliable way for
preventing SD is via high doses of NMDAR antagonists; blockers with a long and unsuccessful
history in ischemic stroke trials. Highlighting overall failures of pharmacological
neuroprotective efforts is the fact that not a single intervention has been approved for the
treatment of ischemic stroke since tPA in 1996. When these trials are examined under the
scrutiny of SD researchers, failures are perhaps attributed to the timing of drug
administration—restricted to the acute period after stroke onset and not during the delayed
phase of SD-mediated lesion growth. Additionally, the inability of NMDAR antagonists to
block SD in more severe cases of injury (i.e. OGD/hypoxia or in peri-infarct tissues) has also
led some to believe that glutamate and NMDAR antagonists are not involved in injury
produced by SD. Complicating matters worse, is evidence that SD itself, in addition to prosurvival roles of tonic NMDAR activation, may provide benefits for repair after injury.

The multifactorial and theoretical issues presented above, generate many challenges for
prospective clinical studies and thus suggest that targeting deleterious consequences of SD
might be a useful approach to ischemic stroke treatment. Due to their unique properties,
functions, and involvement in pathophysiology, many drugs have been developed and tested
in humans targeting NMDARs (Gladstone et al., 2002). While none of these compounds are
currently approved in ischemic stroke patients, the NMDAR antagonist ketamine has shown
promise for reducing SD incidence (Carlson et al., 2018; Hertle et al., 2012; Sakowitz et al.,
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2009; Schiefecker et al., 2015). Therefore, studies in this dissertation focused on testing
ketamine in the context of reducing consequences of SD that can be deleterious to vulnerable
brain.

As discussed previously, ketamine had no effect on SD initiated in response to OGD exposures
in brain slices or in vivo after global ischemia. However, in reorganizing our thinking about
the SD (Hartings et al., 2017) pharmacological interventions found to not prevent cell death in
vivo after CBF arrest or in vitro after OGD/hypoxia may still provide protection against SDmediated injury in vulnerable brain. While most work with ketamine in the past has focused
on blockade of SD (Gorelova et al., 1987; Marrannes et al., 1988b), the literature provided
hints that ketamine could reduce the metabolic demand of SD by limiting DC shift durations—
observed in the healthy brain in vivo and in brain slices (Gorelova et al., 1987; Krüger et al.,
1999). Findings in humans support these preclinical results by confirming that the NMDAR
antagonist ketamine is capable of dose-dependently suppressing SD in brain injured patients
(Carlson et al., 2018; Hertle et al., 2012; Sakowitz et al., 2009; Schiefecker et al., 2015).

Based on the discussion above, experiments were designed to test the hypothesis that ketamine
lessens deleterious consequences of SD in neuro— measured using optical (IOS, Ca2+) and
functional (DC shifts, EPSPs) indicators of SD demand and neuronal recovery (Chapter 2).
Chapter 4 of this dissertation focused on translating findings from brain slices to in vivo
experiments in mice after dMCAo. In these studies, it was of particular interest to test
ketamine’s efficacy on NMDAR-mediated consequences in peri-infarct tissues where
diminished perfusion and related elevations in extracellular K+ (Branston et al., 1977) reduce
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the potency of NMDAR block of SD ((Petzold et al., 2005). This assumption indicates that
ketamine would only block SD in healthy brain where it is not damaging (and may even be
protective), and furthermore confer no protection to regions most vulnerable to SD-induced
injury. It was thus important in this dissertation to provide the first direct comparison of effects
of ketamine on SD consequences in locations both remote and proximal to the lesion core after
dMCAo.

In order to rigorously test drug effects of ketamine on consequences that occur after passage
of the SD wave front (while also enabling SD in healthy brain), ketamine was used at
concentrations (or doses) that did not prevent SD in healthy brain tissues (Chapters 2 & 4). In
brain slice studies, 30 µM ketamine reliably did not block SD in adequately superfused,
nominally healthy brain slices with physiological levels of extracellular K+ (3mM).

In

alignment with prior reports (Petzold et al., 2005), we saw that the ability of ketamine in
inhibiting SD was diminished in aCSF with elevated basal K+ (8mM) (Chapter 2). In these
slice experiments ketamine reduced DC shift durations, accelerated EPSP recovery, and was
associated with reduced intracellular Ca2+ accumulation during SD (in GCaMP5G expressing
mice). This suggests that decreased neuronal Ca2+ loading during the DC shift reduces the
demand of SD. The reduced duration of A1-mediated suppression of neuronal activity is likely
due to less adenosine production (and thus ATP hydrolysis) during repolarization from ionic
disturbances, although this was not directly tested. Further examinations of MAP2 or other
markers for neuronal integrity would also be useful, as described previously.
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In vulnerable preparations, Ca2+ loading during SD was also decreased by ketamine, even in
elevated K+ -supplemented aCSF. Evoked synaptic potentials were also improved after SD in
ketamine treated slices, perhaps a result of reduced ATP requirements that would normally be
utilized for Ca2+ sequestration and extrusion processes. Residual adenosine may partially
explain the incomplete recovery of EPSPs (as described previously) in these experiments.
Interestingly, though vulnerable EPSPs appeared to recover quicker in the presence of DPCPX
(Figure 3.4) versus ketamine (Chapter 2), ketamine prevented transmitted light signals
associated with slice dysfunction, while DPCPX had no effect on this read-out. This suggests
a possible disconnect between recovery of cortical activity and neuron health, in some
situations.

Overall, slice studies showed that NMDAR-mediated excitotoxicity and signs of neuronal
dysfunction after SD were minimized by ketamine, even in metabolically compromising
environments. This same concentration of ketamine did not prevent SD in healthy preparations
and subsequent in vivo experiments therefore employed non-blocking doses of ketamine and
evaluated damaging consequences of SD in both remote (nominally healthy) and peri-infarct
tissues after focal ischemia.

Early studies in the late 1980s found that high doses of ketamine (>40 mgkg-1) in vivo were
capable of blocking SD induced in the healthy cortex (Gorelova et al., 1987; Marrannes et al.,
1988a). Recent in vivo work has also demonstrated that high dose infusion of the more potent
S-ketamine (4mg/kg/h) can prevent SD induced by K+ stimulation in the non-injured cortex of
pigs (Schöll et al., 2016). Based on these reports and experiments showing that peak
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concentrations are achieved in the brain within 30 min. of i.p. injection in mice (Toki et al.,
2018) pilot studies here identified a dose of racemic ketamine (5 mgkg-1 dose, i.p.) that reliably
did not prevent recurrent SD induction when administered 30 min. after dMCAo (Chapter 4).
Consistent with findings in brain slices, ketamine improved the recovery of intracellular Ca2+
loading in neurons located closer to the stroke injury as well as the duration of depolarization;
processes that delayed SD-induced progression of neuronal Ca2+ dysfunction into the remote
cortex. These studies confirmed the relevance of brain slice studies in excitotoxic mechanisms
during SD in penumbral brain regions in vivo after dMCAo.

5.5.1 Mechanisms of ketamine
The ability of ketamine to reduce NMDAR-mediated currents is influenced its stereospecificity
(R versus S) and by NMDAR receptor subunit compositions with IC50s ranging from ~1 to ~5
µM for racemic ketamine (Khlestova et al., 2016). Ketamine also has a use-dependent
mechanism of action as it’s binding site overlaps with Mg2+ within the channel pore. Therefore,
ketamine competes with Mg2+ for access within the pore and thus requires glutamate and
concomitant membrane depolarization (i.e. Mg2+ release) for activity-dependent blockade of
NMDARs (Johnson et al., 2015) Due to differences in the relative strength of Mg2+ binding,
and thus open channel probability of specific NMDAR subtypes, ketamine blockade varies
depending on NMDAR subunit compositions (i.e. is most effective block at GluN2Ccontaining NMDARs) (Khlestova et al., 2016).

While this dissertation focused predominantly on NMDAR sources of Ca2+ influx into neurons,
this does not imply that additional sources of intracellular Ca2+ cannot also contribute to
cytosolic increases during SD. These can include plasma membrane and mitochondrial
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Na+/Ca2+ exchangers (NCX) and mitochondrial calcium uniporters (MCU) shown to reverse
during ischemia (Lai et al., 2014); perhaps due to electrochemical gradient breakdown during
the DC shift of SD. Recent evidence also suggests that even when NMDAR-mediated currents
are blocked using MK801, metabotropic NMDAR activity initiates the formation of complexes
that can then recruit other nonconical ion channels and processes to ignite intracellular Ca2+
dysregulation (during OGD in cell cultures) (Weilinger et al., 2016). Interestingly, some
studies indicate that delayed cytosolic Ca2+ elevations (discussed during the ischemic cascade
in Introduction) can contribute to delayed cell death in cell cultures, though are considered
“fully trigged” at the initial onset of ischemia. Future work in vulnerable brain slices could
help resolve mechanisms of intracellular Ca2+ to confirm that dysfunction is temporally
restricted to SD. Findings could thus help guide interventions that target deleterious
consequences of SD in vivo; perhaps using combinations of low concentrations of ketamine or
other neuroprotective agents.

5.6. Summary of studies
Collectively, this dissertation work provides evidence that extended glutamate accumulation
and NMDAR-mediated Ca2+ influx promote deleterious consequences of SD in vulnerable
tissues both in vitro and in vivo after dMCAo. Additionally, low dose ketamine attenuated
deleterious consequences in both experimental models by reducing DC shift durations and
NMDAR-mediated Ca2+ loading in neurons. Importantly this work provides the first evidence
that NMDAR antagonist can be effective at reducing deleterious consequences of SD even in
conditions with elevated K+ concentrations including peri-infarct tissues. This supports future
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work with NMDAR blockers and SD as it remains unknown whether they can confer
protection to the compromised brain where SD is difficult to prevent.

Chapters 2 & 3 in this dissertation examined the degree of glutamate and neuronal Ca2+
accumulation during SD in metabolically vulnerable brain slices and found that these
excitotoxic mechanisms were intermediate between SD in healthy and OGD conditions. These
data further substantiate the SD continuum shift in our thinking about SD consequences, and
suggest that incomplete metabolic compromise may be a useful tool for future studies
examining mechanisms of SD. In addition, experiments demonstrated the feasibility of
protecting neurons from deleterious consequences of SD using concentrations of ketamine that
do not prevent SD in either vulnerable or healthy brain slices. These findings were then applied
in vivo to examine excitotoxic mechanisms that occur during SD in penumbral brain regions
after dMCAo (Chapter 4).

Overall findings indicate that drugs targeting NMDAR Ca2+ influx or other mechanisms of
cytosolic Ca2+ elevations during SD may be useful therapeutic approaches in brain injured
patients. Findings that non-blocking doses of ketamine can reduce excitotoxicity during SD in
metabolically compromised brain are especially important while the role of SD in brain
recovery after injury remain unknown. Based on experiments in the body of this dissertation,
future work is required in order to answer whether SD can be beneficial to the recovering brain.
In the meantime, trials could be designed to examine dose-dependent effects of ketamine on
SD characteristics (DC shifts, ECoG recovery) as well as infarct sizes and long-term functional
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outcomes—in hopes of solidifying the causal role of SD in lesion progression and poor clinical
prognoses.

5.7 Future studies and beneficial outcomes of SD
5.7.1 Recovery and repair after injury
An emerging fundamental property of the brain is its capacity to undergo remodeling
throughout life, even after brain injury (Rumpel, 2018). The construction and elimination of
synapses and plasticity processes are also important after brain injury, especially in distant
regions outside of the lesion core that are theoretically responsible for cortical remapping of
the ipsilateral cortex after stroke (Murphy and Corbett, 2009). The reconfiguration of brain
circuitry is important for regaining functionality after stroke and this “recovery phase” may be
ongoing in the days to months after injury (Rumpel, 2018). Recent preclinical studies have
shown that activity-dependent incorporation of AMPA- type receptors into synapses can
modulate functional recovery days after stroke injury and can also be enhanced using small
molecule therapeutics (Abe et al., 2018; Chambers and Rumpel, 2017). These dynamic
changes that occur after stroke (even in the absence of intervention) underlies the importance
of understanding intrinsic mechanisms that improve or prevent cortical remapping processes.
During the recovery phase there are additional changes in gene expression, release of growth
factors, and the regrowth of neuronal processes (Rumpel, 2018). Mounting evidence shows
that SD can also initiate these (among many other) cellular responses. Preliminary work in this
dissertation in brain slices (Appendix B) demonstrated that a single SD could elicit (in ~30
min.) a significant increase in mRNA expression of the neurotropic factor BDNF lasting at
least 60 min post SD and is in accordance with prior studies of SD preconditioning (described
in Introduction). These are the first data to show acute increases in plasticity-related genes in
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the hippocampus of mouse brain slices. In these studies, moderate levels of protection from
deleterious SD consequences was observed when slices were subjected to a subsequent SD in
metabolically compromising conditions (i.e. vulnerable brain slice model) at the time of
maximal BDNF increases (45-60 min). This was confirmed using optical read-outs of slice
health (IOS). Additional pilot experiments (Appendix B) also showed that ketamine did not
interfere with SD-induced BDNF increases (measured 45 min. after SD) and, when combined
with preconditioning measures, enabled full recovery of postsynaptic potentials after SD in
vulnerable metabolic conditions. These data provide the first evidence in brain slices that a)
preconditioning with SD (or tolerance induced by SD) increases BDNF levels which may
confer protection against the energetic demands of SD in “at-risk” tissues.

5.7.2 Role of SD-mediated adenosine accumulation and potential for protection
Providing more substrates to tissues could be an alternative approach for supporting neurons
that are at risk for injury during SD. D-ribose and adenine (RibAde) has been shown to increase
ATP levels in brain slices (Frenguelli, 2017). This theoretically should supplement ATP levels
that are depleted upon breakdown of electrochemical gradients during the DC shift. However,
in hydrolyzing more ATP this would likely also elevate extracellular adenosine levels after
SD. Although prolonged A1-receptor mediated suppression and corresponding ECoG
suppression in humans may indicate injury, suppression of neuronal activity may be important
for preventing the likelihood of subsequent SDs (Canals et al., 2008a), activating KATP
channels or other tolerance mechanisms involved with adenosine and/or A1R activation (as
discussed in introduction). Preliminary experiments conducted during this dissertation work
(data not shown) supplemented brain slices with RibAde prior to SD in vulnerable recording
conditions. This supplementation attenuated decreases in transmitted light and improved
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functional recovery (EPSPs) after SD in vulnerable brain slices. Importantly, the duration of
A1-mediated synaptic depression after SD was significantly longer than healthy control brain
slices, and future work is needed to confirm extracellular adenosine increases as well as the
role of A1Rs in tolerance mechanisms.

If SD is important for adaptation/tolerance during subsequent ischemia, there are many other
questions that arise. If SD is beneficial then why doesn’t the initial SD (that occurs within
minutes of experimental occlusion) protect against further tissue deterioration? Furthermore,
SDs can spontaneously erupt for days in many malignant stroke patients (Dohmen et al., 2008;
Woitzik et al., 2013). Do these SDs initiate endogenous protection mechanisms in remote brain
regions (i.e. a form of postconditioning)? Do the damaging effects of SD in vulnerable brain
regions outweigh any benefits of SD in healthier brain tissues? Along the lines of dual roles
for NMDARs in promoting cell survival or mediating cell death cascades, perhaps SD causes
injury to metabolically compromised brain regions but are essential for recovery and repair
after stroke. Are these processes downstream of SD? Although these questions are beyond the
scope of this dissertation work, they highlight how much is unknown regarding SD and stroke
outcomes and may provide some hesitation with regards to interventions that block SD. It is
thus essential to determine if SD is important for brain recovery and repair after stroke or other
acute brain injuries. This would not only help guide clinical decision-making in whether SD
should be blocked in the ICU but could also inform rehabilitation practices in the aftermath of
an injury.
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5.8 Conclusions
The main objective of this dissertation was to evaluate the influence of metabolic status on
excitotoxic consequences of SD. Experiments tested the central hypothesis that prolonged
glutamate release during SD in metabolically vulnerable tissue underlies excitotoxic NMDARFigure 5.3
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mediated neuronal injury. The ability of the NMDAR antagonist ketamine to reduce
excitotoxic consequences, as a potential candidate for clinical utility, was also examined.
Figure 5.3 illustrates a proposed model of SD consequences based on this dissertation work in
the context of the SD continuum (Hartings et al., 2017). Findings from these studies, here,
extend our knowledge about cellular mechanisms involved with tissue demise and thus serve
as a theoretical starting point for targeting these processes pharmacologically in brain injured
patients.

Studies were first conducted in well-controlled brain slices using a novel model of energy
substrate restriction that increased neuronal susceptibility to the additional ‘hit’ of SD. From
these findings, it is now known that extended (extracellular) glutamate and (intracellular)
NMDAR-mediated Ca2+ accumulation are associated with poor neuronal recovery from SD.
Additionally, these data help identify mechanisms that may in-part explain neuroprotective
effects of ketamine observed in the injured brain—i.e. the attenuation of neuronal Ca2+ loading
after passage of the wave front. Chapter 4 transitioned findings from brain slices to test SD
mechanisms and interventions in vivo after focal ischemia. The degree of SD-induced
excitotoxic consequences. Similar to brain slice results, ketamine improved intracellular
neuronal Ca2+ accumulation during SD and associated with reduced DC shift durations.
Collectively, this work extends our knowledge of cellular mechanisms that confer vulnerability
to SD-mediated injury and provide further evidence that ketamine (or other interventions that
target excitotoxic SD consequences) may be useful for improving tissue recovery after
ischemic stroke or other acute brain injuries.
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Studies that examined therapeutic interventions in this dissertation project were largely focused
on the NMDAR antagonist ketamine, as it is clinically used in the ICU setting and has shown
efficacy at reducing SD frequency in brain injured patients (Carlson et al., 2018; Hertle et al.,
2012). Prior to the work presented here, it was largely assumed that the only way to prevent
damaging effects of SD was to completely block its initiation and/or propagation. In most
cases, this requires a substantial degree of NMDAR inhibition and thus high ketamine doses
in animals (Amemori and Bures, 1990; Hernándéz-Cáceres et al., 1987; Marrannes et al.,
1988). In addition to challenges of preventing SD in peri-infarct brain (Petzold et al., 2005),
the outright inhibition of SD may occlude any theoretical benefits of propagation in undamaged
brain regions after stroke (Hartings et al., 2017, Dreier, 2011). Based on our knowledge that
neurons are particularly vulnerable to injury when NMDARs are activated during the late phase
of the DC shift (Aiba, 2012), studies examined if ketamine could be employed to reduce
glutamate-mediated consequences (i.e. Ca2+ loading via NMDARs) of SD. Findings from this
dissertation work suggest that ketamine may be used during discrete periods of increased SD
frequency and clinical worsening to limit detrimental consequences of SD.
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Abstract
Spreading depolarization (SD) is thought to be a key mediator of secondary lesion progression
after acute brain injuries, including ischemic stroke. Characterized by a large negative shift in
the extracellular direct current (DC) potential, the duration of this “DC shift” is associated with
poor clinical prognoses after brain trauma. The late-phase of the DC shift is particularly
challenging for compromised tissues and is characterized by persistent glutamate release and
N-Methyl-D- aspartate receptor (NMDAR) activation. Interventions that reduce the frequency
and/or duration of the late phase of SD are thus promising therapeutic approaches for reducing
secondary lesion progression after ischemic stroke. The NMDAR antagonist memantine can
decrease the number of SDs in vivo, but the effect of memantine on the late phase of SD is
unknown. We utilized electrophysiological and optical recordings to monitor neuronal
consequences associated with the late-phase of SD in acutely prepared brain slices from
C57Bl/6 and GCaMP5G-expressing mice. SDs were initiated by oxygen glucose deprivation
(OGD) or by localized microinjection of K+ in the hippocampus of preparations, and the effect
of memantine (10-300µM) on SD onset (after OGD), DC shift duration, neuronal Ca2+ loading,
and recovery of postsynaptic responses was examined. We found that even high concentrations
(up to 300µM) of memantine did not prevent SD in any experiments and low concentrations
(10µM) did not alter any SD properties. During repetitive SDs (K+ induced at 15 min intervals),
100µM memantine accelerated the recovery of synaptic activity which was related to reduced
propagation rates and durations of DC shifts. However, this concentration had no effect on SD
onset following OGD exposure—conditions that model the core of the ischemic infarct
deprived of metabolic substrates. In slices with less severe metabolic impairment the extent
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of neuronal Ca2+ loading consequences of SD were attenuated by memantine. These data
indicate that memantine can limit NMDAR-mediated neuronal Ca2+ loading during SD that is
deleterious in metabolically impaired tissues. Memantine may therefore be a therapeutic option
for protecting salvageable penumbral brain areas that are extremely vulnerable to SD-mediated
injury in the days following ischemic stroke.
Keywords:
Spreading depression; excitotoxicity; NMDA receptor; brain slice; calcium; neuronal injury;
metabolic compromise; oxygen glucose deprivation, OGD
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A.1 Introduction
Spreading depolarization (SD) is a propagating wave of near-complete neuronal and glial
depolarization (Somjen, 2001) that occurs in migraine with aura traumatic brain injury, stroke,
and other acute brain injuries (Hartings, 2017). Initiated by stimuli that cause depolarization
of a volume of excitable tissue (Tang, 2017) SD travels slowly at 2-4 mm min-1 and is
characterized by a large negative shift in the extracellular direct current (DC) potential and
“spreading depression” of spontaneous and evoked synaptic activity (Leao 1944, 1947).
In the injured brain, SD clusters are associated with poor outcomes in both animal models
(Back et al., 1996, Hartings et al., 2003) and clinical studies (Dreier, 2011; Hartings, et al.
2011). Additionally, SDs with prolonged DC shift durations increase the metabolic demand of
recovery and contribute to the progression of acute brain injury (Dreier, 2009, Oliveira-Ferreira
et al. 2010). However, while prospective studies are needed to determine if blockade of SD
confers better outcomes in patients, there is the possibility that inhibiting SD prevent any
theoretical benefits of SD in healthy brain regions (Hartings, 2017). Targeting SD
consequences in vulnerable brain may be an alternative therapeutic approach for reducing SDmediated damage, as opposed to outright block.

The late phase of the DC shift is accompanied by substantial glutamate release and excitotoxic
N-Methyl-D- aspartate receptor (NMDAR) activation. In metabolically compromised tissue,
NMDAR- mediated Ca2+ entry during late-SD contributes to irrecoverable neuronal injury
(Aiba and Shuttleworth ,2012). In animal and clinical studies, the use-dependent NMDAR
antagonist ketamine can reduce the frequency of SDs (Sanchez-Porras et al., 2014; Hertle et
al., 2012, Carlson et al., 2018). There is also evidence that ketamine can reduce deleterious
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consequences of SD in brain slices and thus may be a promising candidate for limiting SDmediated injury in ICU patients (Reinhart and Shuttleworth, 2018). However, ketamine is
often associated with unwanted side-effects and high abuse potential.

The goal of this study is to examine another use-dependent NMDAR antagonist memantine
and test whether deleterious consequences of SD can be limited without employing high drug
concentrations that block SD. We used electrophysiology and imaging techniques and found
that memantine reduced the duration of DC shifts and accelerated recovery of synaptic activity
after SD in brain slices. Additionally, we examined SD consequences in tissues with severe
(OGD) and moderate metabolic compromise (described previously in Reinhart and
Shuttleworth, 2018) and found that memantine attenuated SD-mediated intracellular Ca2+
loading in moderately impaired neurons that was otherwise irrecoverable in the absence of
drug. The protective effect of memantine in reducing deleterious consequences of SD in brain
slices support future studies to evaluate whether this protection can be observed after in vivo
stroke and in clinical settings.

A.2 Materials and Methods
A.2.1 Animals and brain slice preparation
All animal procedures were performed in accordance with protocols approved by the UNM
Health Sciences Center Institutional Animal Care and Use Committee. Brain slices were
prepared from adult (6-8 week) C57Bl/6 mice purchased from The Jackson Laboratory. In
experiments studying SD-mediated neuronal Ca2+ accumulation mice expressing the
fluorescent Ca2+ indicator GCaMP5G were used. For all pharmacological intervention
experiments, drug-treated SDs were compared to same-slice control SDs for each animal
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unless stated otherwise. Brain slices were prepared as previously described (Shuttleworth et
al., 2003). Briefly, animals were deeply anaesthetized with a ketamine-xylazine mixture and
decapitated. Brains were quickly removed into ~150mL of oxygenated ice-cold cutting
solution (in mM): Sucrose, 220; NaHCO3, 26; KCl, 3; NaH2PO4, 1.5; MgSO4, 6; glucose, 10;
CaCl2 0.2; equilibrated with 95% O2/5% CO2 supplemented with 0.2mL ketamine (100mg mL1

) to limit excitotoxicity during the cutting procedure. Coronal cortico-hippocampal slices

(350µm) were prepared with a Pelco 102 Vibratome (Ted Pella, Inc., Redding, CA) and
hemisected. Slices were transferred to artificial cerebrospinal fluid [aCSF; containing (in
mM): NaCl, 126; NaHCO3, 26; glucose, 10; KCl, 3; CaCl2, 2, NaH2PO4, 1.5; MgSO4, 1;
equilibrated with 95% O2/ 5% CO2 ], at 35°C for 60 min. After this recovery period aCSF was
replaced with chilled (20°C) aCSF and allowed to equilibrate to room temperature prior to
recording sessions.

Generation of SD and metabolic compromise
Individual brain slices were transferred to a submersion recording chamber with nylon slice
supports (RC-27, Warner Instruments, Hamden, CT). Moderate metabolic compromise was
achieved by inverting the slice support and reducing super fusion of aCSF below the slice, as
previously described (Reinhart and Shuttleworth, 2018). Severe compromise was achieved by
substituting O2 with N2 bubbling of aCSF containing sucrose as a replacement for glucose,
creating OGD conditions. For all recordings, slices were continuously super fused with aCSF
at 2.4mL min-1 and bath temperature was maintained throughout experiments at 32°C by an
inline heater assembly (TC-344B, Warner Instruments). After placement of the slice (and
recording/stimulating electrodes), slices were allowed a 15-minute equilibration period prior
to the start of recordings. In experiments testing the effect of drug application in moderately
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compromised and during repetitive SDs, aCSF was replaced with modified aCSF containing
8mM KCl ([K+]-aCSF) during warm up and continued throughout the recording. Following 15
minutes of equilibration SD was generated in the hippocampal stratum radiatum of CA1 by
localized microinjection (10-40ms, 30psi) of KCl (1M) via a glass micropipette (1.8-6 MΩ)
using a picospritzer (Parker Hannifin, OH, USA) or was spontaneously initiated after exposure
to OGD. In experiments testing repetitive SDs (up to 7), each SD was generated (via K+) at
15 minutes intervals to allow for full recovery between events. Two control SDs prior to drug
application were generated to enable in-slice comparison of SD characteristics. After the
second control SD, memantine was washed in for 10 minutes prior to the next SD stimulation.

Electrophysiology
Extracellular recordings were made using glass microelectrodes filled with aCSF (tip
resistance 1.8-6MΩ) placed at a depth of 50µm in the CA1 stratum radiatum >200µm from the
KCl micropipette. Extracellular DC potential was acquired at 1 kHz with an Axon MultiClamp
700A amplifier and Clampex 9.2 (Molecular Devices, Sunnyvale, CA), and digitized with a
Digidata 1332 digitizer. For extracellular excitatory postsynaptic potential (EPSP) recordings,
a concentric bipolar electrode (FHC) was positioned 50µm deep into the CA1 stratum radiatum
between the KCl micropipette and recording electrode for stimulation of Schaffer collateral
inputs. After electrode placements, slices were allowed to equilibrate for 15 min during which
an input-output curve was generated (final 5 min of equilibration). Test pulses were delivered
(50µs, 0.1Hz) at intensities that gave 50-60% of maximum EPSP responses (150 – 600µA).
Responses were recorded at 10kHz and SD was generated after stabilization of baseline EPSPs.
All analyses were performed using Clampfit 10.4 software and DC shift durations during SD
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were measured as the width between 20% of the initial downward deflection of the peak
amplitude to 80% of recovery to baseline levels.

Imaging
SD initiation and propagation were examined by monitoring brain slice intrinsic optical signals
(IOS) trans-illuminated with visible light (≥600nm) using a 4x objective (Olympus 0.10 NA).
IOS data were captured (0.5Hz) using a cooled CCD camera (Till Photonics) and analyzed
with TillVision software (TillPhotonics, version 4.01). Data analysis involved normalizing to
baseline transmitted light and expressing IOS as percent change in transmission (∆T/T0 x 100).
Fluorescence imaging of intracellular neuronal Ca2+ loading during SD was preformed using
slices prepared from GCaMP5G animals. Slices were excited (480nm) at 4Hz using a 20X
objective (Olympus) using a monochromator (TillPhotonics).

Emitted light was passed

through a dichroic mirror (515DCLP) prior CCD capture. Data analysis involved background
subtraction and normalization of pixel intensities to pre-SD (baseline). Fluorescence values
are thus expressed as the percent change in fluorescence from baseline (∆F/F0 x 100).

Drugs
All chemicals including salts and sugars used in aCSF were obtained from Sigma-Aldrich (St.
Louis, MO, USA) unless otherwise stated. Memantine-HCl was prepared as a 100mM stock
in deionized water and stored in aliquots at -20°C until daily use.

Statistical Analysis
All data analyses and statistical tests were performed using GraphPad Prism 8.1.2. Unless
otherwise stated, all data are represented as mean ± SEM.
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A.3 Results
Repetitive SDs in hippocampal slices
We first evaluated the effect of low memantine concentrations (10µM) on single K+ induced
SDs in aCSF containing standard concentrations of K+ (3mM). In this data set (n=9 slices for
control and n=8 for memantine) there was no effect of memantine on SD propagation rate (3.4
± 0.3 vs. 3.3 ± 0.4 mm min-1 for control and memantine, respectively; P>0.8), DC shift peak
amplitudes (-6.3 ± 0.7 vs -5.9 ± 2.6 mV for control and memantine, respectively; P>0.7), or
DC shift duration (34.6 ± 4.4 vs. 26.5 ± 2.5 s for control and memantine, respectively; P>0.1).
We next verified recording conditions for repetitive SDs in slice according to our previous
work (Reinhart and Shuttleworth, 2018). As shown in images of Figure 1A, SD was evoked
via KCl microinjection into the hippocampal CA1 region, and intrinsic optical signals (IOS)
used to track progression across the slice. The rate of SD spread was measured at the wave
front which could be clearly distinguished based on IOS transmission changes. As noted in
Methods, aCSF contained elevated basal K+ (8mM; ([K+]-aCSF), to facilitate repetitive SD
initiation in both control and metabolically impaired slices. As previously reported (Reinhart
and Shuttleworth, 2018) this modest elevation of K+ did itself not generate SDs, but enhanced
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SD propagation rate compared to 3mM KCl aCSF (Mean ±SEM) 3.2 ± 0.2 mm min -1 (n=18)
vs. 6.2 ± 0.3 mm min-1 (n=6); P < 0.0001), while other SD characteristics remained unchanged.
Figure 6.1
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Memantine slows SD and reduces DC shift duration
Memantine exposures (up to 300µM) did not prevent initiation of SD in any preparation, but
100-300 µM reliably slowed propagation rate across the CA1 subfield. Figure 1A shows an
example of slowed progression in 100 µM memantine, compared to the control SD within the
same slice. Figure 1B (left panel) shows mean data from 6 preparations and demonstrates that
significant effects took time to develop during acute memantine exposures. Thus, the first SD
after onset of memantine exposures (10 min) were not significantly different from control, but
second and third SDs in memantine were reliably depressed. The lack of an effect of 100 µM
memantine on the first SD was also observed in preliminary data sets conducted using 3mM
KCl – supplemented aCSF (2.5 ± 0.3 vs. 2.6 ± 0.3 mm min-1 for control (n=8) and memantine
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(n=7), respectively; P>0.9). When slices were incubated with memantine prior to recordings
(3 or more hours), SD propagation rates were immediately slower, and did not require
successive SDs to achieve the maximum effect (Figure 1B (right panel); n=5). Extended preexposures have also been utilized in earlier work which identified a slow time course of 100
µM memantine inhibition (as well as recovery) of NMDAR-mediated currents (EPSCs)
(Frankiewicz, 1996). This indicates that memantine does not require the presence large
depolarizations in order to reduce the spread of SD but does not rule out the possibility of useFigure 6.2
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dependency of memantine block being contributed to by ongoing synaptic activity during long
pre-exposures.

Consistent with previous studies (Reinhart and Shuttleworth, 2018) there was a gradual rundown on DC shift peak amplitude during successive SDs (data not shown) and thus was not
attributed to NMDAR antagonist exposure. Figure 2A shows a representative trace
demonstrating the effect of memantine wash in on the characteristics of DC potential shifts
recorded during SD. Consistent with the related NMDAR antagonists including ketamine, the
most drastic effect of memantine was on the duration of SD, and in particular the late phase of
the DC shift present after passage of the wave front. The maximum effect on DC duration was
also apparent during successive SDs at 15-minute intervals (Figure 2B (left panel)) or
following extended incubation prior to recordings (Figure 2B, right panel). From the data set
shown in Figure 2, EPSPs were recorded in 6/11 slices and results from these experiments are
described below.
Memantine accelerates recovery of postsynaptic potentials after SD
To determine the physiological significance of shorter extracellular DC shifts, we monitored
adenosine-A1 receptor (A1R) -mediated suppression of evoked excitatory postsynaptic
potentials (EPSPs) as a read-out of the metabolic demand of SD. In slices not exposed to
memantine, there was a tendency for postsynaptic responses to recover more quickly after
repetitive SDs (6.3 ± 0.6 vs. 5.5 ± 0.3 min, SD2 vs. SD5; P=0.06, n=5, paired t-test), perhaps
a result of SD-induced plasticity mechanisms. Memantine further augmented this effect as
revealed with successive SDs during acute drug exposures. Figure 3A shows a representative
time course of EPSP recovery after the control SD (SD2) and the third SD following exposure
to memantine (SD5) within the same slice. Mean data from such experiments are shown in the
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right panel of Figure 3A demonstrating the further acceleration of EPSP recovery by the third
SD in the presence of memantine (P= 0.0008, n=6). In the same preparations, shorter DC
durations were correlated with shorter durations of EPSP suppression (Figure 3B). This
suggests that memantine may reduce deleterious consequences of prolonged depolarizations
allowing for quicker recovery of normal synaptic transmission in the wake of SD.
Figure 6.3

Memantine reduces neuronal Ca2+ loading during SD
Memantine prolongs duration of zinc transients during SD
Previous studies in our lab have demonstrated that increased glutamate release and subsequent
NMDAR activation during late-SD contribute to long-lasting depolarization and prolonged
Ca2+ elevations in neurons (Aiba & Shuttleworth, 2012). Additionally, recent work suggests
that presynaptic NMDAR activation plays an important role in feedforward glutamate release
during SD (Zhou et al., 2013). We utilized zinc fluorescence imaging to evaluate the effect of
memantine on neurotransmitter release during SD. In this study, slices were pre exposed to
memantine (100uM) for ≥3 hours in order to immediately achieve the maximum effect.
Figure 4A (i) shows a representative change in zinc fluorescence during SD in memantine and
interleaved control slices. In mice lacking synaptic zinc (ZnT3KO), there was no change in
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fluorescence during SD (n=3). Summary data (Figure 4Aii), demonstrates that memantine
(n=9) prolongs zinc transient durations compared to interleaved control (n=7) preparations
(P=0.0101). To ensure that the effect of memantine was not an artifact of slow SD propagation,
extracellular potassium was reduced to 3mM which significantly slowed SD propagation
compared to [K+]-aCSF (2.52± 0.30 vs. 4.68 ± 0.22 mm/min, 3mM (n=9) vs. 8mM KCl-aCSF
(n=6), P=0.0002 unpaired two tailed t-test), but did not influence the duration of zinc
transients (1921±209.9 vs. 2197 ±329.0 arbitrary units (a.u.s), 3mM (n=9) vs. 8mM KCl-aCSF
(n=7), P= 0.5199 unpaired two-tailed T-test) . Figure 4B plots zinc transient duration as a
function of SD propagation rate in memantine, [K+]-aCSF, and 3mM KCl-aCSF demonstrating
that slow SD spread has little effect on zinc fluorescence changes.

A.4 Discussion
General
We examined SD in brain slices exposed to varying degrees of metabolic impairment ranging
from nominally healthy to severely compromised (OGD).

In healthy slices, extended

antagonist exposure to moderate concentrations (100 µM) or repeated SDs revealed that
memantine could reduce SD propagation and DC shift durations. Shorter DC shift durations
suggest that memantine reduces the energetic demand of SD which was also supported by
accelerated synaptic recovery after SD observed in memantine.

However, this same

concentration of memantine (100 µM) did not influence SD or the resulting IOS decreases
following OGD exposure, suggesting that memantine administration will likely not protect
against SD-mediated injury in the core of ischemic infarcts.

We next tested whether

memantine could reduce deleterious consequences of SD in conditions of moderate
compromise as memantine could still serve a protective role in tissues that are viable until the
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additional hit of SD. We found that memantine in these conditions reduced intracellular
neuronal Ca2+ consequences of SD that were irrecoverable in untreated preparations.
Deleterious consequences of SD mediated by NMDAR activation
SDs with long DC shift durations increase the metabolic demand of recovery and contribute to
the progression of acute brain injury (Oliveira-Ferreira et al., 2010; Hartings et al., 2017). In
addition to playing a role in SD initiation, NMDAR opening is prominent during the late-phase
of SD when neurons are completely depolarized and presynaptic glutamate release is enhanced
(Aiba and Shuttleworth, 2012). NMDAR antagonists are thus promising candidates for
reducing deleterious NMDAR-mediated consequences of SD in hopes of improving outcomes
after stroke and other acute brain injuries. Targeting consequences (rather than outright block)
may be of further interest if future studies identify an important role of SD in recovery and
repair mechanisms after injury.

In this study, memantine reduced the propagation (Figure 1) and duration of DC shifts (Figure
2) during successive SDs. DC shifts were most notably minimized (by memantine) during the
late-phase of the DC shift (demonstrated in traces from one experiment in Figure 2) and this
phase contributes to significant neuronal NMDAR-mediated Ca2+ (and likely Na+ ) loading
after passage of the SD wave front (Aiba and Shuttleworth, 2012). Subsequent experiments
(Figures 3, 4) show improved recovery from adenosine-mediated synaptic suppression
suggesting that SDs in memantine were less metabolically challenging (Lindquist and
Shuttleworth, 2014).
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Memantine
Memantine is an FDA approved use-dependent NMDAR antagonist that is used to improve
cognition in symptomatic Alzheimer’s disease patients. Memantine has also gained interest as
a potential therapy for reducing migraine frequency based on previous findings that SD
frequency (initiated by KCl) is reduced in vivo after memantine exposure in rats (Peeters et al.,
2007). In addition to its clinical tolerability, the chemical structure and mode of action of
memantine at NMDARs is almost indistinguishable from the related antagonist ketamine
(Johnson, 2015). Preclinical and clinical studies have shown that high dose ketamine can
reduce SD frequency after brain injury ((Hertle et al., 2012; Carlson et al., 2018) while lower
non-blocking concentrations can limit deleterious consequences in brain slices (Reinhart and
Shuttleworth, 2018). Problems with ketamine include psychotic behaviors, tolerance, potential
for abuse and thus memantine may serve as an alternative option in some patients.

Previous work has demonstrated that memantine can be effective at reducing the size of
infarction when administered acute prior to or after experimental stroke (Chen HS,et al. 1998,
Gorgulu A, et al, 2000; Lapchak PA, 2006; Hao J, et al., 2008; Babu CS and Ramanathan M,
2009; Liu C, et al, 2009; Shih AY, et al, 2013). Beyond the acute stage of injury, chronic
memantine treatment (30mg/kg per day) beginning >2 hours after photothrombotic stroke in
mice can facilitate circuit recovery in peri-infarct brain regions via brain-derived neurotrophic
factor (BDNF) signaling mechanisms (Lopez-Valdes, 2014). This study found no differences
in infarct size but observed significant improvements in motor control 28 days after stroke.
This is consistent with our findings that memantine does not prevent or delay SD (and
associated structural demise based on IOS signals) following OGD exposure but can
significantly limit deleterious consequences to neurons in metabolically vulnerable conditions.
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Even though Lopez-Valdes and colleagues did not monitor SD after the thrombosis, we
anticipate that oral delivery of 30mg/kg (per day) of memantine would not inhibit SD
frequency, as memantine does not appear to have a potent effect on blocking SD. The ability
of memantine to prevent SD after stroke would be further hindered by the ionic imbalances,
including elevated extracellular K+ (Petzold et al., 2005), observed in peri-infarct tissues. Even
in studies conducted by Peeters and colleagues in the uninjured brain, i.p. injection of 10mg/kg
memantine achieved prominent brain concentrations (~100µM) but could not prevent 100% of
SDs initiated by KCl (Peeters et al., 2007). As such, inhibiting SD frequency after photo
thrombosis may not be the mechanism behind memantine’s promising outcomes, however it
remains plausible that memantine exerts a protective effect by reducing neuronal consequences
of SD.

It remains unresolved as to the potential benefits of SD, particularly in brain regions with
preserved cerebral perfusion after focal ischemia. There is mounting preclinical evidence that
SD stimulated days prior to a subsequent stroke induces preconditioning mechanisms resulting
in a reduction in subsequent infarct size. This has largely been attributed to upregulation of
BDNF (Yanamoto et al., 2004). If it is found that SD is a central upstream initiator of BDNF
after focal ischemia, drugs that block these events may reduce the size of an infarct but at the
expense of potential SD-mediated functional repair. Therefore, interventions like memantine
or low concentration ketamine may provide approaches for reducing the damaging
consequences of SD in vulnerable brain without preventing preconditioning and/or protective
effects in metabolically intact tissues. Perhaps prior work (Lopez-Valdes, 2014) provides an
initial test of this hypothesis, as BDNF was upregulated in memantine-treated animals.
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Conclusions
In this study we tested whether the NMDAR antagonist memantine could reduce consequences
of SD that are especially deleterious to metabolically vulnerable neurons. Collectively, this
work provides initial evidence that memantine administration in the ICU may provide some
protection against deleterious consequences of SD in salvageable brain tissues without
preventing any benefits remotely.
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Appendix B: Theoretical protective effects of SD
B.1 Abstract
Spreading depolarizations (SD) are slowly propagating waves of neuronal and glial
depolarization that occur in stroke brain. SD causes irrecoverable injury to metabolically
compromised tissues by over-excitation of NMDA receptors. On the other hand, SD may also
promote NMDA receptor-dependent synaptic plasticity and protective preconditioning in
healthy tissues surrounding infarcts. Previous work in vivo suggests that beneficial effects of
SD (i.e. preconditioning) are mediated via upregulation of brain derived neurotrophic factor,
BDNF (Yanamoto et al., 2000, 2004; Shen P et al., 2016). In these studies, SD was initiated
days prior to subsequent middle cerebral artery occlusion, and therefore the acute protective
role of SD remains unknown. Additionally, most studies have evaluated SD preconditioning
effects in vivo and thus experiments in well-controlled brain slices would be useful for
understanding the cellular mechanisms of SD-induced protection. Results of such studies are
important for determining whether all SDs should be blocked in brain injured patients.

To determine if BDNF mRNA is upregulated in vitro after SD, acute cortico-hippocampal
brain slices were prepared from C57Bl/6 mice. SD was initiated by KCl microinjection in CA1
and confirmed via extracellular DC potentials and loss of evoked excitatory postsynaptic
potentials (EPSPs). The time course of BDNF mRNA changes after SD were assessed by rtqPCR. We also tested the influence of ketamine (30µM – a concentration known to reduce
deleterious consequences without blocking SD) on SD-induced BDNF changes. Total BDNF
(BDNF-Pan) and activity-dependent BDNF (BDNF-L) mRNA from hippocampus was
assessed before and 5,15,30,45, and 60min after SD. We found significant upregulation of both

184

total and activity-dependent
BDNF mRNA beginning ~30
min. after SD (45 min. for
total BDNF) that remained
elevated at the 60 min time
point (Figure 1, left panels).
Based on these findings, we
examined the 45 min. time
point and found that ketamine
did not reduce (and perhaps
may increase) SD-induced
BDNF upregulation (Figure 1,
right panels). To determine if
upregulation of BDNF could
protect brain slices from SD in
conditions

of

metabolic

compromise, we initiated SD
(via KCl microinjection) and
allowed slices to recover for
45 min. prior to initiation of a second SD in metabolically vulnerable conditions (Figure 2).
There was a modest improvement in the percent of slices that recovered from SD in damaging
conditions, measured as the percent of slices capable of propagating successive SDs. However,
this effect was greatly enhanced in the presence of ketamine. Similar effects were observed in
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EPSP recordings where ketamine conferred enhanced protection when combined with SD in
healthy tissues (prior to subsequently deleterious SD).

These findings suggest that low ketamine concentrations can protect against damaging effects
of SD while permitting propagation into peri-infarct regions. Such SDs could potentially
contribute to protective preconditioning and support recovery and repair.
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Appendix C: The degree of SD-induced excitotoxic glutamate increases is related to
extent of brain slice metabolic impairment
Figure 6.4
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